<PAGE> 1
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 19, 2000.
REGISTRATION NO. 333-30764
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------------
AMENDMENT NO. 3
TO
FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
FIRST HORIZON PHARMACEUTICAL CORPORATION
(Exact name of registrant as specified in its charter)
<TABLE>
<S> <C> <C>
DELAWARE 2834 58-2004779
(STATE OR OTHER JURISDICTION OF (PRIMARY STANDARD INDUSTRIAL (I.R.S. EMPLOYER
INCORPORATION OR ORGANIZATION) CLASSIFICATION CODE NUMBER) IDENTIFICATION NUMBER)
</TABLE>
660 HEMBREE PARKWAY, SUITE 106
ROSWELL, GA 30076
(770) 442-9707
(Address, Including Zip Code, and Telephone Number, Including Area Code, of
Registrant's Principal Executive Offices)
---------------------
MAHENDRA G. SHAH, PH.D.
CHAIRMAN AND CHIEF EXECUTIVE OFFICER
FIRST HORIZON PHARMACEUTICAL CORPORATION
660 HEMBREE PARKWAY, SUITE 106
ROSWELL, GA 30076
TELEPHONE: (770) 442-9707
(Name, Address, Including Zip Code, and Telephone Number, Including Area Code,
of Agent for Service)
---------------------
Copies to:
<TABLE>
<S> <C>
STEPHEN D. FOX, ESQ. LESLIE E. DAVIS, ESQ.
ARNALL GOLDEN & GREGORY, LLP TESTA, HURWITZ & THIBEAULT, LLP
2800 ONE ATLANTIC CENTER 125 HIGH STREET
1201 WEST PEACHTREE STREET BOSTON, MA 02110
ATLANTA, GA 30309 TEL: (617) 248-7000
TEL: (404) 873-8500
</TABLE>
APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC:
As soon as practicable after the effective date of this Registration
Statement.
If any of the securities registered on this Form are to be offered on a
delayed or continuous basis pursuant to Rule 415 under the Securities Act of
1933, check the following box. [ ]
If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, check the following box and
list the Securities Act registration statement number of the earlier effective
registration statement for the same offering. [ ]
If this Form is a post-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. [ ]
If this Form is a post-effective amendment filed pursuant to Rule 462(d)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. [ ]
If delivery of the prospectus is expected to be made pursuant to Rule 434,
please check the following box. [ ]
CALCULATION OF REGISTRATION FEE
<TABLE>
<CAPTION>
- --------------------------------------------------------------------------------------------------------------------------------
- --------------------------------------------------------------------------------------------------------------------------------
PROPOSED MAXIMUM PROPOSED MAXIMUM AMOUNT OF
AMOUNT TO BE OFFERING PRICE AGGREGATE OFFERING REGISTRATION
TITLE OF SECURITIES TO BE REGISTERED REGISTERED(1) PER SHARE(2) PRICE(1) FEE(2)
- --------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Common Stock, $0.001 par value per share 4,370,000 shares $14.00 $61,180,000 $16,151.52
- --------------------------------------------------------------------------------------------------------------------------------
- --------------------------------------------------------------------------------------------------------------------------------
</TABLE>
(1) Includes 570,000 shares to cover an over-allotment option granted by the
Registrant to the Underwriters.
(2) Estimated solely for the purpose of determining the registration fee
pursuant to Rule 457(a) promulgated under the Securities Act. This fee was
paid previously.
THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR
DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL
FILE A FURTHER AMENDMENT THAT SPECIFICALLY STATES THAT THIS REGISTRATION
STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(A) OF
THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME
EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(A),
MAY DETERMINE.
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
<PAGE> 2
THE INFORMATION IN THIS PROSPECTUS IS NOT COMPLETE AND MAY BE CHANGED. WE
MAY NOT SELL THESE SECURITIES UNTIL THE REGISTRATION STATEMENT FILED WITH
THE SECURITIES AND EXCHANGE COMMISSION
IS EFFECTIVE. THIS PROSPECTUS IS NOT AN OFFER TO SELL SECURITIES, AND WE
ARE NOT SOLICITING OFFERS TO BUY THESE SECURITIES, IN ANY STATE WHERE THE
OFFER OR SALE IS NOT PERMITTED.
PROSPECTUS SUBJECT TO COMPLETION, DATED MAY 19, 2000
3,800,000 SHARES
1ST HORIZON LOGO
COMMON STOCK
This is an initial public offering of common stock by First Horizon. We are
selling 3,800,000 shares of common stock. We estimate that the initial public
offering price will be between $12.00 and $14.00 per share.
------------------
Prior to this offering, there has been no public market for our common
stock. Our shares of common stock have been approved for quotation on the Nasdaq
National Market under the symbol FHRX.
------------------
<TABLE>
<CAPTION>
Per Share Total
--------- -----
<S> <C> <C>
Initial public offering price............................... $ $
Underwriting discounts and commissions......................
Proceeds to First Horizon, before expenses..................
</TABLE>
We have granted the underwriters an option for a period of 30 days to
purchase up to 570,000 additional shares of common stock.
------------------
INVESTING IN OUR COMMON STOCK INVOLVES A HIGH DEGREE OF RISK.
SEE "RISK FACTORS" BEGINNING ON PAGE 5.
------------------
NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES
COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE
ADEQUACY OR ACCURACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A
CRIMINAL OFFENSE.
CHASE H&Q
BANC OF AMERICA SECURITIES LLC
THOMAS WEISEL PARTNERS LLC
, 2000
<PAGE> 3
NITROLINGUAL(R) PUMPSPRAY is an oral spray of nitroglycerin used for the
acute relief or prevention of angina pectoris, which is the medical term for
chest pain due to coronary heart disease.
[GRAPHICS-BOTTLE OF NITROLINGUAL PUMPSPRAY]
<PAGE> 4
TABLE OF CONTENTS
<TABLE>
<CAPTION>
PAGE
----
<S> <C>
Summary..................................................... 1
Risk Factors................................................ 5
Tradenames and Trademarks used in this Prospectus........... 15
Forward-Looking Statements.................................. 15
Use of Proceeds............................................. 15
Dividend Policy............................................. 16
Capitalization.............................................. 17
Dilution.................................................... 18
Selected Financial Data..................................... 19
Management's Discussion and Analysis of Financial Condition
and Results of Operations................................. 20
Business.................................................... 27
Management.................................................. 40
Certain Relationships and Related Transactions.............. 51
Principal Stockholders...................................... 53
Description of Capital Stock................................ 55
Shares Eligible for Future Sale............................. 58
Underwriting................................................ 60
Legal Matters............................................... 62
Experts..................................................... 62
Additional Information...................................... 62
Index to Financial Statements............................... F-1
</TABLE>
i
<PAGE> 5
SUMMARY
THE COMPANY
First Horizon Pharmaceutical Corporation markets and sells brand name
prescription drugs. We focus on the treatment of chronic conditions, including
cardiovascular diseases, respiratory and gastroenterological disorders, and pain
and inflammation. Our strategy is to acquire pharmaceutical products that other
companies do not actively market that we believe have a high sales growth
potential and complement our existing products. In addition, we seek to develop
new patentable formulations, use new delivery methods and seek regulatory
approval for new indications of existing products.
Large multinational companies dominate the U.S. prescription pharmaceutical
market. These companies are increasingly divesting products which, as a result
of consolidation or lack of strategic fit, do not meet the threshold level of
sales required for continued marketing and promotion. In 1999 alone, we acquired
and licensed products from American Home Products Corporation and Aventis
(formerly Rhone-Poulenc Rorer).
Since 1992, we have introduced 12 products, three of which use the same
brand name. We market our products through our nationwide sales and marketing
force of 133 professionals. Our key products include the angina product,
Nitrolingual, the gastrointestinal products, Robinul and Robinul Forte, and the
liquid cold and allergy product, Tanafed. In 1999, we acquired marketing rights
from Aventis and Pohl-Boskamp to Nitrolingual, a product used for the acute
relief or prevention of chest pain resulting from heart disease. According to
information from IMS Health Retail and Provider Perspective Audits, this product
had U.S. sales to drug stores and non-retail purchasers of approximately $12
million in 1998, a 12.6% increase over 1997. In February 2000, we launched an
improved version of this product called Nitrolingual Pumpspray. We acquired
Robinul and Robinul Forte from American Home Products Corporation in January
1999. Since 1993, we have marketed Tanafed, a liquid cold and allergy product
primarily for children. Third parties manufacture all of our products.
We recently concluded development agreements with Penwest Pharmaceuticals
Co. and Inpharmakon Corporation for a product that we are developing for the
treatment of migraine headache. The FDA has approved the marketing of the active
ingredient in this product for the treatment of other conditions. We are also
currently developing a new use of the active ingredient in Robinul to treat
symptoms associated with the excessive production of saliva.
Our net revenues have grown from approximately $1.6 million for the year
ended December 31, 1995 to approximately $18.6 million for the year ended
December 31, 1999. We achieved this through a combination of increased sales of
existing products and acquisitions.
RECENT DEVELOPMENTS
On April 14, 2000, we acquired from Warner-Lambert Company exclusive rights
to market, distribute and sell a prescription product called "Ponstel" in the
United States. The FDA has approved this product for the relief of mild to
moderate pain for patients 14 years of age and older when therapy for the pain
will not exceed one week and for pain associated with menstruation. The purchase
price for the rights to this product was $13 million. We paid $9.5 million in
cash, which we borrowed under a bridge loan from LaSalle Bank National
Association, and we issued a promissory note to Warner-Lambert for the remaining
$3.5 million. We intend to repay LaSalle Bank and Warner-Lambert from the
proceeds of this offering. Based on customary due diligence with the seller, we
believe Ponstel had U.S. sales of approximately $3.3 million in 1999, a 16%
increase over 1998.
In addition, on April 14, 2000, we entered into an agreement with
Warner-Lambert to purchase exclusive rights in the United States and other
countries to market, distribute and sell a product called "Cognex", as well as
all of Warner-Lambert's rights to a new unapproved version of Cognex,
1
<PAGE> 6
called "Cognex CR". The FDA has approved Cognex for the treatment of mild to
moderate dementia associated with Alzheimer's disease. The purchase of Cognex is
contingent on Warner-Lambert receiving FTC approval for the transaction and upon
satisfaction of other specified conditions. Warner-Lambert must divest certain
assets in order to complete its pending merger with Pfizer Inc. and the FTC must
approve its product divestitures. If we conclude this acquisition, we will be
required to pay $3.5 million in cash for the product. Based on customary due
diligence with the seller, we believe Cognex had sales of approximately $7.7
million in 1999, a decline of 35% from 1998, $2.7 million of which was in the
United States.
We must pay Warner-Lambert up to an additional $1.5 million in purchase
price if we receive FDA approval to market a new version of Cognex, called
Cognex CR. If approved, Cognex CR will also treat mild to moderate dementia
associated with Alzheimer's disease, but we believe that the new version will
offer convenience to patients by reducing the number of tablets required from
four times per day to one time per day.
We believe that the acquisition of the rights to these products complements
our growth strategy of acquiring products that others do not actively market.
We incorporated in 1992. Our principal office is located at 660 Hembree
Parkway, Suite 106, Roswell, Georgia 30076 and our telephone number is (770)
442-9707. Our corporate Internet address is www.horizonpharm.com. We do not
intend the information contained on our website to be a part of this prospectus.
2
<PAGE> 7
THE OFFERING
<TABLE>
<S> <C>
Common stock offered................................. 3,800,000 shares
Common stock to be outstanding after the
offering(1)........................................ 12,339,643 shares
Use of proceeds...................................... We estimate that the net proceeds from the
sale of the 3,800,000 shares that we are
offering will be $44,942,000. We intend to
apply the proceeds from the offering as
follows: to repay approximately $12,680,000
of debt outstanding as of April 14, 2000
under our credit facility with LaSalle
Bank, to pay $3,500,000 under our
promissory note with Warner-Lambert
relating to the purchase of Ponstel, to pay
$3,500,000 if we conclude the purchase of
Cognex, to pay a $200,000 fee due under our
amended product development agreement, and
for general corporate purposes, including
the development of new products, the
expansion of our sales and marketing force
and new product acquisitions.
Nasdaq National Market symbol........................ FHRX
</TABLE>
- ------------------------------
(1) This number excludes 1,767,500 shares subject to options granted under our
stock plans.
The information presented in this prospectus assumes that the underwriters
do not exercise their over-allotment option.
3
<PAGE> 8
SUMMARY FINANCIAL DATA
The following summary historical and as adjusted financial data should be
read together with "Management's Discussion and Analysis of Financial Condition
and Results of Operations" and our financial statements and related notes
included elsewhere in this prospectus. The as adjusted balance sheet data
summarized below reflects the sale of the 3,800,000 shares of common stock we
are offering at an assumed initial public offering price of $13.00 per share
after deducting the underwriting discounts and commissions and our estimated
offering expenses and the use of proceeds from the offering to repay $3,720,000
of debt outstanding as of March 31, 2000.
<TABLE>
<CAPTION>
THREE
MONTHS ENDED
YEAR ENDED DECEMBER 31, -------------------------
----------------------------------------------------------------- MARCH 31, MARCH 31,
1995 1996 1997 1998 1999 1999 2000
----------- ----------- ---------- ---------- ----------- ----------- -----------
(UNAUDITED) (UNAUDITED) (UNAUDITED) (UNAUDITED)
----------- ----------- ----------- -----------
<S> <C> <C> <C> <C> <C> <C> <C>
STATEMENT OF
OPERATIONS DATA:
Net revenues.......... $1,620,720 $2,516,616 $5,557,700 $9,252,058 $18,624,514 $4,199,934 $7,119,638
Operating income
(loss).............. (37,715) (395,185) (288,018) 269,421 1,655,049 697,380 (10,952)
Net income (loss)..... (92,025) (344,348) (180,446) 135,554 770,464 375,901 (38,531)
Net income (loss) per
common share:
Basic:............ $ (0.02) $ (0.06) $ (0.02) $ 0.02 $ 0.10 $ 0.05 $ (0.00)
Diluted:.......... $ (0.02) $ (0.06) $ (0.02) $ 0.02 $ 0.09 $ 0.04 $ (0.00)
Weighted average
common shares
outstanding:
Basic:............ 5,636,137 5,830,000 7,576,580 7,978,234 8,028,673 7,981,248 8,539,643
Diluted:.......... 5,636,137 5,830,000 7,576,580 8,584,329 8,975,493 8,759,904 8,539,643
</TABLE>
<TABLE>
<CAPTION>
MARCH 31, MARCH 31,
2000 2000
----------- -----------
ACTUAL AS ADJUSTED
(UNAUDITED) (UNAUDITED)
----------- -----------
<S> <C> <C>
BALANCE SHEET DATA:
Cash and cash equivalents................................... $ 735,337 $41,957,337
Working capital............................................. (1,002,183) 42,699,817
Total assets................................................ 13,683,087 54,905,087
Borrowings under revolving loan agreement................... 2,000,000 --
Long-term debt including current portion.................... 2,575,708 855,708
Accumulated deficit......................................... (935,353) (935,353)
Total stockholders' equity.................................. 3,664,302 48,606,302
</TABLE>
4
<PAGE> 9
RISK FACTORS
RISKS RELATED TO OUR BUSINESS
WE CURRENTLY DEPEND ON TWO KEY PRODUCTS FOR A LARGE PORTION OF OUR SALES, AND
SUBSTANTIAL DECLINES IN EITHER OF THEM WOULD RESULT IN OUR BEING UNPROFITABLE.
Any factor that adversely affects the sale of our key products could
significantly decrease our sales and profits. Tanafed accounted for 24% and
Robinul and Robinul Forte accounted for 28% of our total revenues in 1999.
OUR GROWTH WILL SUFFER IF WE DO NOT ACQUIRE RIGHTS TO NEW PRODUCTS AND INTEGRATE
THEM SUCCESSFULLY.
We depend on acquisitions of rights to products from others as our primary
source for new products. Risks in acquiring new products include the following:
- the availability of new products that we find attractive and
complementary to our business; and
- the price to acquire or obtain a license for these products.
We often face significant competition from other pharmaceutical companies
in acquiring rights to products, which makes it more difficult to find
attractive products on acceptable terms. On February 1, 2000, we introduced
Nitrolingual Pumpspray and have no prior experience selling this product. On
April 14, 2000, we acquired Ponstel and immediately took over all of the
responsibilities relative to managing and selling this product. We are also
presently in the process of seeking to acquire a new product called Cognex. We
have only two senior managerial personnel devoted to product introductions and
we believe that these recent activities, together with other duties may cause
these persons to have insufficient time to integrate new products while
simultaneously continuing to effectively market existing products. Failure to do
this successfully could limit our ability to sell existing and new products.
WE MAY ENCOUNTER PROBLEMS IN THE MANUFACTURE OF OUR PRODUCTS THAT COULD LIMIT
OUR ABILITY TO SELL OUR PRODUCTS.
We depend entirely on third parties to manufacture our products.
Third parties manufacture all of our products, and we do not currently have
the ability to manufacture products. Except for any rights and remedies which we
may have because of contracts with our manufacturers, we have no control over
the availability of our products, or their quality or cost to us. We do not
maintain alternative manufacturing sources for any of our products and we may
not be able to locate alternative manufacturers on commercially acceptable terms
in the event of a manufacturing interruption. We do not have business
interruption insurance. Furthermore, due to the patent held on Nitrolingual
Pumpspray by our supplier, Pohl-Boskamp, no alternative source for Nitrolingual
exists. Similarly, the manufacturing process for producing the raw materials for
Tanafed is patented, and no other source for these materials is currently
available.
We will need to replace our supply source for Ponstel.
Warner-Lambert has agreed to manufacture Ponstel for us only until December
31, 2000, and will manufacture only specified quantities of Ponstel even if
demand increases. We must secure a new manufacturer to commence supplying
Ponstel at the time that the Warner-Lambert manufacturing agreement expires. We
may not be able to timely locate and contract with a manufacturer capable of
manufacturing and supplying us with Ponstel at an acceptable cost. In addition,
our supply agreement requires that we purchase a fixed quantity of Ponstel. If
demand for Ponstel increases or we are delayed in securing a replacement
manufacturer, we may have insufficient quantities of Ponstel to fulfill orders.
5
<PAGE> 10
We have no written agreements for the manufacture of our Zoto-HC and Protuss-D
products.
Because we do not have a written agreement with the manufacturer of our
Zoto-HC and Protuss-D products, we may lack rights and remedies which may be
available under a written supply agreement.
Our existing supply agreements may prohibit us from entering into potentially
more favorable supply relationships with others.
Our third-party manufacturing agreements for our Nitrolingual, Robinul,
Tanafed, Zebutal and Protuss products require that we purchase all of our
product requirements from the manufacturers that are a party to those
agreements. This could hinder our ability to enter into manufacturing agreements
with other manufacturers for these five products that may be more beneficial or
less costly to us.
THE AVAILABILITY OF A PREVIOUS VERSION OF OUR NITROLINGUAL PRODUCT COULD REDUCE
ITS SALES.
The availability of a previous version of our Nitrolingual Pumpspray
product may affect our sales. We have exclusive rights to sell Nitrolingual
Pumpspray in the United States. However, Aventis previously marketed another
version of this product named Nitrolingual Spray. Although Aventis has never
manufactured and no longer markets this product, existing inventories of
Nitrolingual Spray remain with distributors which, along with retailers, may
wish to sell these existing inventories prior to purchasing our Nitrolingual
product. In addition, Aventis did not actively market Nitrolingual in 1999 and
we believe that it will take time to rebuild loyalty to Nitrolingual and restore
sales to formerly achieved levels.
WE FACE COMPETITION FROM GENERIC PRODUCTS THAT COULD LOWER PRICES AND UNIT
SALES.
Nitrolingual competes with a generic tablet product. Our Zebutal Capsules,
Protuss Liquid, Protuss-DM Tablets, Protuss-D Liquid, Zoto-HC ear drops and
Mescolor Tablets are not protected by patents and face competition from less
expensive generic products. In addition, competitors could develop generics to
compete with our Robinul, Robinul Forte and recently acquired Ponstel products
which are not protected by patents. Third-party payors and pharmacists can
substitute generics for our products even if physicians prescribe them.
Government agencies and third-party payors often put pressure on patients to
purchase generic products instead of brand-name products as a way to reduce
healthcare costs. An increase in the amount of generic competition against any
one or more of our products could lower prices and unit sales.
STRONG COMPETITION EXISTS FOR DEVELOPING AND OUR MARKETING PRODUCTS AND
COMPETITORS HAVE INTRODUCED NEW PRODUCTS AND THERAPIES THAT COULD MAKE OUR
PRODUCTS OBSOLETE.
Our Protuss line and Tanafed, Zebutal, Defen-LA and recently acquired
Ponstel products compete against products sold both over-the-counter and by
prescription and which are marketed by larger pharmaceutical companies with
greater financial resources for marketing and manufacturing. In addition,
barriers to entry for products competitive with these products are low, which
makes it easier for smaller companies to enter the market. Competitors have
recently introduced new products to treat angina and short-term pain.
Competitors have also recently developed a new therapy for pain and a surgical
procedure to treat angina. These technological changes and new therapies may
reduce the need for our products. The high level of competition in our industry
could force us to reduce the price at which we sell our products or require us
to spend more to market our products.
6
<PAGE> 11
A SMALL NUMBER OF CUSTOMERS ACCOUNT FOR A LARGE PORTION OF OUR SALES AND THE
LOSS OF ONE OF THEM, OR CHANGES IN THEIR PURCHASING PATTERNS, COULD RESULT IN
THE INABILITY TO SUCCESSFULLY SELL OUR PRODUCTS.
We sell most of our products to a small number of wholesale drug
distributors. In 1999, sales to Bergen Brunswig Corporation, Cardinal Health,
Inc. and McKesson HBOC, Inc. represented approximately 10%, 19% and 28%,
respectively, of our total sales. Because of the small number of wholesale drug
distributors, further consolidation in this industry or financial difficulties
of these distributors could result in the combination or elimination of
warehouses, which could increase returns of our products or, as a result of
distributors reducing inventory levels, delay the purchase of our products.
IF OUR PRODUCTS UNDER DEVELOPMENT FAIL IN CLINICAL STUDIES OR IF WE FAIL OR
ENCOUNTER DIFFICULTIES IN OBTAINING REGULATORY APPROVAL FOR NEW PRODUCTS OR NEW
USES OF EXISTING PRODUCTS, WE WILL HAVE EXPENDED SIGNIFICANT RESOURCES FOR NO
RETURN.
We are beginning clinical studies of our migraine headache product under
development and plan to initiate clinical trials for our excessive salivation
product under development. If we cannot obtain FDA approval for these or other
products which we may seek to develop in the future, our rate of sales growth
will suffer. We do not have experience in obtaining FDA approval for new
products or new uses of already-approved products. As a result, we rely on
third-parties to formulate, develop and manufacture the materials needed for
clinical trials for our products under development to treat migraine headache,
excessive salivation and a once-a-day formulation for Cognex. We also rely on
third parties to conduct clinical trials for us. If our product is not
successful in clinical trials or if we do not obtain FDA approval, we will have
expended significant resources with no return.
Our ongoing clinical studies might be delayed or halted for various
reasons, including:
- these products are not shown to be effective;
- we do not comply with requirements concerning the protection of the
rights and welfare of human subjects;
- patients experience unacceptable side effects or die during clinical
trials;
- patients do not enroll in the studies at the rate we expect; and
- product supplies are not sufficient to treat the patients in the studies.
In addition, the party from whom we license rights to develop a component
of our migraine product could terminate the agreement if we fail to achieve
certain scheduled performance milestones, including the completion of clinical
trials by April 2002 and applying for FDA approval of the product within six
months after completing clinical trials.
7
<PAGE> 12
WE OR THIRD-PARTIES MAY VIOLATE GOVERNMENT REGULATIONS AND WE MAY INCUR
SIGNIFICANT EXPENSES TO COMPLY WITH SUCH REGULATIONS.
All of our third-party manufacturers and product packaging companies are
subject to inspection by the FDA and, in appropriate cases, the Drug Enforcement
Administration and foreign regulators. From time to time, some of our
third-party manufacturers have received warning letters from the FDA concerning
noncompliance with manufacturing requirements. If our third-party manufacturers
do not comply with FDA regulations in the future, they may not be able to
deliver products to us or we may have to recall products. Many government
agencies regulate our business, including the following:
- the FDA;
- the Drug Enforcement Administration;
- the Consumer Product Safety Commission;
- the Occupational Safety and Health Administration;
- the Health Care Financing Administration;
- the Environmental Protection Agency; and
- state, local and foreign governments.
IF THIRD-PARTY PAYORS DO NOT ADEQUATELY REIMBURSE PATIENTS FOR OUR PRODUCTS,
DOCTORS MAY NOT PRESCRIBE THEM.
Because our products are sold by prescription, we depend on third-party
payors, such as the government, private healthcare insurers and managed care
organizations, to include these products on their lists of products for which
third-party payors will reimburse patients. Third-party payors continuously
challenge the pricing of medical products and services by substituting cheaper
products on their approved lists. Because our Nitrolingual, Zebutal, Protuss,
Zoto, Mescolor, Robinul and Ponstel products are susceptible to generic
competition and because of the new entrants that compete with Nitrolingual and
Ponstel, we face an increased risk of third-party payors substituting these
products. If third-party payors remove any of these products from their lists or
choose not to pay for our product prescriptions, patients and pharmacies may not
continue to choose our products.
WE DEPEND ON HIGHLY TRAINED MANAGEMENT, AND WE MAY NOT BE ABLE TO KEEP CURRENT
MANAGEMENT OR HIRE QUALIFIED MANAGEMENT PERSONNEL IN THE FUTURE.
We currently have only nine key regulatory, technical and management
personnel. The loss of any of these persons therefore would hurt our ability to
develop and market products. If we are able to sustain our rate of growth, we
will need to attract new operational and marketing personnel, and we may have
difficulty hiring personnel at an acceptable cost. In addition, Dr. Mahendra G.
Shah, our chief executive officer, does not provide exclusive full-time services
to us.
PRODUCT LIABILITY CLAIMS AND PRODUCT RECALLS COULD LIMIT OUR ABILITY TO SELL
PRODUCTS.
Side effects could occur from our Ponstel, Nitrolingual and Robinul
products. Side effects or marketing or manufacturing problems pertaining to any
of our products could result in product liability claims or adverse publicity.
These claims could be expensive, or could result in withdrawal of approval to
market the product or recall of the product. These problems often occur with
little or no notice in connection with the sale of pharmaceutical products. For
instance, we instituted a voluntary recall on our Protuss-DM product in January
1999 because of a labeling error. However, we quickly corrected the error and
the financial impact was immaterial to our results of operations.
8
<PAGE> 13
OUR LEVEL OF DEBT COULD REDUCE OUR GROWTH.
As of April 14, 2000, we had total outstanding indebtedness of
approximately $17,036,000, or approximately 82% of our total capitalization.
Even after this offering and the repayment of the term loan and bridge loan
under our credit facility with LaSalle Bank, we expect that we may incur
additional indebtedness to implement our growth strategy.
Significant debt could:
- limit our operating flexibility as a result of requirements of our
lender;
- require us to use a large portion of our cash flow from operations for
debt payments that would reduce the availability of our cash flow to fund
operations, product acquisitions, the expansion of our sales force and
facilities and research and development efforts; and
- limit additional acquisitions due to restrictive covenants in our credit
facility.
WE EXPECT TO REQUIRE ADDITIONAL FUNDING AND IF WE CANNOT OBTAIN IT, OUR SALES,
PROFITS, ACQUISITIONS AND DEVELOPMENT PROJECTS COULD SUFFER.
After the offering, we expect that we will need additional funds to acquire
or obtain licenses for new products, expand our sales force, support the
marketing and sales of new products and facilities and develop and test new
products. We may seek additional funding through public and private financing,
including equity and debt offerings. Adequate funds for these purposes, whether
through the financial markets or from other sources, may not be available when
we need them or on terms acceptable to us. Insufficient funds could cause us to
delay, scale back, or abandon some or all of our product acquisitions, licensing
opportunities, marketing, and product development programs and manufacturing
opportunities.
IF WE DO NOT SECURE OR ENFORCE OUR PATENTS OR OTHER INTELLECTUAL PROPERTY
RIGHTS, WE COULD ENCOUNTER INCREASED COMPETITION THAT COULD ADVERSELY AFFECT OUR
OPERATING RESULTS.
We do not hold patent rights covering the products we are distributing and
do not in some cases have the right to enforce patents our licensors hold. We
obtained exclusive distribution rights in the United States to distribute our
Nitrolingual Pumpspray and Tanafed products but have no or only limited rights
to enforce the patents relating to these products. We have a license from
Penwest Pharmaceuticals Co. to use the patented TIMERx technology in our
migraine product under development. If we complete the Cognex acquisition, we
will acquire certain patent rights relating to the use of an active ingredient
in Cognex to treat conditions associated with Alzheimer's disease. Any
exclusivity afforded by any of these patents could cease because the other party
could terminate the license or because we have no or only limited rights to
enforce patents or to require enforcement actions by the owners of the patents.
Proceedings involving our rights in patents or patent applications could
result in adverse decisions. In addition, the confidentiality agreements
required of our employees and third-parties may not provide adequate protection
for our trade secrets, know-how and other proprietary information which we rely
on to develop and sell our products. If any of our employees or third-parties
disclose any of our trade secrets or know-how, we could encounter increased
competition.
OUR PRODUCTS COULD INFRINGE THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES,
WHICH COULD REQUIRE US TO PAY LICENSE FEES OR DEFEND LITIGATION THAT COULD BE
EXPENSIVE OR PREVENT US FROM SELLING PRODUCTS.
The manufacture, use or sale of our products may infringe on the patent,
trademark and other intellectual property rights of others. Based on the nature
of competition, patent and trademark infringement problems occur frequently in
connection with the sale and marketing of cough, cold, allergy, headache and
other pharmaceutical products. If we do not avoid infringement of the
9
<PAGE> 14
intellectual property rights of others, we may have to seek a license to sell
our products, defend an infringement action or challenge the validity of the
intellectual property in court, all of which could be expensive and time
consuming. In addition, if we are found liable for infringing a patent, we may
have to stop selling some of our products and pay damages.
Even though most of our product agreements under which we license
intellectual property rights from others contain provisions that allow us to
recover costs and damages if we have to defend or are found liable for
infringing a patent of a third party, the agreements under which we obtained
rights to Nitrolingual and Ponstel and our agreement to acquire Cognex do not
contain these indemnification provisions. It could be very costly if we have to
defend the patents or trademarks covering Nitrolingual Pumpspray, Ponstel or
Cognex, or if we were found liable for infringement.
THE REGULATORY STATUS OF SOME OF OUR PRODUCTS MAKES THESE PRODUCTS SUBJECT TO
INCREASED COMPETITION AND OTHER RISKS.
The regulatory status of our Protuss, Protuss-D, Protuss-DM, Zoto-HC,
Tanafed, Mescolor and Defen-LA products allows third parties to more easily
introduce competitive products, and may make it more difficult for us to sell
these products in the future. Currently, an FDA program allows us to manufacture
and market these products and permits others to manufacture and market the same
and similar products without submitting safety or efficacy data. These markets
are already highly competitive and, except for a license to one of the raw
materials in Tanafed, we do not hold rights in patents protecting us against
such competitive pressures. This results in increased competition because other
companies can enter the market without having to submit safety and efficacy data
to sell competing products. On several occasions, the FDA has considered
changing the classification of these types of drugs from prescription to
over-the-counter use. If they do change the classification, we might have to
reformulate them, submit safety and efficacy data on our products which could be
costly, or we might have to discontinue selling these products if the FDA does
not approve our marketing application. We could lose third-party reimbursement
for the products and face increased competition. We are unable to predict the
timing of any of these actions, but they could occur soon.
WE HAVE BEEN INVOLVED IN CONFLICTS IN THE PAST UNDER ONE OF OUR DEVELOPMENT
AGREEMENTS WITH A RELATED PARTY AND MAY ENCOUNTER CONFLICTS IN THE FUTURE.
John N. Kapoor, Ph.D., our majority stockholder and director, also
beneficially owns 50% of the common stock of Inpharmakon Corporation, a party to
one of our product development agreements. Mahendra G. Shah, Ph.D., our Chairman
and Chief Executive Officer, is a director and the Chairman of Inpharmakon. The
other owner of Inpharmakon has in the past renegotiated some of the terms of our
development agreement by seeking to terminate our development agreement with
Inpharmakon. On May 3, 2000, we entered into an amendment to this agreement in
which both parties released each other from any previous claims or disputes
under the agreement. Conflicts between the parties may develop in the future and
may not be resolved in our favor. Under some circumstances, if Inpharmakon
terminates this agreement, it will have rights to develop and market this
product using the data and information that we have developed and for which we
have expended significant resources.
POHL-BOSKAMP CAN TERMINATE OUR RIGHTS TO NITROLINGUAL.
Based on industry data suggesting that Nitrolingual had sales of
approximately $12 million in 1998, Nitrolingual may become one of our key
products. Pohl-Boskamp can terminate our distribution agreement for Nitrolingual
if a company with a product competitive with Nitrolingual acquires direct or
indirect influence or control over our company or if a very significant change
in our stockholders occurs so that Kapoor-Pharma Investments and our employees,
management and directors, and any of their respective affiliates, do not in the
aggregate directly or indirectly
10
<PAGE> 15
beneficially own at least 20% of our shares. These provisions could reduce the
price some investors might be willing to pay for our shares of common stock, and
could delay or prevent a third-party from acquiring us.
OUR AGREEMENT TO ACQUIRE COGNEX CREATES ADDITIONAL RISKS.
Our growth will suffer if we do not conclude the purchase of Cognex.
Our agreement to purchase rights to market and sell Cognex is contingent
upon receiving FTC approval of the purchase and the satisfaction of other
customary conditions. If the FTC does not approve the purchase, or if the other
conditions to closing are not satisfied, we would encounter lost sales
opportunities.
Our sales force has no experience selling products like Cognex.
As a drug for the treatment of conditions associated with Alzheimer's
disease, Cognex is primarily prescribed by neurologists, psychiatrists and
geriatric physicians. Our sales force has not made sales to neurologists,
psychiatrists and geriatric physicians in the past and is not trained in this
area. We will be required to incur additional selling expenses to develop our
sales staff to sell Cognex, and we risk delays and inefficiencies in the sale of
Cognex pending completion of our sales force development for these purposes.
If the Cognex acquisition closes, we will sell the product outside the United
States and we have no experience with international sales and regulations.
If the Cognex transaction closes, we intend to actively market Cognex both
in the United States and abroad. We have no experience selling products outside
the United States. We are not familiar with registering or obtaining other
regulatory approvals outside of the United States and we have no international
marketing presence or sales force. We intend to enter into a transition services
agreement with Warner-Lambert under which it will provide some transitional
administrative services to us until November 30, 2000 in connection with the
sale of Cognex in specified European countries. We currently have no
arrangements for third party support to sell and market Cognex in Europe, or to
provide administrative, selling and marketing services for international markets
other than several specified countries in Europe. To the extent we are unable to
obtain, either internally or from third parties, necessary administrative and
selling and marketing services for international sales of Cognex, we may be
forced to suspend or abandon such sales which accounted for approximately 65% of
1999 sales of Cognex.
Potential adverse side effects may cause the FDA to revoke its approval of
Cognex.
One of Cognex's potential side effects is a short term increase in liver
enzymes which can cause liver malfunction problems. The FDA could decide to
revoke its marketing approval for Cognex based on these side effects.
Cognex has declining sales and new competing products may further erode its
sales.
We believe worldwide sales of Cognex declined from $11.8 million in 1998 to
$7.7 million in 1999. We also face competition from existing and new Alzheimer
drugs. For instance, Pfizer Inc. began marketing "Aricept", a product for the
treatment of conditions associated with Alzheimer's disease, in 1997. Aricept
has some marketing advantages over Cognex including that it is a once a day
formulation and that it does not require liver monitoring. Novartis Inc.
recently received FDA approval to market another product for the treatment of
conditions associated with Alzheimer's disease called "Excellon". Novartis
currently markets this product worldwide. Shire Pharmaceuticals Group plc and
Janssen Pharmaceutica have entered into an agreement to co-market a product
called "Remanyl" for patients suffering from Alzheimer's disease. The FDA has
not approved
11
<PAGE> 16
Remanyl yet, however these companies have marketed the product in other
countries. The marketing and selling of Excellon and Remanyl may further erode
sales of Cognex.
We may not be able to obtain rights to market Cognex CR.
Because Cognex CR has not yet been approved by the FDA, we must obtain such
approval before we can market Cognex CR. In addition, a third-party controls the
manufacture and the intellectual property rights for the drug delivery system of
Cognex CR. If we are not able to obtain a license from this third-party or enter
into a manufacturing and supply agreement with this party, we may not be able to
manufacture or market and sell Cognex CR.
The FTC may order us to return Cognex to Warner-Lambert.
Our agreement to acquire Cognex states that the FTC may order us to return
Cognex to Warner-Lambert to then be sold by Warner-Lambert to a third party if
we voluntarily cease to sell Cognex for 60 days or more, or we otherwise fail to
pursue good efforts to sell Cognex in the United States, other than for reasons
outside our control. In addition, the FTC may order us to return Cognex to
Warner-Lambert if we fail to pursue the sale and manufacture or third party
manufacture of Cognex within one year from receiving FTC approval, subject to an
extension.
RISKS RELATED TO OUR OFFERING
AFTER THE OFFERING, EXISTING OFFICERS, DIRECTORS AND OUR PRINCIPAL STOCKHOLDER
WILL RETAIN A SUBSTANTIAL BLOCK OF STOCK THAT WILL ALLOW THEM TO ELECT DIRECTORS
AND DIRECT THE OUTCOME OF MATTERS REQUIRING STOCKHOLDER APPROVAL.
After the offering, our officers, directors and principal stockholder will
beneficially own approximately 65% of our outstanding common stock.
Kapoor-Pharma Investments, L.P. will own approximately 53% of our outstanding
common stock after the offering. As majority stockholder, Kapoor-Pharma
Investments has the power to elect all of our directors. As long as
Kapoor-Pharma Investments has the right to elect a majority of the board of
directors, it will hold significant control or influence over our policies and
acts. John N. Kapoor, Ph.D., one of our directors, is president and sole
shareholder of EJ Financial Enterprises, Inc. EJ Financial Enterprises is the
managing general partner of Kapoor-Pharma Investments, L.P. In addition,
Mahendra G. Shah, Ph.D., our Chairman and Chief Executive Officer, is
vice-president of EJ Financial Enterprises.
THE MARKET PRICE OF OUR COMMON STOCK AFTER THE OFFERING MIGHT NOT EXCEED THE
OFFERING PRICE.
Prior to this offering, there was no public market for our common stock,
and a significant public trading market may not develop or continue after this
offering. We and the underwriters determined the initial public offering price
through negotiations. If the market price of the common stock after the offering
does not exceed the initial public offering price, investors will not realize
any return on their investment. If the market price of the common stock after
the offering is less than the initial public offering price, investors may lose
some or all of their investment.
OUR STOCK PRICE COULD BE VOLATILE AND COULD DECLINE.
The market prices for securities of drug companies are highly volatile.
Various factors, including factors that are not related to our operating
performance, may cause significant volume and price fluctuations in the market.
The following factors may cause fluctuations in our stock price:
- fluctuations in operating results;
- rates of product acceptance;
12
<PAGE> 17
- timing or delay of regulatory approvals, including our migraine product
under development or our line extension of Robinul to treat symptoms
associated with excessive salivation;
- whether third-party manufacturers experience interruptions in the supply
of raw materials or encounter regulatory problems;
- failure to meet financial estimates or expectations of securities
analysts;
- developments in or disputes regarding patent or other proprietary rights;
and
- future sales of substantial amounts of common stock by our existing
stockholders.
FUTURE SALES OF OUR COMMON STOCK IN THE PUBLIC MARKET AFTER THE OFFERING COULD
CAUSE THE PRICE OF OUR COMMON STOCK TO DECLINE.
Our shareholders could sell substantial amounts of our common stock in the
public market following the offering. As a result, the aggregate number of
shares of our common stock available to the public would increase and,
consequently, the price of our common stock could fall. We cannot predict the
timing or amount of future sales of shares of our stock or the effect, if any,
that market sales of shares, or the availability of shares for sale, will have
on the prevailing market price of our common stock. Upon completion of the
offering, we will have 12,339,643 outstanding shares of common stock, assuming
no exercise of outstanding options. Of these shares, the 3,800,000 shares sold
in this offering will be freely tradeable. This leaves 8,539,643 currently
outstanding shares that will be eligible for sale in the public market as
follows:
- 100,000 available for immediate sale on the date of this prospectus; and
- 8,439,643 available for sale 180 days after our stock begins trading on
the Nasdaq National Market, subject in some cases to volume and other
restrictions
In addition, 1,767,500 shares are issuable upon the exercise of currently
outstanding options. These shares will be eligible for sale 180 days after our
stock begins trading on the Nasdaq National Market, subject in some cases to
restrictions contained in stock option agreements which defer the exercisability
of the options.
After this offering, we expect to file a registration statement covering
shares of common stock issuable upon exercise of options and other grants under
our stock plans. This will allow shares purchased upon the exercise of such
options to be sold in the public markets, subject in some cases to volume and
other restrictions.
ANTI-TAKEOVER PROVISIONS COULD DISCOURAGE A THIRD PARTY FROM MAKING A TAKEOVER
OFFER THAT COULD BE BENEFICIAL TO STOCKHOLDERS.
Some of the provisions in our Restated Certificate of Incorporation and
bylaws, and the anti-takeover provisions under Delaware Law could delay or
prevent a third party from acquiring us or replacing members of our board of
directors, even if the acquisition or the replacements would be beneficial to
our stockholders. These provisions could also reduce the price that certain
investors might be willing to pay for shares of our common stock and result in
the market price being lower than it would be without these provisions. Our
charter documents contain anti-takeover devices including:
- only one of the three classes of directors is elected each year;
- stockholders cannot amend our bylaws unless at least two-thirds of the
shares entitled to vote approve it;
- our board of directors can issue shares of preferred stock without
shareholder approval under any terms, conditions, rights and preferences
that the board determines; and
13
<PAGE> 18
- stockholders must give advance notice to nominate directors or to submit
proposals for consideration at stockholder meetings.
STOCKHOLDERS WILL EXPERIENCE SUBSTANTIAL DILUTION IN THE NET TANGIBLE BOOK VALUE
OF THEIR COMMON STOCK.
Investors will suffer immediate and substantial dilution. The initial
public offering price per share will significantly exceed the net tangible book
value per share of ($0.22). Accordingly, investors will suffer immediate and
substantial dilution. This dilution will result because our existing investors
paid substantially less than the initial public offering price when they bought
their shares of our common stock. The exercise of outstanding options to
purchase our common stock will result in further dilution to new investors.
THE NET PROCEEDS FROM THE OFFERING MAY BE ALLOCATED IN WAYS WITH WHICH YOU AND
OTHER STOCKHOLDERS MAY NOT AGREE.
Except for repayment of our bridge loan with LaSalle Bank, the payment of a
$200,000 fee to Inpharmakon Corporation under our amended development agreement
and the payment of our promissory note with Warner-Lambert, management will have
significant flexibility in applying the net proceeds of this offering.
Therefore, management could use these proceeds for purposes other than those
contemplated at the time of the offering.
14
<PAGE> 19
TRADENAMES AND TRADEMARKS USED IN THIS PROSPECTUS
We own or have rights to tradenames and registered trademarks that we use
in connection with the sale of our products. We have filed an application to
register the trademark Zebutal in the United States. We own the U.S. registered
trademarks Ponstel(R), Tanafed(R), Protuss(R), Mescolor(R), Zoto-HC(R) and
Defen(R). If we complete our acquisition of Cognex, we will acquire the U.S.
registered trademark Cognex(R) and its international counterparts currently held
by Warner-Lambert. Nitrolingual(R), Robinul(R) and TIMERx(R) are registered U.S.
trademarks of G. Pohl Boskamp GmbH & Co., American Home Products Corporation and
Penwest Pharmaceuticals Co., respectively.
FORWARD-LOOKING STATEMENTS
Many statements made in this prospectus under the captions "Summary," "Risk
Factors," "Management's Discussion and Analysis of Financial Condition and
Results of Operations" and "Business" and elsewhere are forward-looking
statements that are not based on historical facts. Because these forward-looking
statements involve risks and uncertainties, there are important factors that
could cause actual results to differ materially from those expressed or implied
by these forward-looking statements, including those discussed under "Risk
Factors."
The forward-looking statements made in this prospectus relate only to
events as of the date on which the statements are made.
USE OF PROCEEDS
We estimate that the net proceeds from the sale of the 3,800,000 shares of
common stock that we are offering will be $44,942,000 after deducting estimated
offering expenses and assuming an initial public offering price of $13.00 per
share. If the underwriters' over-allotment option is exercised in full, assuming
an initial public offering price of $13.00 per share, we estimate that the net
proceeds will be $51,833,300.
We anticipate using the net proceeds from this offering as follows: for
general corporate purposes, including the development of new products, the
expansion of our sales and marketing force, new product acquisitions, repayment
of approximately $12,680,000 of debt outstanding as of April 14, 2000 under the
term loan and bridge loan of our credit facility with LaSalle Bank, repayment of
$3,500,000 under our promissory note with Warner-Lambert and payment of a
$200,000 fee due under our amended product development agreement with
Inpharmakon Corporation. If we acquire Cognex, we will use $3,500,000 of the net
proceeds to fund the acquisition.
Borrowings under the term loan bear interest at our choice of either the
prime rate of interest or LIBOR plus 2%, and the note matures on May 2, 2001.
Borrowings under the bridge loan, which we used to purchase Ponstel, bear
interest at our choice of the prime rate of interest or LIBOR plus 1.5%.
Borrowings under the bridge loan mature on our receipt of the proceeds from this
offering. Our promissory note with Warner-Lambert, which we entered into to pay
the remaining amount of the purchase price of Ponstel, is interest-free and
matures upon our receipt of the proceeds from this offering.
We will retain broad discretion over the use of the net proceeds of this
offering. The amounts and timing of the expenditures may vary significantly
depending on numerous factors, such as the progress of our development efforts,
technological advances and the competitive environment for our products. We
might also use a portion of the net proceeds to acquire or invest in
complementary businesses, products and technologies. Other than the agreement to
acquire Cognex and other than as described under "Business -- Product
Development", we are not currently a party to any agreements to acquire or
invest in any new businesses, products or technologies. However, we regularly
review opportunities for new acquisitions and investments.
15
<PAGE> 20
Pending use of the net proceeds, we intend to invest the net proceeds in
short-term, interest-bearing, investment-grade securities.
DIVIDEND POLICY
We have never paid cash dividends on our common stock. The payment of cash
dividends is subject to the discretion of our board of directors and will be
dependent upon many factors, including our earnings, our capital needs and
general financial condition. We anticipate that for the forseeable future, we
will retain earnings, if any, in order to finance the expansion and development
of our business. Our credit facility prohibits the payment of any dividends or
other distributions on any shares of our stock.
16
<PAGE> 21
CAPITALIZATION
The following table sets forth as of March 31, 2000, the actual
capitalization of our company and our capitalization, as adjusted to reflect the
issuance and sale of the 3,800,000 shares of common stock we are offering at an
assumed public offering price of $13.00 per share and the use of the proceeds
from the offering to repay $3,720,000 of debt outstanding as of March 31, 2000.
This table should be read in conjunction with our financial statements and the
notes to the financial statements and "Management's Discussion and Analysis of
Financial Condition and Results of Operations."
<TABLE>
<CAPTION>
AS OF MARCH 31, 2000
----------------------------------
ACTUAL AS ADJUSTED
----------- --------------------
<S> <C> <C>
Borrowings under revolving credit facility.............. $ 2,000,000 $ 0
Long-term debt, including current portion............... 2,575,708 855,708
Stockholders' equity:
Preferred stock, $0.001 par value; 1,000,000 shares
authorized, no shares outstanding, actual and as
adjusted........................................... -- --
Common stock, $0.001 par value; 40,000,000 shares
authorized, 8,539,643 shares issued and outstanding
in 1999 and 12,339,643 as adjusted shares issued
and outstanding.................................... 8,540 12,340
Additional paid-in capital.............................. 5,788,220 50,726,420
Deferred compensation................................... (1,197,105) (1,197,105)
Accumulated deficit..................................... (935,353) (935,353)
----------- ------------
Total stockholders' equity.................... 3,664,302 48,606,302
----------- ------------
Total capitalization.......................... $ 8,240,010 $ 49,462,010
=========== ============
</TABLE>
The number of shares of common stock to be outstanding after this offering
does not include:
- 1,767,500 shares issuable upon exercise of options outstanding as of May
3, 2000, at a weighted average exercise price of $1.61 per share; and
- 570,000 shares issuable pursuant to the underwriters' over-allotment
option.
The board of directors approved the grant of options under our 2000 Stock
Plan to purchase 187,950 shares subject to completion of this offering at an
exercise price equal to the initial public offering price per share in this
offering. Following this grant, there will be 1,812,050 shares available for
future grants under this plan.
17
<PAGE> 22
DILUTION
Our net tangible book value as of March 31, 2000 was ($1.865) million, or
($0.22) per share of common stock. Net tangible book value per share represents
the amount of total tangible assets less total liabilities divided by the number
of shares of common stock outstanding at that date. After giving effect to the
sale of the 3,800,000 shares of common stock at an assumed initial public
offering price of $13.00 per share, and after deducting underwriting discounts
and commissions and estimated offering expenses, our as adjusted net tangible
book value as of March 31, 2000 would have been $43.077 million, or $3.49 per
share. This represents an immediate increase in pro forma net tangible book
value of $3.71 per share to existing stockholders, and an immediate dilution of
$9.51 per share to new investors. The following table illustrates this per share
dilution:
<TABLE>
<S> <C> <C>
Assumed initial public offering price per share............. $13.00
Net tangible book value per share at March 31, 2000....... ($0.22)
Increase per share attributable to new investors.......... 3.71
------
Pro forma net tangible book value per share after this 3.49
offering..................................................
------
Dilution per share to new investors......................... $ 9.51
======
</TABLE>
The following table summarizes, on an as adjusted basis as of March 31,
2000, the differences between the number of shares of common stock that we
issued, the total consideration paid and the average price per share paid by
existing stockholders and by the new investors purchasing shares in this
offering at an assumed initial public offering price of $13.00 per share.
<TABLE>
<CAPTION>
SHARES ISSUED TOTAL CONSIDERATION AVERAGE
-------------------- --------------------- PRICE
NUMBER PERCENT AMOUNT PERCENT PER SHARE
---------- ------- ----------- ------- -------------
<S> <C> <C> <C> <C> <C>
Existing
stockholders......... 8,539,643 69.2% $ 4,234,900 8.6% $ 0.50
New investors.......... 3,800,000 30.8 44,942,000 91.4 11.83
---------- ----- ----------- -----
Total........ 12,339,643 100.0% 49,176,900 100.0%
========== ===== =========== =====
</TABLE>
The discussion regarding dilution and these tables assumes no exercise of
any outstanding stock options. The discussion does not include: (a) 1,767,500
shares issuable upon exercise of options outstanding under our 1997
Non-Qualified Stock Option Plan at a weighted average exercise price of $1.61 or
(b) 570,000 shares issuable at an assumed price of $13.00 per share pursuant to
the underwriters' over-allotment option. The board of directors approved the
grant of options to purchase 187,950 shares under our 2000 Stock Plan subject to
completion of this offering, at an exercise price equal to the public offering
price per share in this offering. Following this grant, there will be 1,812,050
shares available for future grants under our 2000 Stock Plan.
18
<PAGE> 23
SELECTED FINANCIAL DATA
The following selected financial data is qualified by reference to and
should be read in conjunction with, our financial statements and the related
notes and other financial information included elsewhere in this prospectus, as
well as "Management's Discussion and Analysis of Financial Condition and Results
of Operations". The selected financial data as of December 31, 1997, 1998, and
1999 and for the years ended December 31, 1997, 1998, and 1999 were derived from
our financial statements that have been audited by Arthur Andersen LLP,
independent public accountants. The selected financial data as of December 31,
1995 and 1996 and March 31, 1999 and 2000 were derived from unaudited financial
statements which, in the opinion of management, include all adjustments,
consisting only of normal recurring accruals, necessary for a fair presentation
of our financial condition and results of operations. These results may not be
indicative of future results.
<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31,
-------------------------------------------------------------------
1995 1996 1997 1998 1999
----------- ----------- ----------- ----------- -----------
(UNAUDITED) (UNAUDITED)
<S> <C> <C> <C> <C> <C>
STATEMENT OF OPERATIONS DATA:
Net revenues.......................... $ 1,620,720 $ 2,516,616 $ 5,557,700 $ 9,252,058 $18,624,514
Operating costs and expenses:
Cost of revenues..................... 329,692 489,905 1,136,691 1,903,054 3,140,416
Selling, general and administrative
expenses, excluding non-cash
compensation expense............... 1,302,766 2,393,018 4,545,254 6,789,358 12,400,439
Non-cash selling, general and
administrative expense............. -- -- 133,500 -- 143,986
Depreciation and amortization........ 25,977 28,878 30,273 35,225 424,274
Research and development............. -- -- -- 255,000 860,350
----------- ----------- ----------- ----------- -----------
Total operating costs and expenses:... 1,658,435 2,911,801 5,845,718 8,982,637 16,969,465
Operating (loss) income............... (37,715) (395,185) (288,018) 269,421 1,655,049
Other (expense) income:
Interest expense..................... (54,310) (67,461) (5,496) (14,017) (356,598)
Interest income...................... -- 3,314 2,909 4,383 11,950
Other................................ -- -- 3,629 (2,749) 8,059
----------- ----------- ----------- ----------- -----------
Total other (expense) income.......... (54,310) (64,147) 1,042 (12,383) (336,589)
----------- ----------- ----------- ----------- -----------
(Loss) income before benefit
(provision) for income taxes......... (92,025) (459,332) (286,976) 257,038 1,318,460
Benefit (provision) for income
taxes................................ -- 114,984 106,530 (121,484) (547,996)
----------- ----------- ----------- ----------- -----------
Net (loss) income..................... $ (92,025) $ (344,348) $ (180,446) $ 135,554 $ 770,464
=========== =========== =========== =========== ===========
Net (loss) income per common share:
Basic................................ $ (0.02) $ (0.06) $ (0.02) $ 0.02 $ 0.10
=========== =========== =========== =========== ===========
Diluted.............................. $ (0.02) $ (0.06) $ (0.02) $ 0.02 $ 0.09
=========== =========== =========== =========== ===========
Weighted average common shares
outstanding:
Basic................................ 5,636,137 5,830,000 7,576,580 7,978,234 8,028,673
=========== =========== =========== =========== ===========
Diluted.............................. 5,636,137 5,830,000 7,576,580 8,584,329 8,975,493
=========== =========== =========== =========== ===========
<CAPTION>
THREE MONTHS ENDED
---------------------------------
MARCH 31, 1999 MARCH 31, 2000
--------------- ---------------
(UNAUDITED) (UNAUDITED)
<S> <C> <C>
STATEMENT OF OPERATIONS DATA:
Net revenues.......................... $4,199,934 $ 7,119,638
Operating costs and expenses:
Cost of revenues..................... 719,432 1,061,737
Selling, general and administrative
expenses, excluding non-cash
compensation expense............... 2,550,153 5,491,653
Non-cash selling, general and
administrative expense............. 10,722 87,269
Depreciation and amortization........ 79,302 114,639
Research and development............. 142,945 375,292
---------- -----------
Total operating costs and expenses:... 3,502,554 7,130,590
Operating (loss) income............... 697,380 (10,952)
Other (expense) income:
Interest expense..................... (55,758) (72,060)
Interest income...................... 2,197 5,591
Other................................ 2,450 9,822
---------- -----------
Total other (expense) income.......... (51,111) (56,647)
---------- -----------
(Loss) income before benefit
(provision) for income taxes......... 646,269 (67,599)
Benefit (provision) for income
taxes................................ (270,368) 29,068
---------- -----------
Net (loss) income..................... $ 375,901 $ (38,531)
========== ===========
Net (loss) income per common share:
Basic................................ $ 0.05 $ (0.00)
========== ===========
Diluted.............................. $ 0.04 $ (0.00)
========== ===========
Weighted average common shares
outstanding:
Basic................................ 7,981,248 8,539,643
========== ===========
Diluted.............................. 8,759,904 8,539,643
========== ===========
</TABLE>
<TABLE>
<CAPTION>
AS OF DECEMBER 31,
------------------------------------------------------------------- AS OF MARCH 31,
1995 1996 1997 1998 1999 2000
----------- ----------- ----------- ----------- ----------- --------------------
(UNAUDITED)
<S> <C> <C> <C> <C> <C> <C>
BALANCE SHEET DATA:
Cash and cash equivalents............ $ 71,652 $ 30,986 $ 244,766 $ 425,023 $ 219,688 $ 735,337
Working capital...................... 188,995 (645,249) 687,426 640,090 (733,884) (1,002,183)
Total assets......................... 643,639 834,238 1,758,872 2,933,101 11,077,744 13,683,087
Borrowings under revolving loan
agreement........................... -- -- -- 602,928 800,000 2,000,000
Long-term debt including current
portion............................. -- -- -- -- 2,898,886 2,575,708
Accumulated deficit.................. (1,278,046) (1,622,394) (1,802,840) (1,667,286) (896,822) (935,353)
Total stockholders' (deficit)
equity.............................. (131,660) (477,011) 814,326 956,130 3,615,564 3,664,302
</TABLE>
19
<PAGE> 24
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
OVERVIEW
We currently market and sell 12 brand name prescription drugs through our
nationwide sales and marketing force of 133 professionals. We seek to acquire
and obtain licenses for pharmaceutical products that other companies do not
actively market and to increase sales through aggressive promotion and
marketing. As part of this strategy, on April 14, 2000, we acquired exclusive
rights to distribute, market and sell Ponstel in the United States, and entered
into an agreement to acquire exclusive rights in the United States and other
countries to distribute, market and sell Cognex, pending FTC approval and other
conditions. In addition, we seek to increase the value of existing products by
developing new formulations and new delivery methods, and seeking new
indications for existing products.
We have historically increased revenues and seek to increase revenues in
the future from our ability to make product acquisitions and increase sales of
current products.
QUARTERS ENDED MARCH 31, 2000 AND MARCH 31, 1999
Net Revenues. Revenues from product sales are recognized upon shipment to
customers and are shown net of sales adjustments. Net revenues are net of
provisions for discounts, rebates to customers, returns, and other adjustments
which are provided in the same period that the related sales are recorded. Net
revenues for the quarter ended March 31, 2000 were $7,120,000 compared to
$4,200,000 for the quarter ended March 31, 1999, a 70% increase. Of this
increase, $2,698,000 is due to our commencing sales of Zebutal in January 1999,
Robinul and Robinul Forte in February 1999 and Nitrolingual Pumpspray in
February 2000. Sales of products sold prior to 1999 or "existing products"
increased $222,000 due to expansion of our sales force into new territories and
increased demand for our products. Deductions from revenue increased $781,000
due to higher Medicaid rebates primarily on Robinul and Robinul Forte, higher
customer rebates for sales of Nitrolingual Pumpspray, and higher discounts due
to customers taking advantage of our prompt pay discount.
Net revenues for the quarter ended March 31, 2000 do not include the effect
of sales of Ponstel. We acquired Ponstel in April 2000, and believe that Ponstel
had annual sales of $3,264,000 in 1999.
Cost of Revenues. Cost of revenues for the quarter ended March 31, 2000
were $1,062,000, compared to $719,000 for the quarter ended March 31, 1999, a
48% increase. Costs of revenues for the quarter ended March 31, 2000 do not
include the cost of revenues for Ponstel.
Gross Margin. Gross margin for the quarter ended March 31, 2000 was 85%,
compared to 83% for the quarter ended March 31, 1999. This increase primarily
resulted from the higher gross margin earned on Robinul and Robinul Forte. Gross
margin for the quarter ended March 31, 2000 does not include the effect of net
revenues and cost of sales of Ponstel. We believe that the gross margin earned
on Ponstel will be comparable to our current gross margin for all products
currently sold.
Selling, General and Administrative Expenses. Selling, general and
administrative expenses consist of salaries, commissions, bonuses, training and
education costs, sample and promotional costs, royalty and commission payments
to product licensors, office expenses, travel expenses, payroll taxes, rent and
utilities, insurance, outside professional services, taxes, bad debts and other
general office expenses. Selling, general and administrative expenses for the
quarter ended March 31, 2000 were $5,492,000, compared to $2,550,000 for the
quarter ended March 31, 1999, a 115% increase. Selling related expenses
increased due to the addition of sales force representatives, increased
commission expense due to higher sales and increased salaries for existing sales
representatives. We also incurred significantly higher marketing and promotional
expense due to the launch of Nitrolingual Pumpspray and increased sampling.
Royalty expense increased due to
20
<PAGE> 25
increased sales of Robinul and Robinul Forte, and due to royalties on sales of
Nitrolingual Pumpspray. Also, on January 1, 2000, we entered into a licensing
agreement with Jame Fine Chemicals, Inc., a supplier of a raw material for
Tanafed. Under the terms of the agreement, we began paying royalties based on
net sales of Tanafed. There was no comparable royalty expense on Tanafed for the
quarter ended March 31, 1999. Management expects selling expenses to continue to
increase for the remainder of 2000 due to marketing and promotional expenses for
the launch of Ponstel and due to continued sales force expansion.
General and administrative expenses increased due to the addition of
managers and support personnel in our corporate headquarters, increased
insurance cost, and higher reserves for doubtful accounts. In addition, in March
2000, we engaged a consulting firm to make recommendations on the alignment and
optimization of our sales force.
Non-Cash Selling, General and Administrative Expense. Non-cash selling,
general and administrative expense for the quarter ended March 31, 2000 were
$87,000, compared to $11,000 for the quarter ended March 31, 1999. This increase
resulted from our issuing stock options at exercise prices that were less than
the market value of our stock at the time of issuance, as determined by an
independent valuation.
Depreciation and Amortization Expense. Depreciation and amortization
expense was $115,000 for the quarter ended March 31, 2000, compared to $79,000
for the quarter ended March 31, 1999, a 46% increase. This increase resulted
from higher amortization expense related to the January 1999 acquisition of
Robinul and Robinul Forte and increased depreciation expense on furniture,
computers and software used in our corporate headquarters.
Research and Development Expense. Research and development expenses
consist primarily of costs incurred to develop formulations, engage contract
research organizations to conduct clinical studies, test products under
development and engage medical and regulatory consultants. We expense all
research and development costs as incurred. Research and development expense was
$375,000 for the quarter ended March 31, 2000, as compared to $143,000 for the
quarter ended March 31, 1999, a 162% increase. This increase resulted from
continued development of our migraine headache product. Also, on January 1, 2000
we entered into the licensing agreement with Jame Fine Chemicals. Under the
terms of the agreement, we paid an up-front license fee of $225,000. We do not
owe any other licensing fees under our agreements, however we will continue to
incur significant research and development expenses as we continue to develop
our migraine headache product. We expect to incur approximately $1,300,000 of
research and development expenses during the remainder of 2000 related to the
development of the migraine headache product.
Interest Expense. Interest expense was $72,000 for the quarter ended March
31, 2000, compared to $56,000 for the quarter ended March 31, 1999, a 29%
increase. This increase resulted from higher average borrowings under our credit
facility.
Income Tax Benefit. The company recorded an income tax benefit of $29,000
for the quarter ended March 31, 2000, compared to a provision for income taxes
of $270,000 for the quarter ended March 31, 1999. This $299,000 change resulted
from the company incurring a pre-tax loss for the quarter ended March 31, 2000
versus pre-tax income for the quarter ending March 31, 1999.
YEARS ENDED DECEMBER 31, 1999 AND DECEMBER 31, 1998
Net Revenues. Net revenues for the year ended December 31, 1999 were
$18,625,000, compared to $9,252,000 for the year ended December 31, 1998, a 101%
increase. Of this increase, $6,206,000 resulted from product acquisitions and
licensing agreements made in 1999, or from products that earned revenues for the
first time in 1999. Sales of existing products were $12,419,000, a $3,167,000 or
34% increase over 1998. This increase primarily resulted from the expansion of
our sales force, increased marketing efforts and the continued increase in
demand for our products as a
21
<PAGE> 26
result of current and prior efforts of our sales force. Rebates and other sales
allowances were $2,156,000 in 1999 primarily related to Medicaid rebates on
Robinul and Robinul Forte.
Net revenues for 1999 do not include the effect of sales of Nitrolingual
Pumpspray or Ponstel. We began selling Nitrolingual Pumpspray in February, 2000
and acquired Ponstel in April, 2000. We believe the U.S. sales of Nitrolingual
were $12,000,000 in 1998, and sales of Ponstel were $3,264,000 in 1999.
Cost of Revenues. Cost of revenues for the year ended December 31, 1999
were $3,140,000, compared to $1,903,000 for the year ended December 31, 1998, a
65% increase. Cost of revenues for 1999 do not include the costs of revenues for
Nitrolingual or Ponstel.
Gross Margin. Gross margin for the year ended December 31, 1999 was 83%,
compared to 79% in 1998. The increase in gross margin primarily resulted from
the higher gross margin earned on Robinul and Robinul Forte which we began
selling in February 1999.
Gross margin for 1999 and 1998 does not include the effect of net revenues
and cost of revenues for Nitrolingual Pumpspray or Ponstel. We believe that the
gross margin for Nitrolingual Pumpspray and Ponstel will be comparable to our
current gross margin for all products currently sold.
Selling, General and Administrative Expenses. Selling, general and
administrative expenses for the year ended December 31, 1999 were $12,400,000,
compared to $6,789,000 for the year ended December 31, 1998, an 83% increase.
Selling-related expenses increased over the previous year due to increased
expenses related to sales force expansion, higher commission and royalty
payments and larger sample, marketing and promotional costs. General and
administrative expenses increased over the previous year due to increased
compensation and related expenses, and increased costs as a result of relocation
of our corporate offices from a 7,603-square-foot facility to a
24,300-square-foot facility in September 1998.
Management expects a significant increase in selling expenses during 2000
due to increased marketing expenses associated with the company's launch of
Nitrolingual Pumpspray and Ponstel. Management also expects an increase in
selling expenses due to expansion of the company's sales force in 2000. In
addition, selling expenses in 2000 and beyond will include royalty expenses and
sales representative commissions for Nitrolingual Pumpspray. The company did not
incur any royalty expense or commission expense for Nitrolingual Pumpspray in
1999.
Non-cash Selling, General and Administrative Expense. Non-cash
compensation expenses were $144,000 for the year ended December 31, 1999,
compared to no expense for the year ended December 31, 1998. This expense
resulted from our issuing stock options in 1999 at exercise prices that were
less than the market value of our stock at time of issuance, as determined by an
independent valuation.
Depreciation and Amortization Expenses. Depreciation and amortization
expenses were $424,000 for the year ended December 31, 1999, compared to $35,000
for the year ended December 31, 1998. This increase primarily resulted from
amortization expense related to the purchase in 1999 of Robinul and Robinul
Forte.
Amortization expenses will increase in 2000 and beyond to reflect
amortization expense related to the company's acquisition of Ponstel in April
2000. This expense could further increase if the company concludes any other
product acquisitions.
Research and Development Expenses. Research and development expenses were
$860,000 for the year ended December 31, 1999, compared to $255,000 for the year
ended December 31, 1998. This increase resulted from our continuing development
of a new product for the treatment of migraine headache and our continuing
development of a line extension of Robinul for the treatment of symptoms
associated with excessive salivation.
22
<PAGE> 27
The company will continue to incur significant research and development
expenses as it continues to develop the migraine headache product. Management
anticipates that the company will incur approximately $1,600,000 of research and
development cost in 2000 related to the migraine headache product and
approximately $3,000,000 in subsequent years through 2002 related to conducting
clinical trials, filing a new drug application and making payments to Penwest
Pharmaceuticals Co., Impharmakon Corporation and Parexel International under our
development agreements.
Interest Expense. Interest expense for the year ended December 31, 1999
was $357,000, compared to $14,000 for the year ended December 31, 1998. The
$343,000 increase resulted primarily from borrowings for the acquisition of
Robinul and Robinul Forte.
Interest Income. Interest income for the year ended December 31, 1999 was
$12,000, compared to $4,000 for the year ended December 31, 1998. This $8,000
increase resulted from increased average cash balances resulting from improved
financial performance.
Income Tax Expense. Income tax expense for the year ended December 31,
1999 was $548,000, compared to $121,000 for the year ended December 31, 1998.
The $427,000 increase resulted from increased pre-tax income.
YEARS ENDED DECEMBER 31, 1998 AND DECEMBER 31, 1997
Net Revenues. Net revenues for the year ended December 31, 1998 were
$9,252,000, compared to $5,558,000 for the year ended December 31, 1997, a 66%
increase. The increase resulted from the expansion of our sales force from 47
sales representatives and three district managers at the end of 1997 to 69 sales
representatives and three district managers at the end of 1998 and the continued
increase in demand for our products as a result of prior efforts of our sales
force.
Cost of Revenues. Cost of revenues for the year ended December 31, 1998
were $1,903,000, compared to $1,137,000 for the year ended December 31, 1997, a
67% increase.
Gross Margin. Gross margins for the years ended December 31, 1998 and 1997
were 79%.
Selling, General and Administrative Expenses. Selling, general and
administrative expenses for the year ended December 31, 1998 were $6,789,000,
compared to $4,545,000 for the year ended December 31, 1997, a 49% increase.
Selling-related expenses increased over the previous year due to increased
expenses related to sales force expansion, higher commission and royalty
payments and larger sample, marketing and promotional costs. General and
administrative expenses increased over the previous year due to increased
compensation and related expenses, and increased costs as a result of relocation
of our corporate offices from a 7,603-square-foot facility to a
24,300-square-foot facility in September, 1998.
Non-cash Selling, General and Administrative Expense. We had non-cash
compensation expenses of $0 for the year ended December 31, 1998, compared to
$134,000 for the year ended December 31, 1997. The 1997 non-cash compensation
expense resulted from our issuing stock options in 1997 at exercise prices that
were less than the market value of our stock at the time of issuance, as
determined by an independent valuation.
Research and Development Expenses. Research and development expenses were
$255,000 for the year ended December 31, 1998, compared to no expenses for the
year ended December 31, 1997. We paid $200,000 in development fees to
Inpharmakon Corporation for the fee for licensing our migraine product under
development.
Depreciation and Amortization Expense. Depreciation and amortization
expense was $35,000 for the year ended December 31, 1998, compared to $30,000
for the year ended December 31, 1997, a 17% increase. The increase resulted from
purchases of computers for new personnel and furniture related to our corporate
office relocation.
23
<PAGE> 28
Interest Income. Interest income for the year ended December 31, 1998 was
$4,000, compared to $3,000 for the year ended December 31, 1997. The $1,000
increase resulted from increased average cash balances resulting from improved
financial performance.
Interest Expense. Interest expense for the year ended December 31, 1998
was $14,000, compared to $5,000 for the year ended December 31, 1997. The $9,000
increase resulted primarily from borrowings on our line of credit with LaSalle
Bank.
Income Tax Expense. Income tax expense for the year ended December 31,
1998 was $121,000, compared to a benefit of $107,000 for the year ended December
31, 1997. The $228,000 increase resulted from 1998 being our first profitable
operating year.
LIQUIDITY AND CAPITAL RESOURCES
Our liquidity requirements arise from debt service, working capital
requirements and funding of acquisitions. We have met these cash requirements
through cash from operations, proceeds from our line of credit, borrowings for
product acquisitions, and the issuance of common stock to our majority
stockholder.
Our cash and cash equivalents were $735,000 at March 31, 2000. Our cash and
cash equivalents at December 31, 1999, 1998 and 1997 were $220,000, $425,000 and
$245,000, respectively. Net cash used in operating activities for the quarter
ended March 31, 2000 was $273,000. This use of cash was primarily the result of
increased purchases of inventories primarily for our launch of Nitrolingual
Pumpspray, partially offset by an increase in accounts payable and accrued
expenses. Net cash provided by operating activities for the year ended 1999 was
$1,018,000. Our sources of cash were primarily from net income and increases in
accounts payable and accrued expenses partially offset by increases in accounts
receivable, inventories and deferred taxes. Net cash used in operating
activities for the years ended 1998 and 1997 was $181,000 and $196,000,
respectively. Our use of net cash was primarily a result of increases in
accounts receivable and inventories partially offset by increases in deferred
taxes, accounts payable and accrued expenses plus net income. We expect to incur
significant cash for operating activities in the future in connection with the
development of our migraine product. We expect to incur approximately $1,300,000
of research and development expenses payable to Penwest Pharmaceuticals Co.
through the end of 2000 and approximately $3,000,000 in 2001 and 2002 payable to
Penwest Pharmaceuticals Co., Inpharmakon Corporation and Parexel International.
Net cash used in investing activities for the quarter ended March 31, 2000
was $69,000 for the purchase of property and equipment for our corporate
headquarters. We purchased intangible assets in 1999 for $4,000,000 in cash with
an additional $1,800,000 financed by the seller of the assets. As a part of the
acquisition, we also assumed estimated liabilities of $218,000 for returns of
products shipped by the seller prior to the acquisition date. In addition, we
spent $186,000 for the purchase of property and computer related items in 1999.
Net cash used in investing activities in 1998 and 1997 was $208,000 and
$121,000, respectively. These investments were primarily for the purchase of
property and computer related items.
Net cash provided by financing activities for the quarter ended March 31,
2000 was $858,000. This cash was the result of increased borrowings from our
line of credit, offset by payments on long term debt. During 1999, we borrowed
$4,000,000 and incurred indebtedness of $1,800,000 for the purchase of
intangible assets. In 1999, we also made payments of $1,235,000 on long-term
debt and had a net increase of $197,000 on our revolving line of credit. During
1998, we borrowed $563,000 under our revolving line of credit. During 1997, we
financed our capital requirements by raising $550,000 through the issuance of
stock to our majority shareholder.
In May 1998, we entered into a credit facility with LaSalle Bank National
Association which was subsequently amended and currently consists of a revolving
loan, a term loan and a bridge loan. The revolving loan is subject to borrowing
base limitations and inventory balances. The
24
<PAGE> 29
revolving credit facility provides for borrowings of up to $3,500,000 which
reduces to $2,500,000 on June 30, 2000. Borrowings under the revolving credit
facility bear interest at the bank's prime rate, and are due on May 2, 2001. At
March 31, 2000, the outstanding balance under the revolving loan was $2,000,000
with an interest rate of 9.00%, and we had additional availability under the
terms of the facility of $1,500,000. We borrowed $2,400,000 under our term loan
facility in January 1999 bearing interest at our choice of either LaSalle's
prime rate or LIBOR plus 2%. The term loan is repayable in monthly payments of
$40,000 plus accrued interest and matures on May 2, 2001. At March 31, 2000
outstanding indebtedness under the term loan was $1,720,000 with an interest
rate of 7.53%. We plan to repay this term loan in full with proceeds from this
offering.
On April 14, 2000, the credit facility was amended to provide for bridge
financing of up to $13,000,000 to finance product acquisitions. On April 14,
2000, we borrowed $9,500,000 under this bridge loan for our purchase of Ponstel.
We will borrow an additional $3,500,000 to purchase Cognex if we conclude this
acquisition prior to conclusion of this offering. Borrowings under the bridge
loan bear interest at our choice of the prime rate of interest or LIBOR plus
1.5%. Interest on the bridge loan is payable monthly beginning on May 1, 2000.
Borrowings under the bridge loan mature on our receipt of the proceeds from this
offering.
As a condition to entering into the bridge loan, LaSalle Bank required that
the bridge loan be secured by a pledge by the 1992 Kapoor Children's Trust to
LaSalle Bank of an interest in securities and investments in the amount of
$10,000,000. We entered into a Reimbursement Agreement with the Trust on April
14, 2000 to obtain this pledge of assets. As consideration for this pledge, we
will pay the Trust a fee in of $100,000 per year, pro rated for the amount of
time that the pledge is in effect, plus all of the Trust's expenses incurred in
connection with the Reimbursement Agreement.
Our credit facility with LaSalle Bank is secured by our accounts
receivable, inventories, equipment and intangible assets including our
intellectual properties.
Under the terms of our credit facility, we must maintain a minimum net
worth plus subordinated debt of $3,300,000 plus 75% of net income, a ratio of
liabilities to net worth plus subordinated debt after the conclusion of this
offering of 2.25 to 1.00, a minimum specified EBITDA, and a fixed charge
coverage ratio ranging from .75 to 1.00 to 1.25 to 1.00. The credit facility
also limits our ability to incur additional indebtedness, and prohibits
substantial asset sales and cash dividends.
On April 14, 2000, we also issued a promissory note to Warner-Lambert
evidencing $3,500,000 of the purchase price of Ponstel. This promissory note is
interest-free and matures upon our receipt of the proceeds from this offering.
We expect that the proceeds from this offering, cash from operations and
borrowings under our credit facility will be adequate to fund our current
operations and current working capital requirements for the next eighteen
months. In the event that we make significant future product acquisitions, we
expect that we will need to raise additional funds. Adequate funds for these
purposes, whether through the financial markets or from other sources, may not
be available when needed or on terms acceptable to us. Insufficient funds may
cause us to delay, scale back or abandon some or all of our future product
acquisition opportunities.
Our future capital requirements and the adequacy of our available funds
will depend on many factors, including:
- the timing and cost of product acquisitions and licensing agreements;
- regulatory approval of our migraine product under development and the
Robinul product extension;
- size and scope of our development efforts for additional products;
- cost, timing and outcomes of regulatory reviews;
25
<PAGE> 30
- expansion of our sales and marketing force;
- determinations as to the commercial potential of our products under
development;
- status of competitive products;
- defending and enforcing intellectual property rights; and
- establishment, continuation or termination of third-party manufacturing
agreements.
IMPACT OF INFLATION
We have experienced only moderate price increases under our agreements with
third-party manufacturers as a result of raw material and labor price increases.
We have passed these price increases along to our customers.
SEASONALITY
Although our business is generally non-seasonal, sales of certain products,
such as cough and cold products, increase slightly between October and March due
to the cold and flu season. We expect the impact of seasonality to decrease as
we acquire or obtain licenses for products that treat chronic conditions.
However, we anticipate that the seasonality may continue to affect sales for the
foreseeable future.
RECENT ACCOUNTING PRONOUNCEMENTS
In June 1998, the FASB issued SFAS No. 133, "Accounting for Derivative
Instruments and Hedging Activities." We must adopt SFAS No. 133 for the year
ending December 31, 2000. SFAS No. 133 established methods of accounting for
derivative financial instruments and hedging activities related to those
instruments as well as other hedging activities. Adoption of SFAS No. 133 is not
expected to have a material impact on our financial condition or results of
operations.
QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISKS
Our operating results and cash flows are subject to fluctuations from
changes in foreign currency exchange rates and interest rates.
Our purchases of Nitrolingual Pumpspray under our agreement with
Pohl-Boskamp are made in German Deutsche marks. Our next purchase obligation
under this agreement is payable on May 24, 2000 and we expect to make purchases
several times per year. In connection with our currently pending purchase
obligation, based on our evaluation of exchange rates with the German Deutsche
mark on April 10, 2000, we purchased a contract payable in $543,200 of U.S.
dollars at an exchange rate of 2.025 Deutsche marks to the dollar to satisfy our
purchase obligation on May 24, 2000. While the effect of foreign currency
translations has not been material to our results of operations to date,
currency translations on export sales or import purchases could be adversely
affected in the future by the relationship of the U.S. dollar with foreign
currencies.
To the extent that following conclusion of this offering we borrow under
our credit facility with LaSalle Bank, we will experience market risk with
respect to changes in the general level of the interest rates and its effect
upon our interest expense. Borrowings under our credit facility with LaSalle
Bank bear interest at variable rates. Because such rates are variable, an
increase in interest rates will result in additional interest expense and a
reduction in interest rates will result in reduced interest expense.
26
<PAGE> 31
BUSINESS
OVERVIEW
We currently market and sell 12 brand name prescription drugs to
high-prescribing primary care and select specialty physicians through our
nationwide sales and marketing force of 133 professionals. Since our formation,
we have introduced 12 products including two line extensions. Our strategy is to
acquire and obtain licenses for pharmaceutical products that other companies do
not actively market and to increase sales through aggressive promotion and
marketing. In addition, we seek to increase the value of existing products by
developing new formulations and new delivery methods, and seeking new
indications. We incorporated in 1992 as the surviving corporation of a merger in
July 1992 between Century Pharmaceutical Corporation and Horizon Pharmaceutical
Corporation. The company originally promoted over-the-counter cough and cold
products. In late 1992, we launched the prescription cough and cold products
Defen-LA and Protuss Liquid and began focusing on prescription drugs for chronic
conditions.
Our key products include Nitrolingual, Robinul and Robinul Forte, and
Tanafed. In 1999, we acquired marketing rights to Robinul and Robinul Forte from
American Home Products Corporation and to Nitrolingual from Pohl-Boskamp. In
February 2000, we began marketing a new version of this product called
Nitrolingual Pumpspray. We have marketed Tanafed since 1993. We recently entered
into development agreements with Penwest Pharmaceuticals Co. and Inpharmakon
Corporation for a product that we are developing for the treatment of migraine
headache. We are also currently developing a line extension of Robinul to treat
symptoms associated with the excessive production of saliva.
Our net revenues have grown from approximately $1.6 million for the year
ended December 31, 1995 to approximately $18.6 million for the year ended
December 31, 1999. We achieved this from a combination of increased sales of
existing products and product acquisitions and licenses.
On April 14, 2000, we acquired exclusive rights to market, distribute and
sell Ponstel in the United States from Warner-Lambert and entered into an
agreement to acquire exclusive rights from Warner-Lambert to market, distribute
and sell Cognex in the United States and other countries, pending FTC approval
and the satisfaction of other customary conditions.
FIRST HORIZON STRATEGY
We believe that our ability to market, acquire and develop brand name
products and our ability to increase our sales and improve our marketing
infrastructure uniquely positions us to continue to grow. We focus on products
that treat chronic conditions primarily because patients and physicians remain
loyal to such products. This results in repeat use over an extended period of
time, generates recurring consistent revenue streams and lowers marketing costs
necessary to maintain existing sales.
The key elements of our strategy include:
- Increase sales of products through targeted promotion. We seek to
increase sales by promoting our products to high-prescribing primary care
and specialty physicians through our nationwide sales and marketing force
that includes 133 professionals. We also use targeted direct mail and
telemarketing to promote our products.
- Identify and license or acquire brand name prescription products. We
seek to acquire the rights to brand name pharmaceutical products that we
believe will benefit from increased marketing efforts to high-prescribing
primary care and specialty physicians, leverage our existing sales
infrastructure, complement our existing products and have the potential
for market exclusivity.
27
<PAGE> 32
- Develop proprietary products and line extensions. We seek to reduce the
costs and risks of development by focusing on drugs that the FDA has
already approved in the United States. We plan to develop products,
including line extensions of our current drugs, using patent-protected
delivery systems or formulations that offer market differentiation and
the potential for market exclusivity.
PRODUCTS
We currently market and sell the following products:
<TABLE>
<CAPTION>
DATE OF
PRODUCT INTRODUCTION PRODUCT INDICATION
- ------- -------------------- ------------------
<S> <C> <C>
Ponstel.......................... 2000 Relief of mild to moderate pain
for patients 14 years of age and
older for therapies lasting less
than a week and for painful
menstruation
Nitrolingual Pumpspray........... 2000 Acute relief or prevention of an
attack of angina pectoris due to
heart disease
Robinul and Robinul Forte........ 1999 Adjunctive therapy for the
treatment of peptic ulcer
Zebutal Capsules................. 1999 Tension headache
Protuss DM Tablets............... 1997 Cough and congestion
Mescolor Tablets................. 1994 Allergy and runny nose
Protuss-D Liquid................. 1994 Cough and congestion
Zoto-HC Ear Drops................ 1994 Swimmer's ear infections
Tanafed Suspension............... 1993 Allergy and cold
Defen-LA Tablets................. 1992 Cough and cold
Protuss Liquid................... 1992 Cough and congestion
</TABLE>
We have entered into an agreement to acquire rights to Cognex pending FTC
approval and the satisfaction of other customary conditions. The FDA has
approved Cognex under a new drug application for the treatment of mild to
moderate dementia associated with Alzheimer's disease.
The FDA approved Ponstel, Nitrolingual Pumpspray, Robinul and Robinul Forte
under new drug applications. The FDA also approved an abbreviated new drug
application for Zebutal. Our other products are classified by the FDA as drugs
that may be marketed without submitting safety and efficacy data.
Nitrolingual
On February 1, 2000, we began marketing Nitrolingual Pumpspray for which we
acquired from Pohl-Boskamp exclusive distribution rights in the United States.
Nitrolingual Pumpspray is an oral spray of nitroglycerin used for the acute
relief or prevention of chest pain associated with angina pectoris that results
from heart disease. Pohl-Boskamp holds a patent that was issued in 1993 on the
formulation of Nitrolingual.
Aventis previously had the rights to market the chlorofluorocarbon (CFC)
version of this product named Nitrolingual Spray. We believe that Nitrolingual
Pumpspray has marketing advantages over Nitrolingual Spray. Unlike the previous
version, Nitrolingual Pumpspray is packaged in a translucent, plastic-coated
glass bottle, that allows patients to easily see the amount
28
<PAGE> 33
of product left in the bottle. In addition, Nitrolingual Pumpspray does not
contain CFC, making it environmentally friendly.
The primary competitor to Nitrolingual Pumpspray is nitroglycerin tablets.
Unlike tablets, which begin to lose their potency immediately upon opening the
bottle, Nitrolingual Pumpspray maintains its potency for two years. Further,
studies have shown that Nitrolingual Pumpspray provides for more rapid
absorption than the tablets. Each metered dose provides for consistent delivery
of nitroglycerin. Also, unlike the tablets, Nitrolingual Pumpspray requires no
special storage or handling to maintain its potency.
According to the American Heart Association, about 6.2 million Americans
suffer from angina pectoris.
Robinul and Robinul Forte
On January 29, 1999, we acquired exclusive rights in the United States to
Robinul and Robinul Forte, which is a higher-strength dosage of Robinul. Both
Robinul and Robinul Forte belong to a class of drugs known as anticholinergics,
which reduce the motion of the gastrointestinal tract. The FDA has approved both
products for use as a therapy in conjunction with other therapeutics in the
treatment of peptic ulcer. Compared to other anticholinergics, the Robinul
product line has an overall better side effect profile and is longer acting,
thereby requiring fewer doses. We are currently developing a line extension and
will seek regulatory approval to use the active ingredient in Robinul to treat
symptoms associated with the excessive production of saliva. Since acquiring the
products, we have substantially increased the sales of Robinul and Robinul
Forte. Industry sources estimate that the U.S. market for anticholinergics was
$130 million in 1999.
Tanafed
Tanafed is a liquid cold and allergy product marketed for children. We
believe that pediatricians prescribe Tanafed because it is effective and
children prefer its taste. The National Center for Health Statistics estimated
that 20 million days were lost from school in 1994 due to colds.
Cough, Cold and Allergy Products
Our other products for the treatment of cough, cold and allergy are
Defen-LA Tablets, Mescolor Tablets and the Protuss product line, which includes
Protuss Liquid, Protuss DM Tablets and Protuss-D Liquid.
Ponstel
On April 14, 2000, we acquired exclusive rights from Warner-Lambert to
market, distribute and sell Ponstel in the United States. Ponstel has been
manufactured and marketed by Warner-Lambert or its affiliates. Ponstel capsules
are used for the relief of mild to moderate pain for patients 14 years of age
and older if therapy will be for less than one week and for primary
dysmenorrhea, which is pain associated with menstruation.
According to the American Pain Foundation, one in three American adults
lose more than twenty hours of sleep each month due to pain. Pain costs an
estimated $100 billion each year and lost workdays due to pain add up to over 50
million days a year. One class of frequently prescribed pain relievers is
nonsteroidal anti-inflammatory drugs ("NSAIDs"). Ponstel is a well known NSAID
and we believe that its advantages are its non-addictive qualities, low
stomach-related side effects and efficacy.
29
<PAGE> 34
Cognex
On April 14, 2000, we entered into an agreement with Warner-Lambert to
purchase exclusive rights in the United States and other countries to market,
distribute and sell Cognex, as well as rights to a new unapproved controlled
release version of Cognex. Our acquisition of this product is subject to FTC
approval of the transaction and the satisfaction of customary conditions. Cognex
is marketed by Warner-Lambert or its affiliates and manufactured by one of its
affiliates. Cognex tablets are used for the treatment of mild to moderate
dementia associated with Alzheimer's disease.
Alzheimer's disease is a progressive, degenerative disease that attacks the
brain and results in impaired memory, thinking and behavior. Although no cure
for Alzheimer's disease is currently available, good planning and medical and
social management can ease the burdens on the patient and family. According to
the Alzheimer's Association, approximately 4 million Americans have Alzheimer's
disease. Cognex is one of only three FDA-approved drug treatments for mild to
moderate dementia associated with Alzheimer's disease.
Cognex is currently sold in twenty-one countries, including the United
States. We intend to actively market the product in the United Sates and in
Europe and intend to enter into an agreement with Warner-Lambert to provide
transitional administrative services in specific European countries until
November 30, 2000. In order for us to continue to sell Cognex outside the United
States, we will be required to obtain, either internally or through third
parties, the necessary administrative and marketing and selling support
services.
Other Products
We sell Zoto-HC ear drops for the treatment of swimmer's ear infections and
Zebutal Capsules for the treatment of tension headaches. A study has shown that
approximately nine out of ten people have at least one headache in any given
year. Headaches account for approximately 18 million outpatient visits annually
to hospitals and healthcare clinics.
PRODUCT DEVELOPMENT
We seek to maximize the value of drugs by developing new patentable
formulations, using new delivery methods and seeking regulatory approval for new
indications. Through the use of these distinct formulations and patent-protected
delivery systems, we plan to create a marketing advantage over generic drugs and
reduce substitution by the pharmacist. Some of these development projects
include line extensions which allow us to extend the life cycle of our key
products. We expect the strength of extensive literature-based clinical data on
the active ingredients in our products under development, current acceptance and
usage of the active ingredients in these products by healthcare professionals,
and the safety profile of the active ingredients in approved products will
reduce development costs and risks associated with FDA approval.
Migraine Product (FHPC 01)
We are developing a proprietary formulation of a product named FHPC 01 for
the treatment of migraine headaches, which contains an active ingredient that is
currently approved by the FDA for other indications. We have entered into a
development agreement with Penwest Pharmaceuticals Co. to develop a product
using Penwest's patented TIMERx controlled-release technology. Penwest has also
granted us the right to reference their Drug Master File as necessary for us to
file a new drug application for this product. A Drug Master File is a submission
to the FDA, often in support of a new drug application, that companies may use
to provide confidential, detailed information about facilities, processes or
articles used in the manufacturing, processing, packaging and storing of one or
more human drugs. We have developed a once a day formulation for this product
and we filed an investigational new drug application for this product on
February 17, 2000 which has been
30
<PAGE> 35
accepted by the FDA. We have engaged Parexel International to conduct clinical
trials for this product. A study has shown that an estimated 23.6 million
Americans suffer from migraine headaches. Of these, approximately half suffer
from migraines that are moderately to severely disabling.
Excessive Salivation Product (FHPC 02)
We are developing a product named FHPC 02 for the treatment of the symptoms
associated with the excessive production of saliva primarily in children. This
product will be a line extension of our Robinul products. We have entered into
an agreement with Mikart to develop a new dosage form. We plan to initiate
clinical trials and file for a supplementary new drug application to market the
product. Excessive salivation, also known as Sialorrhea, is a socially
embarrassing condition that occurs in patients who suffer from cerebral palsy
and Parkinson's disease.
Formulation and Clinical Trials
We generally seek to contract third parties to formulate, develop and
manufacture materials needed for clinical trials and to perform scale-up work.
We select third-party contractors that we believe have the capability to
commercially manufacture the products. By selecting qualified third parties
capable of both developing formulations and providing full-scale manufacturing
services, we believe we will be able to shorten development and scale-up times
necessary for production. The key advantage to this approach is that the
third-party contractor will have the equipment, operational parameters and
validated testing procedures already in place for the commercial manufacture of
our products. Our management team has experience in selecting and managing
activities of third-party contract companies.
SALES AND MARKETING
To maximize the effectiveness of our selling efforts, our sales force
focuses on high-prescribing primary care and select specialty physicians. Our
sales force seeks to develop close relationships with these physicians and
respond to their needs. We intend to enhance our existing marketing and sales
channels to expand and increase the penetration of our products. We have
expanded our sales and marketing force to 133 professionals nationwide.
We sell our products to pharmaceutical wholesalers (who in turn distribute
to pharmacies), chain drug stores, other retail merchandisers and, on a limited
basis, directly to pharmacies. In 1999, sales to our top five pharmaceutical
wholesalers accounted for over 72% of all of our sales. Three of the five
wholesalers each accounted for 10% or more of all of our sales: McKessonHBOC
(28%), Cardinal Health (19%) and Bergen Brunswig (10%).
We have traditionally targeted our sales efforts in areas with low
managed-care penetration in which it is easier to establish a presence. In
addition, we have a group of sales professionals that focuses exclusively on
building relationships with managed-care organizations that can be leveraged
across markets. We continue to strengthen this group to gain access to
formularies and develop long-term working relationships that may lead to
adoption of our products.
During 1999, our Robinul line accounted for 27.5% of our revenues and our
cough, cold and allergy products accounted for 57.5% of our revenues. During
1998, our cough, cold and allergy products accounted for 82.0% of our revenues
and Zoto-HC accounted for 18.0% of our revenues. During 1997, our cough, cold
and allergy products accounted for 80.9% of our revenues and Zoto-HC accounted
for 19.1% of our revenues.
31
<PAGE> 36
THIRD-PARTY AGREEMENTS
Nitrolingual Pumpspray
In July 1999, we acquired from Pohl-Boskamp the exclusive rights to
distribute, market and sell Nitrolingual Pumpspray beginning on February 1, 2000
in the United States for five years plus an additional five-year renewal period
subject to establishing mutually acceptable minimum purchase requirements. Under
the agreement, Pohl-Boskamp supplies us with our requirements of product at
prices that decrease as volume purchased in each year increases. We must
purchase designated minimum quantities in each year of the agreement and pay a
royalty on net sales of the product. Also, Pohl-Boskamp can terminate our
distribution agreement for Nitrolingual if a company with a product competitive
with Nitrolingual acquires direct or indirect influence or control over our
company, or if a very significant change in our stockholders occurs so that
Kapoor-Pharma Investments and Horizon employees, management, directors, and any
of their respective affiliates, do not in the aggregate directly or indirectly
beneficially own at least 20% of our shares.
Aventis had exclusive rights through January 2000, to a version of the
product containing CFC named Nitrolingual Spray. To promote earlier adoption of
Nitrolingual Pumpspray, we obtained exclusive marketing rights from Aventis to
market Nitrolingual Spray in the United States as of November 22, 1999. We
promoted Nitrolingual Spray for a short period of time to reduce inventories of
the product in the distribution channels. Since the launch of Nitrolingual
Pumpspray, we have not marketed this CFC product.
Robinul/Robinul Forte
On January 29, 1999, we acquired exclusive rights in the United States to
Robinul and Robinul Forte tablets from American Home Products Corporation. We
will pay the $647,302 aggregate remaining portion of the purchase price
quarterly through February 2001. In addition, we must pay royalties on net
sales. We negotiated for American Home Products Corporation or its designee to
continue to manufacture and supply the product to us until January 29, 2001. We
have an agreement with Mikart, dated April 23, 1999, for Mikart to become
qualified under applicable regulations to manufacture and supply our
requirements for Robinul. Under this agreement, Mikart will manufacture the
products for five years from the time Mikart becomes a qualified manufacturer
plus renewal terms of one year until either party elects not to renew. The
agreement with Mikart requires that we purchase certain designated minimum
quantities.
Tanafed
On January 1, 1996, we obtained exclusive distribution rights from
Unisource, Inc. to Tanafed in North America through December 31, 2003 plus an
additional seven years at our option. The agreement requires us to purchase all
of our requirements for Tanafed from Unisource, including at least certain
minimum quantities of Tanafed in each year of the agreement. We entered into a
patent license agreement with Jame Fine Chemicals, Inc., a supplier of a raw
material for Tanafed, effective January 1, 2000. This agreement grants us a
semi-exclusive license to use, sell and distribute finished products containing
an active ingredient used in Tanafed. The licensed patent covers the
manufacturing process of an active ingredient used in Tanafed. The license
continues through the life of the licensed patent which expires in 2014. We paid
an upfront license fee and agreed to pay certain royalties based on net sales of
Tanafed at rates which we believe are within industry customary ranges. Another
party also has a license for one of the active ingredients in Tanafed.
Migraine Product (FHPC 01)
On October 31, 1998, we entered into an agreement with Inpharmakon
Corporation in which we acquired rights to the proprietary information for the
migraine product FHPC 01 for which we plan to conduct clinical studies and
submit a new drug application. The agreement expires on
32
<PAGE> 37
October 31, 2008, but we may renew it indefinitely after expiration. On May 3,
2000, we entered into an amendment to this agreement in which Inpharmakon
Corporation released us from all previous claims that Inpharmakon Corporation
may have had under the agreement, and deleted the required time within which we
must commence clinical trials and file for regulatory approval of the product.
Under the amended agreement, we must develop a workable once-a-day formulation
for the drug, conduct clinical trials, and file for and exert reasonable efforts
to obtain regulatory approval for the drug. If we do not obtain regulatory
approval of the drug within three years after filing for such approval and
thereafter commence and continue to aggressively market and sale the product,
Inpharmakon may terminate the agreement. In the event that Inpharmakon
terminates the agreement for failure to achieve these milestones, Inpharmakon
may purchase rights to develop the drug at our costs to date. We must also pay
up to an aggregate of $950,000 in non-refundable fees to Inpharmakon at various
developmental milestones through and including regulatory approval of the
product, and, in the event of commercial sales of the product, we must pay
royalties at rates which we believe are within industry customary ranges. We
must also pay Inpharmakon $200,000 within 30 days after this offering. If we
elect to sell the business opportunity to a third party, we must share the
proceeds of the sale with Inpharmakon.
On March 25, 1999, we acquired rights from Penwest Pharmaceuticals Co. to
use Penwest's TIMERx controlled-release technology to develop a product
containing the active ingredient in FHPC 01. Under the Penwest agreement, we
have the right to manufacture, use and sell the developed product in North
America and Mexico for a period extending fifteen years from the date a new drug
application is issued for the product, as well as a license under certain
Penwest patents. We must pay Penwest up to an aggregate of approximately
$2,600,000 of non-refundable fees upon achieving specified development
milestones through the first anniversary of the first commercial sale of the
product following regulatory approval and royalties upon any sales of the
migraine product at rates which we believe are within industry customary ranges.
Penwest may terminate the agreement in the event we fail to timely achieve
designated performance milestones within prescribed time periods.
Ponstel
On April 14, 2000, we acquired exclusive rights from Warner-Lambert to
market, distribute and sell Ponstel in the United States. The total purchase
price for the rights to Ponstel was $13 million. We paid $9.5 million in cash,
which we borrowed under a bridge loan from LaSalle Bank, and issued a promissory
note to Warner-Lambert for $3.5 million for the rights to this product. Under
the asset purchase agreement, we purchased the following:
- the U.S. Ponstel trademark;
- all regulatory approvals and regulatory applications for Ponstel in the
United States, including its new drug application;
- all technical information, know-how and market research results relating
to the manufacture, packaging, testing, development, distribution,
marketing, use and sale of Ponstel, including the raw materials used in
its manufacture; and
- managed care agreements used for the sale of Ponstel.
Under this agreement, we also assumed certain specified and customary
liabilities and obligations arising out of our ownership of Ponstel which arise
after the closing of the transaction.
In addition we agreed to purchase all of the current inventories of Ponstel
for approximately $100,000.
On April 14, 2000, we also entered into a supply agreement under which
Warner-Lambert will supply and we will purchase designated quantities of Ponstel
until December 31, 2000. We will pay Warner-Lambert an agreed upon price for the
supply of Ponstel. We plan to secure a replacement
33
<PAGE> 38
manufacturer for Ponstel in the near future and are currently in negotiations
with a potential manufacturer.
Cognex
On April 14, 2000, we entered into an agreement with Warner-Lambert to
purchase exclusive rights in the United States and other countries to market,
distribute and sell Cognex as well as rights to a new unapproved version of
Cognex, called Cognex CR. The purchase of Cognex is contingent on Warner-Lambert
receiving FTC approval for the transaction and the satisfaction of other
customary conditions. If we acquire Cognex, we will be required to pay $3.5
million in cash for the product. Warner-Lambert may terminate this agreement if
the transaction has not closed by June 30, 2000, unless it has not closed
because of a delay in receiving FTC approval. The purchase agreement provides
for the purchase of the following:
- the U.S. Cognex trademark and its international counterparts;
- certain patent rights relating to the use of an active ingredient in
Cognex to treat conditions associated with Alzheimer's disease.
- all worldwide regulatory approvals and regulatory applications for
Cognex, including its new drug application in the United States;
- all technical information, know-how and market research results relating
to the manufacture, packaging, testing, development, distribution,
marketing, use and sale of Cognex, including the raw materials used in
its manufacture;
- all of the royalties that Warner-Lambert has prepaid with respect to a
patent covering the use of an active ingredient in Cognex; and
- all promotional materials related to Cognex, including advertising,
promotional and sales training materials owned by Warner-Lambert.
In addition, we acquired rights to a new unapproved version of Cognex,
called Cognex CR. We must pay Warner-Lambert up to $1.5 million in additional
purchase price if we obtain FDA approval to market Cognex CR. If approved,
Cognex CR will also treat mild to moderate dementia associated with Alzheimer's
disease, but we believe that the new version will offer convenience to patients
by reducing the number of tablets required from four times per day to one time
per day. Warner-Lambert has provided us with the new drug application package
for our use in seeking this approval from the FDA and international regulatory
authorities. We may have to undertake additional clinical studies for this
approval.
Under this agreement, if the Cognex transaction closes, we must submit
reports to the FTC regarding the status of FDA approvals of Cognex and our
efforts to market the product. In the event that we voluntarily stop selling
Cognex for 60 days or more, or we otherwise fail to pursue good efforts to sell
Cognex in the United States other than for reasons outside our control, the FTC
may order that Cognex revert back to Warner-Lambert and be divested by the FTC
to another purchaser. In addition, the FTC may order us to return Cognex if we
fail to pursue the sale and manufacture or third party manufacture of Cognex
within one year from receiving FTC approval, subject to an extension.
Under the purchase agreement for the Cognex transaction, we will be
required to pay royalties on net sales of Cognex. However, we will be entitled
to apply the amount of royalties that Warner-Lambert has prepaid for these
patents and we do not expect to pay significant royalties in the near future.
The asset purchase agreement for Cognex provides for a supply agreement
under which an affiliate of Warner-Lambert will manufacture and supply to us
either Cognex or the active ingredient in Cognex for two years after the Cognex
transaction closes, subject to a one year
34
<PAGE> 39
renewal. We will pay an agreed upon price for the supply of Cognex and the
active ingredient. The supply agreement contains designated quantities of Cognex
and its active ingredient that Warner-Lambert's affiliate will supply to us and
that we must purchase. We plan to secure a replacement manufacturer for Cognex
and are currently in negotiations with a potential manufacturer.
Pursuant to the purchase agreement, we intend to enter into a transition
services agreement with Warner-Lambert under which it will provide transitional
administrative services to us until November 30, 2000 in connection with the
sale of Cognex in certain specified European countries. These services will
include maintenance of Cognex registrations, contact with regulatory authorities
including reporting requirements, responding to customer complaints, sales
administration, shipping management, billing, processing of returns, storage,
responding to any regulatory inquiries or investigations, responding to any
customer complaints and communicating with physicians in relation to the
product. Warner-Lambert may terminate this agreement if any person or entity
acquires ownership or control of 50% or more of our common stock or acquires
substantially all of our assets.
Other Products
Generally, our other products are manufactured pursuant to manufacturing
and supply agreements for remaining terms ranging from one to five years.
Generally, these agreements require that we purchase all of our requirements for
these products from the manufacturers which are a party to these agreements,
including specified minimum purchase quantities of the product for each year.
Except for our Defen-LA, Protuss-D and Zoto-HC products, these agreements
generally state that the product supplier will provide products only to us.
MANUFACTURERS AND SINGLE SOURCE SUPPLIERS
We use third-party manufacturers for the production of our products for
development and commercial purposes. Given the general under-utilization of
resources, the availability of excess capacity for manufacturing in the
marketplace, and the lower cost of outsourcing, we intend to continue to
outsource our manufacturing for the near-term.
We currently use the services of seven third-party manufacturers for our
products. These manufacturers manufacture our products pursuant to our product
specifications. We have manufacturing and supply agreements with six of these
manufacturers. The terms of these agreements generally range from two years to
ten years except that we have a transitional supply agreement with
Warner-Lambert for Ponstel which expires December 31, 2000. Under some of these
agreements, the manufacturers or other third-parties own the rights to the
product that we have under our marketing licenses. We have not entered into
agreements for alternative manufacturing sources for any of our products. The
suppliers of Nitrolingual Pumpspray and the raw material for Tanafed hold
patents relating to their respective products. The patents may provide us with a
competitive advantage because the patents create a barrier to entry to other
companies that might otherwise seek to develop similar products.
TRADEMARKS
Because of the large number of products on the market which compete with
our products, we believe that our brand names are an important factor in
establishing product recognition. We have a U.S. registered trademark for
Horizon Pharmaceutical and have filed for the trademark for First Horizon
Pharmaceutical. Our products are sold under a variety of trademarks registered
in the United States, including Ponstel, Zoto-HC, Protuss, Mescolor, Defen and
Tanafed. We have filed for the trademark Zebutal. Further, we have been licensed
rights to use the Nitrolingual and Robinul trademarks in the United States from
Pohl-Boskamp and American Home Products, respectively. We have rights to the
TIMERx trademark pursuant to our rights to market the product we have under
development with Penwest. If we acquire Cognex, we will own the U.S. rights to
the Cognex
35
<PAGE> 40
trademark and its international counterparts. Our trademark registrations could
be challenged by others which could result in the loss of use of one or more of
our trademarks. Maintenance of our trademarks requires that we enforce our
rights by preventing infringement by third parties, and we may not have the
resources to stop others from infringing our trademarks.
PATENTS
We consider the protection afforded by patents important to our business.
We intend to seek patent protection in the United States and selected foreign
countries where deemed appropriate for products we develop.
Nitrolingual Pumpspray
By virtue of our distribution agreement with Pohl-Boskamp for Nitrolingual
Pumpspray, we are afforded marketing exclusivity arising from Pohl-Boskamp's
1993 U.S. patent relating to the product. This patent expires in 2010.
Tanafed
We entered into a licensing agreement with the raw material supplier for
our Tanafed product effective January 1, 2000. This agreement grants us a
license to market and distribute Tanafed for which the manufacturer has a patent
covering the manufacturing process of one of its active ingredients. This patent
expires in 2014.
Migraine Product (FHPC 01)
Pursuant to our development agreement with Penwest for a once-a-day
migraine product, we are the licensee of certain Penwest patents for the purpose
of manufacturing and marketing the product under development. These patents
expire from 2008 through 2016.
Active Ingredient in Robinul/Robinul Forte
In 1999, we filed a patent application directed to the use of
glycopyrrolate for the treatment of certain new indications. Glycopyrrolate is
the active ingredient in Robinul and Robinul Forte.
Cognex
In the event we acquire Cognex pursuant to our purchase agreement with
Warner-Lambert, we may acquire certain patent rights relating to the use of an
active ingredient in Cognex to treat conditions associated with Alzheimer's
disease. These patents expire from 2001 to 2007.
COMPETITION
The market for drugs is highly competitive with many established
manufacturers, suppliers and distributors actively engaged in all phases of the
business. We believe that competition in the sale of our products is based
primarily on price, service, availability and product efficacy. Our brand-name
pharmaceutical products may be subject to competition from alternate therapies
during the period of patent protection and thereafter from generic equivalents.
Some of our products have generic equivalents in the marketplace.
We also compete with other pharmaceutical companies for new products and
product line acquisitions. These competitors include Dura Pharmaceuticals, Inc.,
Forest Laboratories, Inc., Watson Pharmaceuticals, Inc., King Pharmaceuticals,
Inc., Shire Pharmaceuticals Group plc, Jones Pharma Inc. and other companies
that acquire branded product lines from other pharmaceutical companies.
36
<PAGE> 41
GOVERNMENT REGULATION
According to the Federal Food, Drug, and Cosmetic Act ("FDC Act"), all new
drugs are subject to premarket approval by the FDA. Applicable FDA law will
treat our development of new products and new uses for approved products or the
development of any of our line extensions as "new drugs," which requires the
submission of a New Drug Application ("NDA") or a supplemental NDA ("sNDA"), and
approval by the FDA.
The steps required for approval of an NDA or sNDA may include:
- pre-clinical studies;
- submission to the FDA of an Investigational New Drug application ("IND"),
which must become effective before human clinical trials commence;
- adequate and well-controlled human clinical trials to establish the
safety and effectiveness of the product;
- submission of an NDA or an sNDA to the FDA; and
- FDA approval of the NDA or sNDA prior to any commercial sale or shipment
of the product.
Pre-clinical studies generally include laboratory evaluation of product
chemistry and formulation, as well as animal studies, if appropriate, to assess
quality and safety. An applicant submits the results of the pre-clinical studies
with chemistry, manufacturing, and control information and pharmacology and
toxicology data to the FDA as a part of an IND and for review by the FDA prior
to the commencement of human clinical trials. Unless the FDA objects to an IND,
the IND will become effective 30 days following its receipt by the FDA.
Clinical trials involve the administration of the investigational new drug
to humans. The trials are subject to extensive regulation including compliance
with Good Clinical Practices, obtaining informed patient consent and review and
approval of each study by an Institutional Review Board. Clinical trials are
typically conducted in three sequential phases, although phases may overlap. In
Phase I, the investigational new drug usually is administered to healthy human
subjects and is tested for safety. Phase II usually involves studies in a
limited patient population to:
- determine the initial effectiveness of the investigational new drug for
specific indications;
- determine dosage tolerance and optimal dosage; and
- identify possible adverse effects and safety risks.
When an investigational new drug is found to be effective and to have an
acceptable safety profile in Phase II evaluation, Phase III trials are
undertaken to further evaluate clinical effectiveness and to further test for
safety within an expanded patient population. The FDA reviews both the clinical
plans and the results of the trials and may require the study to be discontinued
at any time if there are significant safety issues. In some cases, the FDA can
request Phase IV clinical studies after approval of the NDA. These studies can
be designed to obtain additional safety and efficacy data, detect new uses for
or abuses of a drug, or determine effectiveness for labeled indications under
conditions of widespread usage. These studies can involve significant additional
expenses.
Once the FDA has approved an NDA, the holder of the NDA may request changes
in the conditions of approval contained in its NDA through a sNDA. The format,
content and procedures applicable to NDA supplements are generally the same as
those for NDAs. However, the only information required in a supplement is that
needed to support the requested change. If the NDA or sNDA is based on new
clinical investigations which are essential to the approval of the application,
other than bioavailability studies, it may qualify for a three-year period of
exclusivity, distinct from any applicable patent protection that may exist. The
FDA may also require user fees for prescription drug NDAs or sNDAs. Supplements
proposing to include a new indication for use in pediatric populations are not
subject to user fees.
37
<PAGE> 42
Another form of an NDA is the so-called "505(b)(2)" NDA, which applicants
submit pursuant to Section 505(b)(2) of the FDC Act. This type of NDA permits
the inclusion of safety and effectiveness studies that the applicant has not
conducted or been granted a right of reference by the sponsor of the studies. In
addition, the FDA recommends a 505(b)(2) NDA for a modification, such as a new
dosage form, of a previously approved drug which requires more than merely
bioequivalence data. This NDA is similar to a full NDA, except that, under
conditions prescribed by the FDA, it may be supported in whole or in part by one
or more study investigations published in scientific literature in lieu of the
applicant's clinical trials. We intend to submit this type of application to
market potential product line extensions or new uses of already-approved
products.
In addition, if we submit a certain type of new drug application, the FDA
will require us to certify as to any patent which covers the drug for which we
seek approval. If there is a patent in existence, a certain type of
certification is made and proper notice to the patent holder of our intent to
market the drugs is given, and the patent holder makes an infringement claim
within a specified time period, then the FDA will not approve our marketing
application for thirty months or until the patent litigation is resolved,
whichever occurs sooner. In addition, distinct from patent considerations,
approval of a certain type of new drug application could be delayed because of
the existence of non-patent exclusivity afforded by the FDA for the innovator
drug.
The least burdensome application for new drug approval is the abbreviated
NDA ("ANDA"), which may apply to a new drug that is shown to be bioequivalent to
a drug previously approved by the FDA for safety and effectiveness and listed as
the drug to which bioequivalence must be shown. An applicant may submit an ANDA
for products that are the same as an approved drug regarding active
ingredient(s), route of administration, dosage form, strength and conditions of
use recommended on the labeling. The ANDA requires bioequivalence data and other
technical and manufacturing information, but typically no safety and
effectiveness studies.
Even after obtaining regulatory approval, such approval may require
post-marketing testing and surveillance to monitor the safety of the product. In
addition, the product approval may be withdrawn if compliance with regulatory
standards is not maintained or if problems occur following initial marketing. At
present, companies cannot export pharmaceutical products that cannot be lawfully
sold in the United States unless certain statutorily prescribed conditions are
met.
FDA regulations require that we report adverse events, submit new marketing
and promotional materials, submit changes we plan to make to the product
manufacturing or labeling and comply with recordkeeping requirements and
requirements relating to the distribution of drug samples to physicians. In the
event that we do not comply with the FDA requirements, the manufacture, sales
and distribution of our products may be suspended, and we may be prevented from
obtaining FDA approval of new products.
Our third-party manufacturers must adhere to FDA regulations relating to
current good manufacturing practice ("cGMP") regulations, which include
requirements relating to organization of personnel, buildings and facilities,
equipment, control of components and drug product containers and closures,
production and process controls, packaging and labeling controls, holding and
distribution, laboratory controls, records and reports, and returned and
salvaged products. Ongoing compliance with cGMP procedures, labeling and other
regulatory requirements are monitored through periodic inspections and market
surveillance by state and federal agencies, including the FDA. Failure by our
third-party manufacturers to comply with these rules could result in sanctions
being imposed, including fines, injunctions, civil penalties, suspension or
withdrawal of FDA approvals, seizures or recalls of products, operating
restrictions and criminal prosecutions. In addition, we rely upon our
third-party manufacturers to provide many of the documents that we use to comply
with our FDA reporting requirements for Ponstel, Robinul, Robinul Forte, and
Nitrolingual.
38
<PAGE> 43
In addition, we are subject to fees under the Prescription Drug User Fee
Act for new drug applications for new drug products and sNDAs for new uses,
except that we may qualify for a waiver of the fee for our first new drug
application. We will be responsible for paying these fees for sNDAs and
subsequent submissions, unless we receive approval from the FDA for a waiver,
reduction or refund.
We are also subject to regulation under other federal and state laws,
including the Occupational Safety and Health Act and other environmental laws
and regulations, national restrictions on technology transfer, and import,
export and customs regulations. In addition, some of our products that contain
controlled substances, such as Protuss and Protuss-D, are subject to Drug
Enforcement Administration regulations relating to storage, distribution,
importation and sampling procedures. We have registered with the Drug
Enforcement Administration under the Controlled Substances Act which
establishes, among other things, registration, security and recordkeeping
requirements. We must also comply with federal and state anti-kickback and other
healthcare fraud and abuse laws.
In addition, whether or not we obtain FDA approval, we must obtain approval
of a pharmaceutical product by comparable governmental regulatory authorities in
foreign countries prior to the commencement of clinical trials and subsequent
marketing of such product in such countries. The approval procedure varies from
country to country, and the time required may be longer or shorter than that
required for FDA approval.
REIMBURSEMENT
Our ability to market our products successfully will depend in part on the
extent to which reimbursement for the costs of the products will be available
from government health administration authorities, private health insurers, and
managed care organizations in the United States and in any foreign markets where
we may sell our products. Third-party payors can affect the pricing or relative
attractiveness of our products by regulating the reimbursement they provide on
our products and competing products. Insurance carriers may not reimburse
healthcare providers for use of our products used for new indications. Domestic
and foreign government and third-party payors are increasingly attempting to
contain healthcare costs by limiting both coverage and the level of
reimbursement for new pharmaceutical products.
PRODUCT LIABILITY INSURANCE
We currently maintain a product liability insurance policy. We do not
currently maintain business interruption insurance.
EMPLOYEES
We had 150 full-time employees as of December 31, 1999, including 127 sales
and marketing employees in the field, and 23 in management, finance and
administration. We also maintain active independent contractor relationships
with various individuals with whom we have consulting agreements. We believe our
employee relations are good. None of our employees is subject to a collective
bargaining agreement.
PROPERTIES
We lease a 24,300 square-foot facility in Roswell, Georgia. Our facility
includes space for offices and a warehouse. This lease expires on August 31,
2003. We also lease executive office space on a short-term basis in Raleigh,
North Carolina, and Phoenix, Arizona, for our regional managers. We believe that
our facilities are adequate for our current requirements; however, we anticipate
that as we grow, we will require additional facilities.
LEGAL PROCEEDINGS
From time to time, we may become involved in routine litigation. Currently,
we are not a party to any material legal proceedings.
39
<PAGE> 44
MANAGEMENT
EXECUTIVE OFFICERS AND DIRECTORS
The following are our executive officers and directors as of the date of
this prospectus:
<TABLE>
<CAPTION>
NAME AGE POSITIONS
- ---- --- ---------
<S> <C> <C>
Mahendra G. Shah, Ph.D............ 55 Chairman of the Board and Chief Executive Officer
R. Brent Dixon.................... 55 President and Director
Gregory P. Hauck.................. 33 Secretary and Vice President, Developed Products
Balaji Venkataraman............... 34 Vice President and Chief Financial Officer
Robert D. Godfrey, Jr............. 38 Vice President, Sales
William G. Campbell............... 44 Controller
John N. Kapoor, Ph.D.(1).......... 56 Director
Pierre Lapalme(1)(2).............. 60 Director
Jon S. Saxe(1)(2)................. 63 Director
</TABLE>
- ------------------------------
(1) Member of the Audit Committee.
(2) Member of the Compensation Committee.
Mahendra G. Shah, Ph.D. is the Chairman of the Board and Chief Executive
Officer. Dr. Shah has been a director since 1993, and his present term as
director will expire in 2001. Dr. Shah became Chief Executive Officer in October
1999. Dr. Shah maintains other employment and expects to dedicate a majority of
his working time to the company. From 1991 to the present, he has been a Vice
President of EJ Financial Enterprises, Inc., which manages a fund that invests
in healthcare companies. From 1996 to the present, he has been the President of
Protomed Pharmaceuticals, Inc. which is a privately-held drug development
company. From 1987 to 1991, he was the Senior Director of New Business
Development with Fujisawa USA, Inc. Prior to that time, he worked in various
scientific and management positions with Schering-Plough and Bristol
Myers-Squibb Company. He serves on the board of Structural Bioinformatics Inc.,
Zarix, Introgen Therapeutics and Inpharmakon Corporation. He previously served
on the board of Unimed Pharmaceuticals. Dr. Shah received a Ph.D. degree in
Industrial Pharmacy from St. John's University. EJ Financial Enterprises, Inc.
is the sole shareholder and managing general partner of Kapoor Pharma
Investments, L.P., our largest shareholder.
R. Brent Dixon is the President and a director of the company. He has been
a director since 1993, and his present term as director will expire in 2002. Mr.
Dixon has been with the company since its formation. He has been our President
since 1993 and served as a Vice-President from 1992 to 1993. He has over 30
years of operational, sales, and strategic market development experience in the
pharmaceutical industry. Prior to working at the company, he was President of
Dixon and Associates, a healthcare consulting company. Prior to that he served
as National Sales Manager for Center Laboratories, a subsidiary of Merck AG. Mr.
Dixon has also served as a Regional and District Manager for Roberts
Pharmaceuticals and Adams Laboratories. Mr. Dixon attended St. Petersburg Junior
College and the University of Mississippi.
Gregory P. Hauck is the Secretary and Vice President of Developed Products.
He has been with the company since its formation and has been serving as
Vice-President since 1993. He is responsible for developing product promotional
materials as well as product line marketing strategies. In his previous position
as Vice President of Sales and Marketing for the company from 1994 to 1997, he
was responsible for implementing its sales strategies. Mr. Hauck began working
with the company in 1992 as the National Sales Manager where he was primarily
responsible for the
40
<PAGE> 45
hiring and training of all new sales representatives. He entered the
pharmaceutical industry in 1989 as a sales representative with Hauck
Pharmaceuticals and Roberts Pharmaceuticals. Mr. Hauck received a B.S. degree in
Education from the University of Georgia and, afterwards, spent a brief period
of time as an educator.
Balaji Venkataraman has been the Vice President and Chief Financial Officer
since October 1999. Between August 1998 and September 1999, he was Vice
President of Corporate Development and Strategic Planning at the company. He
also served as a consultant to the company during his employment as the Director
of Strategic Planning at EJ Financial Enterprises, Inc. from September 1997 to
August 1998. From 1995 to 1997, he was an Associate, Licensing and New Business
Start-Up, at the University of Pennsylvania Center for Technology Transfer. From
1994 to 1995, he was the Marketing Manager at Curative Technologies Inc., a
wound care services company. From 1993 to 1994, he was a Technical Sales
Representative for Millipore Corporation. From 1991 to 1993 he was the Senior
Research Chemist at Scios Inc. He has also held product management and finance
positions at Schering Plough and Pfizer. Mr. Venkataraman received an M.S.
degree in Organic Chemistry from Case Western Reserve University and an M.B.A.
degree from the Wharton School at the University of Pennsylvania.
Robert D. Godfrey, Jr. has been Vice President of Sales since 1998. He
served as the National Sales Manager between 1996 and 1998. He began his career
with the company in 1992 as a Sales Representative for the Jacksonville,
Florida, territory and was promoted in 1994 to District Manager of the entire
Florida sales territory. At that time, in addition to his managerial
responsibilities, he continued to promote First Horizon products to physicians
and pharmacies until 1995. Prior to his career with the company, Mr. Godfrey
held the position of Marketing Research Consultant with MGT Information Systems
and also worked independently as a Research Consultant in the southeastern
United States. Mr. Godfrey received an M.B.A. degree and a B.S. degree in
Marketing from Jacksonville University.
William G. Campbell has been our Controller and Treasurer since 1998. Prior
to joining First Horizon, from 1995 to 1998, Mr. Campbell was the Controller/CFO
of DialysisAmerica, Inc. He was the Associate Administrator/CFO of Stringfellow
Memorial Hospital from 1993 to 1995; and from 1989 to 1993, he was the Director
of Budgets, Costs and Reimbursement at Grady Memorial Hospital, a large public
teaching hospital. His prior professional experience also includes a number of
profit and not-for-profit consulting, big five public accounting, governmental
auditing and internal audit positions. Mr. Campbell is a Certified Public
Accountant and received a B.A. degree in Accounting from Walsh College of
Accountancy and Business Administration and an M.B.A. degree in Accounting from
Kennesaw State College.
John N. Kapoor, Ph.D. has been one of our directors since 1996, and his
present term as director will expire in December 2000. Dr. Kapoor has over 20
years of experience in the healthcare field through his ownership and management
of healthcare-related businesses. In 1990, Dr. Kapoor founded Kapoor-Pharma
Investments, L.P., our largest stockholder, and its managing partner, EJ
Financial Enterprises, Inc., of which he is the President and sole shareholder.
EJ Financial provides funds and strategic advice to healthcare businesses. Dr.
Kapoor is the Chairman of OptionCare, Inc., Akorn, Inc. and NeoPharm, Inc. Dr.
Kapoor is a director of Integrated Surgical Systems, Inc., as well as a Chairman
of a private company and a director of several other private companies. Dr.
Kapoor received a B.Sc. degree from Bombay University and a Ph.D. degree in
medicinal chemistry from the State University of New York.
Dr. Kapoor was previously the chairman and president of Lyphomed Inc.
Fujisawa Pharmaceutical Co. Ltd. was a major stockholder of Lyphomed from the
mid-1980s until 1990, at which time Fujisawa completed a tender offer for the
remaining shares of Lyphomed, including the shares held by Dr. Kapoor. In 1992,
Fujisawa filed suit in federal district court in Illinois against Dr. Kapoor
alleging that between 1980 and 1986, Lyphomed filed a large number of allegedly
fraudulent new drug applications with the FDA, and that Dr. Kapoor's failure to
make certain
41
<PAGE> 46
disclosures to Fujisawa constituted a violation of federal securities laws and
the Racketeer Influenced and Corrupt Organizations Act. Fujisawa also alleged
state law claims. Dr. Kapoor countersued, and in 1999, the litigation was
settled on terms mutually acceptable to the parties. The terms of the settlement
are subject to a confidentiality agreement. Dr. Kapoor also controls Inpharmakon
Corporation, a party to one of our development agreements.
Pierre Lapalme was elected a director in April 2000. His term as director
will expire in 2002. Mr. Lapalme has served as President and Chief Executive
Officer of the North American division of Ethypharm, Inc. since 1997. Mr.
Lapalme is the non-executive Chairman of the Board of DiagnoCure Inc. From 1994
to 1997, he served as President and General Manager of Lavipharm Inc. Mr.
Lapalme served as Senior Vice President and General Manager for the North
American division of Rhone-Poulenc Rorer Inc. U.S.A. from 1990 to 1993 and as
President and Chief Executive Officer of the North American division of
Rhone-Poulenc Pharmaceuticals from 1979 to 1990. From 1964 to 1979, Mr. Lapalme
held various executive positions at Ciba-Geigy Pharmaceuticals in Canada. Mr.
Lapalme received a Business Administration degree in Marketing from the
University of Western Ontario.
Jon S. Saxe was elected a director in January 2000. His term as director
will expire in December, 2001. He also serves as a Director of Protein Design
Labs, Inc. Mr. Saxe served as President of Protein Design Labs, Inc. from
January 1995 to May 1999. In addition, he is a Director of Questcor
Pharmaceuticals Inc., Incyte Pharmaceuticals Inc., ID Biomedical Corporation,
InSite Vision, and is Chairman of Point Biomedical Corporation and Iconix
Pharmaceuticals. Mr. Saxe served as President of Saxe Associates, a
biotechnology consulting firm, from May 1993 to December, 1994. He served as the
President, Chief Executive Officer and a Director of Synergen, Inc., a
biopharmaceutical company, from October 1989 to April, 1993. Mr. Saxe served in
various positions including Vice President of Licensing and Corporate
Development and Head of the Patent Law Department for Hoffmann-LaRoche, Inc.
from 1960 through 1989. Mr. Saxe received a B.S. Ch.E. degree from
Carnegie-Mellon University, a J.D. degree from George Washington University
School of Law, and an L.L.M. degree from New York University School of Law.
EXECUTIVE OFFICERS
Each officer serves at the discretion of our board of directors and holds
office until his successor is elected and qualified or until his earlier
resignation or removal. There are no family relationships among any of our
directors or executive officers.
ELECTION OF DIRECTORS
Dr. Shah, Mr. Dixon and Dr. Kapoor were elected to the board under a
stockholder agreement. Under the terms of this agreement, the board of directors
was set at three members. In addition, Kapoor-Pharma Investments has the right
to elect two directors, and Dr. Shah, Mr. Dixon and Mr. Hauck have the right to
elect one director by majority vote. This agreement will terminate upon
completion of this offering.
Our board of directors increased the number of directors from three to five
in January 2000. Pursuant to our bylaws, the board filled the two vacancies
created by the increase by appointing Jon S. Saxe and John E. Robson as
directors. Mr. Robson resigned as director in April 2000 and the board filled
the resulting vacancy by appointing Pierre Lapalme.
BOARD COMPOSITION
Pursuant to our Restated Certificate of Incorporation, the board of
directors is divided into three classes of directors:
- Class A, whose term will expire at the annual meeting of stockholders to
be held in the year 2000;
42
<PAGE> 47
- Class B, whose term will expire at the annual meeting of stockholders to
be held in the year 2001;
- Class C, whose term will expire at the annual meeting of stockholders to
be held in the year 2002.
John N. Kapoor is a Class A director. Mahendra G. Shah and Jon S. Saxe are
Class B directors. R. Brent Dixon and Pierre Lapalme are Class C directors.
Directors within each class are elected to serve three-year terms and
approximately one-third of the directors sit for election at each annual meeting
of the Company's stockholders.
A classified board of directors may have the effect of deterring or
delaying any attempt by any group to obtain control of the company by a proxy
contest since a third party would be required to have its nominees elected at
two separate meetings of the board of directors in order to elect a majority of
the members of the board.
BOARD COMMITTEES
The board of directors has formed an audit committee to review the results
and scope of the audit of our annual financial statements, to discuss various
matters with the auditors, to receive statements from the auditors and to make
recommendations to the board of directors regarding the inclusion of audited
financial statements in our annual reports. The current members of our audit
committee are Jon S. Saxe, John E. Kapoor and Pierre Lapalme.
The board of directors has also formed a compensation committee to
recommend salaries and incentive compensation for executive officers and to
administer our stock plan. The members of the compensation committee are Jon S.
Saxe and Pierre Lapalme.
COMPENSATION COMMITTEE INTERLOCKS AND INSIDE PARTICIPATION
In January 2000, our board of directors established a compensation
committee. Messrs. Lapalme and Saxe currently serve as members of the
compensation committee. For the year ended December 31, 1999, the entire board
of directors determined executive compensation. Two members of our board of
directors, Mahendra G. Shah and R. Brent Dixon, are also employees. Dr. Shah has
participated in certain transactions with us in the past. See "Certain
Relationships and Related Transactions."
DIRECTOR COMPENSATION
We reimburse each member of our board of directors for out-of-pocket
expenses incurred in connection with attending board meetings. Each director who
is not an employee also receives a fee of $12,000 per year and $1,000 for each
board meeting attended. Each director who is not an employee and not affiliated
with a greater than 10% stockholder receives options to purchase shares of our
common stock upon election to the board.
SCIENTIFIC ADVISORY BOARD
We have engaged a scientific and medical advisor to advise us on issues
related to specific pharmaceutical products. The current advisor is an expert in
clinical development, medical sciences and drug development. We plan to add
additional members with different expertise to support our growth. In certain
cases, this advisor has agreed to be available for consultation for a specified
number of days each year, but he may consult and meet informally with us on a
more frequent basis. Our current scientific and medical advisor may have other
commitments that may limit his availability to us. Our scientific advisory board
consists of the following individual:
Nelson L. Levy, M.D., Ph.D., is currently the Chief Executive Officer of
the CoreTechs Corporation, which implements a unique paradigm of technology
transfer and which starts science-
43
<PAGE> 48
based companies. He was previously President of Fujisawa Pharmaceutical Company,
where he refocused and revitalized the sales and marketing organizations,
in-licensed two major pharmaceuticals and filed an NDA for FK-506 (Prograf),
Fujisawa's leading product. From 1981 to 1984, he was the Vice President for
Pharmaceutical Research at Abbott Laboratories. He is on the board of directors
of two public and three private companies and on the scientific advisory boards
of three other companies, two of which are publicly traded. He is a Summa Cum
Laude graduate of Yale University, received his M.D. degree from the Columbia
College of Physicians and Surgeons and a Ph.D. degree in Immunology from Duke
University.
44
<PAGE> 49
EXECUTIVE COMPENSATION
The following table sets forth summary information concerning the
compensation awarded to or earned by our chief executive officer and by each of
our four other most highly compensated executive officers (the "Named Executive
Officers") who earned in excess of $100,000 in cash compensation during the year
ended December 31, 1999.
SUMMARY COMPENSATION TABLE
<TABLE>
<CAPTION>
ANNUAL LONG-TERM
COMPENSATION COMPENSATION AWARDS ALL
------------------ ---------------------- OTHER
SHARES COMPEN-
NAME AND PRINCIPAL POSITION SALARY BONUS UNDERLYING OPTIONS SATION(1)
- --------------------------- -------- ------- ---------------------- ---------
<S> <C> <C> <C> <C>
Mahendra G. Shah, Ph.D.(1).............
Chairman and Chief Executive
Officer........................... $ -- $55,200 300,000 $ --
R. Brent Dixon
President and Director............... 100,000 27,600 60,000 1,570(2)
Balaji Venkataraman
Vice President and Chief Financial
Officer........................... 93,400 21,250 200,000 24(3)
Gregory P. Hauck
Vice President, Developed Products... 89,000 20,000 50,000 624(4)
Robert D. Godfrey, Jr.
Vice President, Sales................ 85,950 20,000 70,000 2,024(5)
</TABLE>
- ------------------------------
(1) Dr. Shah did not receive a salary in 1999.
(2) Represents $1,546 contributed under the 401(k) plan and $24 for term life
insurance premiums.
(3) Represents $24 for term life insurance premiums.
(4) Represents $600 contributed under the 401(k) plan and $24 for term life
insurance premiums.
(5) Represents $2,000 contributed under the 401(k) plan and $24 for term life
insurance premiums.
STOCK OPTION GRANTS
The following tables show for the year ended December 31, 1999, information
regarding options granted to, and held at year end by, the Named Executive
Officers.
Amounts reported in the potential realizable value column below are
hypothetical values that may be realized upon exercise of the options
immediately prior to the expiration of their term, calculated by assuming that
the stock price on the date of grant as determined by the board of directors
appreciates at the indicated annual rate compounded annually for the entire term
of the option (10 years). The 0% annual rate of appreciation shows the value at
the grant date based upon the stated market price of the stock on the date of
grant. The 5% and 10% assumed rates of appreciation are mandated by the rules of
the Securities and Exchange Commission and do not represent our estimate or
projection of the future common stock price.
45
<PAGE> 50
OPTION GRANTS IN FISCAL YEAR 1999
<TABLE>
<CAPTION>
INDIVIDUAL GRANTS
--------------------------------------------------------------------
NUMBER OF PERCENTAGE OF
SECURITIES TOTAL OPTIONS MARKET
UNDERLYING GRANTED TO EXERCISE PRICE ON
OPTIONS EMPLOYEES IN PRICE PER DATE OF
NAME GRANTED FISCAL YEAR(1) SHARE GRANT EXPIRATION DATE
- ---- ---------- -------------- --------- -------- ---------------
<S> <C> <C> <C> <C> <C>
Mahendra G. Shah, Ph.D....... 25,000(2) 3.2% $2.50 $3.08 3/17/09
275,000(3) 35.0 2.65 4.48 10/22/09
R. Brent Dixon............... 60,000(4) 7.6 2.50 3.08 3/17/09
Balaji Venkataraman.......... 40,000(5) 5.1 1.88 4.48 9/1/09
60,000(3) 7.6 1.88 4.48 10/22/09
100,000(3) 12.7 2.65 4.48 10/22/09
Robert D. Godfrey, Jr........ 20,000(4) 2.5 2.50 3.08 3/17/09
50,000(3) 6.4 2.65 4.48 10/22/09
Gregory P. Hauck............. 50,000(4) 6.4 2.50 3.08 3/17/09
<CAPTION>
POTENTIAL REALIZABLE VALUE OF
ASSUMED ANNUAL RATES OF
STOCK PRICE APPRECIATION
FOR OPTION TERM
----------------------------------
NAME 0% 5% 10%
- ---- -------- ---------- ----------
<S> <C> <C> <C>
Mahendra G. Shah, Ph.D....... $ 14,500 $ 62,925 $ 137,218
503,250 1,278,048 2,466,741
R. Brent Dixon............... 34,800 151,020 329,324
Balaji Venkataraman.......... 104,000 216,698 389,599
156,000 325,047 584,398
183,000 464,745 896,997
Robert D. Godfrey, Jr........ 11,600 50,340 109,775
91,500 232,372 448,498
Gregory P. Hauck............. 29,000 125,850 274,436
</TABLE>
- ------------------------------
(1) In 1999, options to purchase a total of 785,500 shares of common stock were
granted.
(2) The option holder may exercise the option to purchase 25% of these shares of
common stock on March 17, 1999 and an additional 25% per year on the next
three anniversaries thereof.
(3) The option holder may exercise the option to purchase 25% of these shares of
common stock on October 22, 2000 and an additional 25% per year on the next
three anniversaries thereof.
(4) The option holder may exercise the option to purchase 25% of these shares of
common stock on March 17, 2000 and an additional 25% per year on the next
three anniversaries thereof.
(5) The option holder may exercise the option to purchase 25% of these shares of
common stock on September 1, 1999 and an additional 25% per year on the next
three anniversaries thereof.
None of our Named Executive Officers exercised stock options in the fiscal
year ended December 31, 1999. The following table sets forth information
concerning the number and value of unexercised options held by each of our Named
Executive Officers on December 31, 1999. There was no public market for our
common stock as of December 31, 1999. Accordingly, the fair market value on
December 31, 1999 is based on an assumed initial public offering price of $13.00
per share. This valuation at December 31, 1999 does not represent the actual
value of our stock at December 31, 1999.
AGGREGATED OPTION EXERCISES IN FISCAL 1999 AND YEAR-END OPTION VALUES
<TABLE>
<CAPTION>
NUMBER OF SHARES VALUE OF UNEXERCISED
UNDERLYING UNEXERCISED IN-THE-MONEY OPTIONS AT
OPTIONS AT YEAR ENDED YEAR ENDED
DECEMBER 31, 1999 DECEMBER 31, 1999
--------------------------- ---------------------------
NAME EXERCISABLE UNEXERCISABLE EXERCISABLE UNEXERCISABLE
- ---- ----------- ------------- ----------- -------------
<S> <C> <C> <C> <C>
Mahendra G. Shah, Ph.D........................ 106,250 293,750 $1,303,125 $3,043,125
R. Brent Dixon................................ 265,000 135,000 3,309,375 1,558,125
Balaji Venkataraman........................... 10,000 190,000 111,200 2,035,800
Robert D. Godfrey, Jr......................... 35,000 115,000 414,375 1,228,125
Gregory P. Hauck.............................. 265,000 125,000 3,309,375 1,453,125
</TABLE>
EXECUTIVE OFFICERS EMPLOYMENT AGREEMENTS
On January 1, 2000, we entered into employment agreements with Mahendra G.
Shah, Ph.D., R. Brent Dixon, Balaji Venkataraman, Robert D. Godfrey, Jr.,
Gregory P. Hauck and William G. Campbell. These employment agreements may be
terminated by us with or without cause. The officers may terminate employment
upon sixty days written notice to us. Upon termination of Messrs. Shah, Dixon
and Venkataraman's employment without cause, as defined in the agreement,
46
<PAGE> 51
each officer will be entitled to receive his salary for twelve months following
termination, a lump sum equal to 100% of the bonus he received the preceding
calendar year, if any, continued health insurance coverage substantially
equivalent to that provided to the officer prior to termination for twelve
months following termination, a car allowance for twelve months following
termination, and all of the officer's unvested options will immediately vest and
become exercisable.
Upon termination of Messrs. Godfrey, Hauck and Campbell's employment
without cause, each officer will be entitled to receive his salary for six
months following termination, a lump sum equal to 50% of the bonus he received
the preceding calendar year, if any, continued health insurance coverage
substantially equivalent to that provided to the officer prior to termination
for six months following termination, a car allowance for six months following
termination and all of the officer's unvested options will immediately vest and
become exercisable.
Upon termination by us for cause, termination in the event of death or
termination by the officer, each officer or his estate is entitled to receive
all accrued but unpaid salary as of the date of termination. Upon any
termination of these agreements, each officer or his estate will have 120 days
from the date of termination to exercise any vested options.
These employment agreements provide for a base salary of $110,000 for Dr.
Shah, $102,000 for Mr. Dixon, $95,000 for Mr. Venkataraman, $90,000 for Mr.
Godfrey, $85,000 for Mr. Hauck and $80,000 for Mr. Campbell. In addition, these
employment agreements entitle each executive officer to receive a bonus based on
the percentage of his salary, if we and/or the officer meets certain performance
goals to be established by the board of directors each year. The compensation
committee will review the performance goals and determine whether or not we
and/or the executive have achieved the performance goals based on our financial
statements. The board retains the right to award additional compensation to each
officer based on the officer's contributions to the company.
The agreements provide that in the event of a change of control, as defined
in the agreements, all options become fully vested and immediately exercisable.
The employment agreements restrict each officer from engaging in or having
any financial interest in a business that is in competition with our business
during that officer's employment with the company and for thirty-six months
following termination of employment. A business is in competition with us if it
involves research and development work involving products that we market at the
time of termination or that were under study by us at that time and were
expected to be marketed within six months. This provision does not prevent the
officers from investing in a publicly held company, provided that the officer's
beneficial ownership of securities does not exceed 5% of the outstanding class
of the publicly held company's securities. The employment agreements also
restrict each officer from soliciting our suppliers, customers or clients for
thirty-six months after employment. This provision does not prohibit an officer
from soliciting wholesale customers, managed care agencies, scientific or
computer consultants, lawyers or manufacturers as long as manufacturers have
excess capacity. The employment agreements also prohibit each officer from
soliciting, employing or engaging any of our employees or affiliates for
thirty-six months following employment. The employment agreements prohibit each
officer from disclosing any of our trade secrets, confidential information or
ideas that the officer may have acquired or developed relating to our business
for twelve months following employment.
EMPLOYEE BENEFIT PLANS
1997 Non-Qualified Stock Option Plan
Our 1997 Non-Qualified Stock Option Plan, as amended, was adopted by our
board of directors and approved by our stockholders June 18, 1997. The 1997 plan
authorizes the issuance of up to 4,000,000 shares of our common stock.
Currently, options to purchase an aggregate of 1,767,500 shares of our common
stock at a weighted average exercise price of $1.61 per share are outstanding
47
<PAGE> 52
under the 1997 plan. Upon the closing of this offering, no additional grants of
stock options will be made under this 1997 plan.
Options granted under the plan are not transferable by the optionee except
by will or by the laws of descent and distribution. Options will become
immediately exercisable in the event of a change of control if the surviving
company does not assume the options granted under the plan.
The 2000 Stock Plan
Our board of directors and stockholders approved the 2000 Stock Plan in
February 2000. This plan provides for the granting of:
- incentive stock options under the Internal Revenue Code of 1986;
- options that do not qualify as incentive stock options;
- stock awards or stock bonuses; and
- sales of stock.
The 2000 Stock Plan provides for the grants of these options and other
awards to officers, directors, full and part-time employees, advisors and
consultants. Only full-time employees may receive incentive stock options. We
have reserved 2,000,000 shares of common stock for issuance under the 2000 Stock
Plan. Our compensation committee administers the 2000 Stock Plan and has the
sole authority to determine:
- the meaning and application of the terms of the plan and all grant
agreements;
- the persons to whom option or stock grants are made;
- the nature and amount of option or stock grants;
- the price to be paid upon exercise of each option;
- the period within which options may be exercised;
- the restrictions on stock awards; and
- the other terms and conditions of awards.
In order to meet one of the requirements of Section 162(m) of the Internal
Revenue Code, the 2000 Stock Plan limits to 500,000 the number of shares that
may be covered by grants to any single person in any one calendar year.
The exercise price per share for incentive stock options cannot be less
than the fair market value of our common stock on the date of the grant. If a
recipient owns more than 10% of our common stock, incentive stock options
granted to that recipient must have an exercise price of not less than 110% of
the fair market value of our common stock on the grant date. Determinations of
fair market value are made in accordance with the plan. The compensation
committee has the authority to determine the exercise price for non-qualified
stock options.
The compensation committee has the authority to determine the term of each
option. However, the term of stock options may not exceed 10 years from the date
of grant. In the case of an incentive option granted to an owner of more than
10% of our common stock, the term may not exceed five years from the date of
grant.
Generally, the recipient of an option may exercise it only while employed
by us, except that a recipient may exercise vested options for 60 days after
termination of employment or such later date as set forth in the grant
agreement, a recipient may exercise vested options for twelve months following
disability, and if a recipient dies while employed by us, his or her estate,
heirs or beneficiaries may exercise vested options held by the recipient within
twelve months following the
48
<PAGE> 53
date of death. The plan also provides for the acceleration of vesting and
exercisability of options and vesting of stock awards if we are subject to a
change of control.
The compensation committee has the authority to award stock under the plan
as stock bonuses. In addition, the compensation committee may issue stock under
the plan for consideration, including promissory notes and services. The
compensation committee also has the authority to determine the terms, conditions
and restrictions of stock awards and sales of stock, which may include
restrictions on transferability, voting, repurchase by us and forfeiture of
shares. If shares of the stock are subject to forfeiture, we will retain all
dividends or other distributions paid on the stock until the shares are no
longer subject to forfeiture, at which time we will pay all accumulated amounts
to the recipient. Unless otherwise determined by the compensation committee,
shares awarded as a stock bonus to an officer or director may not be sold until
six months after the date of the award. All shares relating to stock awards or
stock sales are counted against the aggregate number of shares available for
granting awards under the 2000 Stock Plan.
If a stock split, stock dividend, consolidations, recapitalizations,
reorganizations or similar event occurs, we will make proportional adjustments
to the number of shares of common stock reserved for issuance under the 2000
Stock Plan and issuable under outstanding options and adjustments to the
exercise prices of outstanding options.
Awards under the plan are not transferable except by will or the laws of
descent and distribution. The 2000 Stock Plan will terminate in February, 2010,
and we may not grant awards under it after termination. Our board of directors
may amend, alter or discontinue the plan at any time, provided that we must
obtain shareholder approval for any change that would increase the number of
shares reserved for issuance or would change the class of persons eligible to
receive grants. In addition, the board may not amend the plan to:
- fix the exercise price per share for incentive stock options at less than
100% of the fair market value of a share of common stock on the date of
grant;
- extend the expiration date of the plan;
- extend the maximum period of ten years during which holders may exercise
options; or
- materially increase the benefits to participants under the plan.
In no event may the board or shareholders amend the plan, alter or impair
the rights of an existing recipient without their consent.
As a condition to the exercise of an option, the vesting or award of a
stock bonus or the vesting or sale of stock, we may require the recipient to pay
over to us all applicable federal, state and local taxes that we must withhold.
At the discretion of the compensation committee and upon the request of a
recipient, the withholding tax requirements may be satisfied by withholding
shares of stock otherwise issuable to the recipient.
The board of directors approved the grant of options, subject to completion
of this offering, to purchase 187,950 shares at an exercise price per share
equal to the public offering price per share in this offering. These options
will be issued upon completion of this offering. Following this grant, there
will be 1,812,050 shares available for future option grants under the 2000 Stock
Plan.
Employee Stock Purchase Plan
Our employee stock purchase plan was adopted in February 2000 and is
intended to qualify as an employee stock purchase plan within the meaning of
Section 423 of the Internal Revenue Code. We have reserved 500,000 shares of
common stock for the stock purchase plan. In order to participate in the stock
purchase plan, employees must meet eligibility requirements, including length of
employment. At present participating employees will be able to direct us to make
payroll deductions of up to 7% of their regular compensation during an offering
period for the purchase of shares of our common stock. Each offering period will
be six months, with the first offering period
49
<PAGE> 54
beginning on the later of July 1, 2000 or the effective date of the registration
statement for the plan. The stock purchase plan will provide participating
employees with the right, subject to specific limitations, to purchase our
common stock at a price equal to 85% of the lesser of the fair market value of
our common stock on the first or last day of the offering period. The stock
purchase plan will terminate on December 31, 2010. The board of directors has
the authority to amend, suspend or discontinue the stock purchase plan as long
as the change will not adversely affect participants without their consent and
as long as we receive any shareholder approval required by law.
401(k) Profit Sharing Plan
We have established a tax-qualified employee savings and retirement plan
for all of our employees who satisfy certain eligibility requirements, including
requirements relating to age and length of service. Under the 401(k) plan,
employees may elect to reduce their current compensation by up to 15% or the
statutory dollar limit, whichever is less, and have us contribute the amount of
this reduction to the 401(k) plan. In addition, we match a percentage of an
employee's contribution that we establish from time to time. Each employee is
fully vested in his or her salary contributions and our matching contributions
vest over six years.
We intend for the 401(k) plan to qualify under Section 401 of the Code so
that contributions by employees or by us to the 401(k) plan, and income earned
on plan contributions, are not taxable to employees until withdrawn from the
401(k) plan. Our contributions, if any, will be deducted by us when made.
50
<PAGE> 55
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
Officers and Directors
Mahendra G. Shah, Ph.D., our Chairman and Chief Executive Officer, is the
Vice President of EJ Financial Enterprises, Inc. John N. Kapoor, Ph.D., one of
our directors, is President and sole shareholder of EJ Financial. EJ Financial
is the Managing General Partner of Kapoor-Pharma Investments, L.P. which
beneficially owns 76% of our Common Stock.
Reimbursement Agreement
On April 14, 2000, we entered into a Reimbursement Agreement with the
Kapoor Children's 1992 Trust (the "1992 Trust"). Under this agreement, the 1992
Trust agreed to pledge to LaSalle Bank as collateral for our bridge loan,
securities and investments in the amount of $10 million. John Kapoor is the
husband of Editha Kapoor, the Trustee of the 1992 Trust, and their children are
the beneficiaries. As consideration for this pledge, we will pay the Trust a fee
of $100,000 per year, pro rated for the amount of time that the pledge is in
effect, plus all of the 1992 Trusts' expenses incurred in connection with the
Reimbursement Agreement.
Collaboration Agreement
In 1998, we entered into a collaboration agreement with Inpharmakon
Corporation under which we acquired rights to the proprietary information for
our migraine product FHPC 01 currently under development. Under the agreement,
we must develop a workable once-a-day formulation for the drug, conduct clinical
trials, file for and obtain regulatory approval, and begin commercial sales of
the product within prescribed times. If we do not reach specified milestones on
a timely basis, Inpharmakon may terminate the agreement. In the event that
Inpharmakon terminates the agreement, the rights to develop FHPC 01 will revert
back to Inpharmakon who will, under certain circumstances, be free to develop
and market the product using the once a day formulation and the data from
clinical trials and all other information acquired or developed by us in
connection with our development efforts. We must also pay up to an aggregate of
$950,000 in non-refundable fees at various developmental milestones through and
including regulatory approval of the product, and, in the event of commercial
sales of the product, we must pay royalties at rates which we believe are within
industry customary ranges. If we elect to sell the business opportunity to a
third party, we must share the proceeds of the sale with Inpharmakon. We paid
$200,000 and $1,352 to Inpharmakon in 1998 and 1999, respectively, under this
agreement. The agreement expires on October 31, 2008 with automatic five-year
renewals thereafter. The terms of this agreement were negotiated at arms' length
by management, and we believe the terms are fair to us. The John N. Kapoor
Trust, dated September 30, 1989 (the "Trust"), owns 50% of the shares of
Inpharmakon Corporation. John N. Kapoor is Trustee of the Trust, and the Trust
is a partner of Kapoor-Pharma Investments. In addition, Dr. Shah is a director
of Inpharmakon Corporation and owns options to purchase 25,000 shares of
Inpharmakon.
The other owner of Inpharmakon has previously sought to renegotiate some of
the terms of this agreement based on disputes concerning our achievement of
milestones. On May 3, 2000, we entered into an amendment of this development
agreement in which both parties released each other from any previous claims or
disputes under the agreement. This amendment deletes provisions permitting
Inpharmakon to terminate the agreement if we do not initiate clinical trials
within a specified time period after completing a clinical biostudy on our
migraine product under development or if we do not file an NDA within a
specified time period after completing clinical trials. In addition, the
amendment provides for an increase in the total aggregate amount of milestone
payments that we must pay for development of the migraine product from $700,000
to $950,000. The amendment also requires that we pay Inpharmakon $200,000 within
thirty days after this offering.
51
<PAGE> 56
Packaging Agreement
In 1997, we entered into a packaging agreement with Diversified Healthcare
Services, Inc., under which we agreed to exclusively use Diversified Healthcare
to package samples of our Defen-LA, Mescolor, Protuss-DM and Zebutal products.
Under this agreement, Diversified Healthcare has the right to provide exclusive
packaging services for these products. We paid $83,000, $132,152 and $282,493 to
Diversified Healthcare in 1997, 1998 and 1999, respectively, under this
agreement. The term of this agreement is three years, with automatic yearly
renewals unless terminated by either party. The terms of this agreement were
negotiated at arm's length by management, and we believe the terms are fair to
us. Warren Hauck, Chief Executive Officer of Diversified Healthcare, is the
father of Gregory P. Hauck, our Vice President of Developed Products, and Daniel
C. Hauck, who currently owns 5.6% of our common stock. Steven Hauck, the
President of Diversified Healthcare, is the brother of Gregory and Daniel Hauck.
Non-compete Agreements
In 1996, we entered into two agreements with Crabapple Enterprises, Inc., a
prior and potential competitor, under which Crabapple agreed not to market
products that compete with our Protuss, Protuss-D and Zoto-HC products. We paid
$91,000, $159,902 and $162,768 to Crabapple in 1997, 1998 and 1999,
respectively, under these agreements. These agreements require us to pay
royalties on sales of these products at rates which we believe are within
industry customary standards. The term of the agreement for Protuss and
Protuss-D is seven years with an option to renew for an additional five years.
The term of the agreement for Zoto-HC is ten years with an option to renew for
an additional five years. Crabapple may cancel these agreements if minimum
royalty amounts are not paid. The terms of these agreements were negotiated at
arm's length by management, and we believe the terms are fair to us. Warren
Hauck, Chief Executive Officer of Crabapple, and Mary Hauck, Secretary of
Crabapple, are the parents of Gregory and Daniel Hauck.
Conversion of Notes into Common Stock
On January 11, 1999, Kapoor-Pharma Investments loaned us $1,600,000 at an
interest rate of 2% over the prime rate. In December, 1999, we converted
principal and $144,984 of accrued interest into 558,395 shares of common stock
pursuant to the terms of the loan agreement. We used this loan to acquire the
Robinul product line.
During 1997, we converted $385,000 in loans from Kamal R. Kapoor plus
$124,363 accrued interest into 814,978 shares of our common stock at a
conversion rate of $0.625 per share. Kamal Kapoor is John N. Kapoor's brother.
During 1997, we converted $150,000 in loans from the Trust plus $3,345
accrued interest into 245,352 shares of common stock at a conversion rate of
$0.625 per share.
During 1997, we converted $100,000 in loans from EJ Financial Enterprises
plus $25,575 accrued interest into 200,918 shares of common stock at a
conversion rate of $0.625 per share.
Sale of Common Stock
On January 27, 1997, we issued 320,000 shares of common stock to the Trust
for $200,000 or $0.625 per share.
On June 30, 1997, we issued 560,000 shares of common stock to Kapoor-Pharma
Investments for $350,000 or $0.625 per share.
52
<PAGE> 57
PRINCIPAL STOCKHOLDERS
The following table sets forth information regarding the beneficial
ownership of our common stock and as adjusted to reflect the sale of the shares
of common stock in this offering, by:
- each person or entity we know to own beneficially more than 5% of our
common stock;
- each of our directors;
- each of the Named Executive Officers; and
- all directors and executive officers as a group.
Unless otherwise indicated, each person or entity named in the table has
sole voting power and investment power, or shares voting and/or investment power
with his or her spouse, with respect to all shares of capital stock listed as
owned by that person or entity. Except as otherwise noted below, the address of
each person listed below is our address.
The number of shares beneficially owned by each stockholder is determined
under rules promulgated by the Securities and Exchange Commission and assumes
the underwriters do not exercise their over-allotment option. the information is
not necessarily indicative of beneficial ownership for any other purpose. Under
these rules, beneficial ownership includes any shares as to which the individual
has sole or shared voting power or investment power and any shares as to which
the individual has the right to acquire beneficial ownership within 60 days of
the date of this prospectus through the exercise of any stock option, warrant or
other right. The inclusion in the following table of those shares, however, does
not constitute an admission that the named stockholder is a direct or indirect
beneficial owner of those shares.
<TABLE>
<CAPTION>
PERCENTAGE OF
SHARES BENEFICIALLY
OWNED
NUMBER OF SHARES --------------------------------
NAME AND ADDRESS OF BENEFICIAL OWNER BENEFICIALLY OWNED BEFORE OFFERING AFTER OFFERING
- ------------------------------------ ------------------- --------------- --------------
<S> <C> <C> <C>
5% STOCKHOLDERS
Kapoor-Pharma Investments, L.P.(1).... 6,487,583 76.0% 52.6%
225 E. Deerpath, Suite 250
Lake Forest, IL 60045
Daniel C. Hauck(2).................... 480,000 5.6 3.9
842 Gable Gate Turn
Roswell, GA 30076
DIRECTORS AND NAMED EXECUTIVE OFFICERS
John N. Kapoor, Ph.D.(1).............. 6,487,583 76.0 52.6
R. Brent Dixon(3)..................... 785,000 8.9 6.2
Gregory P. Hauck(4)................... 782,500 8.9 6.2
Mahendra G. Shah, Ph.D.(5)............ 424,560 4.9 3.4
Robert D. Godfrey, Jr.(6)............. 55,000 * *
Balaji Venkataraman(7)................ 10,000 * *
Pierre Lapalme........................ -- -- --
Jon S. Saxe........................... -- -- --
All directors and executive officers
as a group (9 persons)(8)........... 8,549,643 91.6 65.1
</TABLE>
- ------------------------------
* Represents less than 1%.
(1) John N. Kapoor, Ph.D., one of our directors, is the president and sole
stockholder of the managing general partner of Kapoor-Pharma Investments,
L.P. In such capacity, Mr. Kapoor has the authority to vote and dispose of
the shares owned by Kapoor-Pharma Investments and is therefore deemed the
beneficial owner of those shares.
(2) Includes 240,000 shares owned through Gable Gate Enterprises, LLP, a family
limited partnership of which Mr. Hauck is the general partner.
53
<PAGE> 58
(3) Includes 305,000 shares of common stock issuable upon exercise of stock
options exercisable within 60 days.
(4) Includes 302,500 shares of common stock issuable upon exercise of stock
options exercisable within 60 days.
(5) Includes 112,500 shares of common stock issuable upon exercise of stock
options exercisable within 60 days. Also includes 10,000 shares that Dr.
Shah owns as custodian for his daughter that he may be deemed to
beneficially own.
(6) Includes 55,000 shares of common stock issuable upon exercise of stock
options exercisable within 60 days.
(7) Includes 10,000 shares of common stock issuable upon exercise of stock
options exercisable within 60 days.
(8) Includes 790,000 shares of common stock issuable upon exercise of stock
options exercisable within 60 days.
54
<PAGE> 59
DESCRIPTION OF CAPITAL STOCK
Our authorized capital stock consists of 40,000,000 shares of common stock,
par value $.001, and 1,000,000 shares of preferred stock, par value $.001. Upon
the closing of this offering, there will be 12,339,643 shares of common stock
outstanding assuming that the underwriters do not exercise their over-allotment
right, and no shares of preferred stock outstanding.
COMMON STOCK
The holders of common stock are entitled to one vote for each share held of
record on all matters submitted to a vote of our stockholders. The holders of
common stock have no cumulative voting rights with respect to the election of
directors or any other matter.
Subject to preferences that may be applicable to any preferred stock
outstanding at the time, the holders of outstanding shares of common stock are
entitled to receive dividends out of assets legally available therefor at such
time and in such amounts as the board of directors may from time to time
determine.
Upon the liquidation, dissolution, distribution of assets or winding up of
the company, holders of common stock are entitled to share ratably, in
proportion to the number of shares of common stock held, all the assets
remaining after distribution of the full preferential amounts due to the holders
of the outstanding shares of preferred stock, if any.
Holders of common stock are not entitled to preemptive rights or rights to
covert their common stock into any other securities. There are no redemption or
sinking fund provisions applicable to the common stock. All outstanding shares
of common stock are, and all shares of common stock to be outstanding upon
completion of this offering will be, fully paid and nonassessable.
PREFERRED STOCK
Under our Restated Certificate of Incorporation, the board of directors has
the authority, without further action by the stockholders, to issue up to
1,000,000 shares of preferred stock in one or more series and to fix the rights,
preferences, privileges and restrictions thereof, including dividend rights,
conversion rights, voting rights, terms of redemption, liquidation preferences,
sinking fund terms and the number of shares constituting any series or the
designation of such series, without any further vote or action by the
stockholders. The issuance of preferred stock could adversely affect the voting
power of holders of common stock and the likelihood that such holders will
receive dividend payments and payments upon liquidation. The issuance of
preferred stock may have the effect of delaying, deferring or preventing a
change in control of the company, which could have a depressive effect on the
market price of our common stock. We have no present plan to issue any shares of
preferred stock.
DELAWARE ANTI-TAKEOVER PROVISIONS
We are subject to Section 203 of the Delaware General Corporation Law
regulating corporate takeovers. Section 203, subject to certain exceptions,
prohibits a Delaware corporation from engaging in any business combination with
any interested stockholder for a period of three years following the date that
such stockholder became an interested stockholder unless:
- Prior to such date, the board of directors of the corporation approved
either the business combination or the transaction that resulted in the
stockholder becoming an interested stockholder;
- Upon consummation of the transaction that resulted in the stockholder
becoming an interested stockholder, the interested stockholder owned at
least 85% of the voting stock of the corporation outstanding at the time
the transaction commenced, excluding those shares
55
<PAGE> 60
owned by persons who are directors and also officers, and employee stock
plans in which employee participants do not have the right to determine
confidentially whether shares held subject to the plan will be tendered
in a tender or exchange offer; or
- On or subsequent to such date, the business combination is approved by
the board of directors and authorized at an annual or special meeting of
stockholders, and not by written consent, by the affirmative vote of at
least two-thirds of the outstanding voting stock that is not owned by the
interested stockholder.
Section 203 defines "business combination" to include:
- Any merger or consolidation involving the corporation and the interested
stockholder;
- Any sale, transfer, pledge or other disposition involving the interested
stockholder of 10% or more of the assets of the corporation;
- Subject to certain exceptions, any transaction that results in the
issuance or transfer by the corporation of any stock of the corporation
to the interested stockholder; or
- The receipt by the interested stockholder of the benefit of any loans,
advances, guarantees, pledges or other financial benefits provided by or
through the corporation.
In general, Section 203 defines an "interested stockholder" as any entity
or person beneficially owning 15% or more of the outstanding voting stock of the
corporation and any entity or person affiliated with or controlling or
controlled by such entity or person.
CHARTER AND BYLAWS ANTI-TAKEOVER PROVISIONS
Pursuant to our Restated Certificate of Incorporation, the board of
directors is divided into three classes of directors. Directors within each
class are elected to serve three-year terms and approximately one-third of the
directors sit for election at each annual meeting of stockholders. A classified
board of directors may have the effect of deterring or delaying any attempt by
any group to obtain control of the company by a proxy contest since a third
party would be required to have its nominees elected at two separate meetings of
the board of directors in order to elect a majority of the member of the board.
A director may be removed only for cause and requires a vote of at least
two-thirds of the shares entitled to vote for election of directors.
In addition, our Restated Certificate of Incorporation also provides that
amendment of our bylaws by shareholders requires a vote of at least two-thirds
of the shares entitled to vote for the election of directors. This supermajority
restriction makes it more difficult for stockholders to require an amendment of
the bylaws and enhances the board's power with respect to matters of corporate
governance that are governed by the bylaws.
Our bylaws establish an advance notice procedure for stockholders to bring
matters before stockholder meetings, including proposed nominations of persons
for election to the board of directors and bringing business matters or
stockholder proposals before a meeting. These procedures specify the information
stockholders must include in their notice and the timeframe in which they must
give us notice. At a stockholder meeting, stockholders may only consider
nominations or proposals specified in the notice of meeting, nominations or
proposals brought before the meeting by or at the direction of the board of
directors, and nominations or proposals by a person who was a stockholder of
record on the record date for the meeting, who is entitled to vote at the
meeting and who has given us timely written notice, in proper form, of his or
her intention to bring that nomination or proposal before the meeting.
The bylaws do not give the board of directors the power to approve or
disapprove stockholder nominations of candidates or proposals regarding other
business to be conducted at a meeting. However, our bylaws may have the effect
of precluding the conduct of that item of business at a meeting if the proper
procedures are not followed. These provisions may discourage or deter a
56
<PAGE> 61
potential third party from conducting a solicitation of proxies to elect their
own slate of directors or otherwise attempting to obtain control of our company.
LIMITATION OF LIABILITY AND INDEMNIFICATION
Our Restated Certificate of Incorporation contains certain provisions
permitted under Delaware law relating to the liability of directors. These
provisions eliminate a director's personal liability for monetary damages
resulting from a breach of fiduciary duty, except in circumstances involving
certain wrongful acts, such as:
- for any breach of the director's duty of loyalty to us or our
stockholders;
- for acts or omissions not in good faith or which involve intentional
misconduct or a knowing violation of law;
- for any acts under Section 174 of the Delaware General Corporation Law;
or
- for any transaction from which the director derives an improper personal
benefit.
These provisions do not limit or eliminate our rights or any stockholder's
rights to seek non-monetary relief, such as an injunction or rescission, in the
event of a breach of a director's fiduciary duty. These provisions will not
alter a director's liability under federal securities laws.
In addition, our Restated Certificate of Incorporation and Bylaws provide
the directors and executive officers indemnification protection to the fullest
extent permitted by Delaware law. We believe that these provisions will assist
us in attracting and retaining qualified individuals to serve as directors and
officers. Our Bylaws permit us to enter into agreements providing to each
officer or director indemnification rights substantially similar to those set
forth in the Bylaws and such agreements have been entered into by each member of
our board of directors and each of our executive officers. Although the form of
indemnification agreement offers substantially the same scope of coverage
afforded by our Bylaws, it provides greater assurances to directors and
executive officers that indemnification will be available because, as a
contract, it cannot be modified unilaterally in the future by the board of
directors or by the stockholders to eliminate the rights it provides.
TRANSFER AGENT AND REGISTRAR
The transfer agent and registrar for our common stock is LaSalle Bank
National Association.
LISTING
The shares of common stock of First Horizon have been approved for
quotation on the Nasdaq National Market under the symbol "FHRX."
57
<PAGE> 62
SHARES ELIGIBLE FOR FUTURE SALE
Prior to this offering, there has been no public market for our common
stock. Future sales of substantial amounts of our common stock in the public
market could adversely affect prevailing market prices of shares of First
Horizon. In addition, since no shares outstanding prior to this offering will be
available for sale shortly after this offering because of certain contractual
and legal restrictions on resale as described below, sales of substantial
amounts of common stock in the public market after these restrictions lapse
could adversely affect the prevailing market price of shares of First Horizon
and our ability to raise equity capital in the future.
Upon completion of this offering, we will have outstanding an aggregate of
12,339,643 shares of common stock, assuming no exercise of the underwriters'
over-allotment option and excluding 1,767,500 shares issuable upon exercise of
outstanding options. Of these shares, all of the shares sold in this offering
will be freely tradable without restriction or further registration under the
Securities Act, unless such shares are purchased by "affiliates" as that term is
defined in Rule 144 under the Securities Act. The remaining 8,539,643 shares of
common stock currently outstanding and 1,767,500 shares issuable upon the
exercise of outstanding options are "restricted securities" as that term is
defined in Rule 144 under the Securities Act. Restricted securities may be sold
in the public market only if registered or if they qualify for an exemption from
registration described below under Rules 144, 144(k) or 701 promulgated under
the Securities Act.
Beginning either on the date of this prospectus or 90 days after the date
of this prospectus, all 8,539,643 shares currently outstanding and 1,767,500
shares issuable upon the exercise of outstanding options will become eligible
for sale in the public market under Rule 144(k), Rule 144 or Rule 701. All but
100,000 of the shares currently outstanding are subject to lock-up agreements.
All 1,767,500 shares issuable upon the exercise of outstanding options are
subject to lock-up agreements. These lock-up agreements provide that the
stockholders will not sell or otherwise dispose of any shares of common stock
without the prior written consent of Chase Securities Inc. for a period of 180
days from the date our shares commence trading on the Nasdaq National Market.
Chase Securities Inc. may release all or any portion of the securities subject
to the lock-up agreements without notice. See "Underwriting."
Rule 144
Under Rule 144, beginning 90 days after the date the registration statement
of which this prospectus is a part is declared effective, a person, or persons
whose shares are aggregated, who has beneficially owned restricted shares for at
least one year, which generally includes the holding period of any prior owner
other than an affiliate, would generally be entitled to sell within any
three-month period a number of shares that does not exceed the greater of:
- 1% of the outstanding shares of our common stock then outstanding, which
will equal approximately 123,396 shares immediately after this offering;
or
- The average weekly trading volume of First Horizon's common stock on the
Nasdaq National Market during the four calendar weeks preceding the
filing of a notice on Form 144 with respect to such sale.
Sales under Rule 144 are also subject to certain manner of sale provisions
and notice requirements and to the availability of current public information
about the company.
Rule 144(k)
Under Rule 144(k), a person who was not an affiliate of the company at any
time during the 90 days preceding a sale, and who has beneficially owned the
shares proposed to be sold for at least two years, which generally includes the
holding period of any prior owner except an affiliate, is entitled to sell such
shares without complying with the manner of sale, public information, volume
limitation or notice provisions of Rule 144.
58
<PAGE> 63
Rule 701
In general, under Rule 701 of the Securities Act, any of our employees,
consultants or advisors, other than affiliates, who purchases or receives shares
from us in connection with a compensatory stock purchase plan or option plan or
other written agreement will be eligible to resell such shares beginning 90 days
after the effective date of the registration statement of which this prospectus
is a part, subject only to the manner of sale provisions of Rule 144, and by
affiliates under Rule 144 without compliance with the Rule 144 holding period
requirements.
We intend to file a registration statement under the Securities Act
covering the 2,000,000 shares of common stock reserved for issuance under our
2000 Stock Plan following completion of this offering. Thereafter, shares that
are issued under the plan will, subject to Rule 144 volume limitations
applicable to affiliates, be available for sale in the open market.
59
<PAGE> 64
UNDERWRITING
Subject to the terms and conditions of the underwriting agreement, the
underwriters named below, through their representatives, Chase Securities Inc.,
Banc of America Securities LLC and Thomas Weisel Partners LLC, have severally
agreed to purchase from us the following numbers of shares of common stock:
<TABLE>
<CAPTION>
NUMBER OF
UNDERWRITER SHARES
- ----------- ---------
<S> <C>
Chase Securities Inc........................................
Banc of America Securities LLC..............................
Thomas Weisel Partners LLC..................................
-------
Total.............................................
=======
</TABLE>
The underwriting agreement provides that the obligations of the
underwriters are conditioned on the absence of any material adverse change in
our business and the receipt of certificates, opinions and letters from us, our
counsel and our independent auditors. The underwriters are committed to purchase
all shares of common stock offered in this prospectus if any shares are
purchased.
The underwriters propose to offer the shares of common stock directly to
the public at the public offering price set forth on the cover page of this
prospectus and to dealers at the public offering price less a concession not in
excess of $ per share. The underwriters may allow and the dealers may
reallow a concession not in excess of $ per share to other dealers. After
the public offering of the shares, the underwriters may change this offering
price and other selling terms. The representatives of the underwriters have
informed us that the underwriters do not intend to confirm discretionary sales
in excess of 5% of the shares of common stock offered by this prospectus.
We have granted to the underwriters an option, exercisable no later than 30
days after the date of this prospectus, to purchase up to 570,000 additional
shares of common stock at the public offering price, less the underwriting
discount set forth on the cover page of this prospectus. To the extent that the
underwriters exercise this option, each underwriter will have a firm commitment
to purchase a number of shares that approximately reflects the same percentage
of total shares the underwriter purchased in the above table. We will be
obligated to sell shares to the underwriters to the extent the option is
exercised. The underwriters may exercise this option only to cover over-
allotments made in connection with the sale of common stock offered in this
prospectus.
The following table shows the per share and total underwriting discounts
and commissions that we will pay to the underwriters. The underwriting discount
was determined based on an arms' length negotiation between the representatives
of the underwriters and us. These amounts are shown assuming both no exercise
and full exercise of the underwriters' over-allotment option to purchase
additional shares.
<TABLE>
<CAPTION>
PAID BY FIRST HORIZON
-----------------------------
NO EXERCISE FULL EXERCISE
----------- -------------
<S> <C> <C>
Per share............................................. $ $
Total................................................. $ $
</TABLE>
We estimate that our share of the total expenses of this offering,
excluding underwriting discounts and commissions, will be approximately
$1,000,000. This offering of the shares is made for delivery when, as and if
accepted by the underwriters and subject to prior sale and to withdrawal,
60
<PAGE> 65
cancellation or modification of this offering without notice. The underwriters
reserve the right to reject an order for the purchase of shares in whole or in
part.
We have agreed to indemnify the underwriters against liabilities, including
liabilities under the Securities Act, and to contribute to payments the
underwriters may be required to make in respect to those liabilities.
Each executive officer and director of First Horizon and substantially all
other holders of our securities have agreed during the period of 180 days after
the effective date of this prospectus, subject to specified exceptions, not to
offer to sell, contract to sell, or otherwise sell, dispose of, loan, pledge or
grant any rights with respect to any shares of common stock or any options or
warrants to purchase any shares of common stock, or any securities convertible
into or exchangeable for shares of common stock owned as of the date of this
prospectus or thereafter acquired directly by those holders or with respect to
which they have the power of disposition, without the prior written consent of
Chase Securities Inc. However, Chase Securities Inc. may, in its sole discretion
and at any time or from time to time, without notice, release all or any portion
of the securities subject to lock-up agreements. There are no existing
agreements between the representatives and any of our stockholders with respect
to any shares subject to a lock-up agreement providing consent to the sale of
shares prior to the expiration of the lock-up period.
In addition, we have agreed that during the lock-up period we will not,
without the prior written consent of Chase Securities Inc., subject to certain
exceptions, consent to the disposition of any shares held by stockholders
subject to lock-up agreements prior to the expiration of the lock-up period, or
issue, sell, contract to sell, or otherwise dispose of, any shares of common
stock, any options or warrants to purchase any shares of common stock or any
securities convertible into, exercisable for or exchangeable for shares of
common stock other than our sale of shares in this offering, the issuance of our
common stock upon the exercise of outstanding options or warrants, and the
issuance of options under existing stock option and incentive plans provided
that those options do not vest prior to the expiration of the lock-up period.
See "Shares Eligible for Future Sale."
At our request, the underwriters have reserved up to five percent of the
shares of common stock to be sold in this offering to be offered for sale,
exclusive of the shares subject to the over-allotment option, at the initial
public offering price, to our directors, officers, employees, business
associates such as customers and suppliers and persons related to, or affiliated
with the foregoing persons. The number of shares available for sale to the
general public in this offering will be reduced to the extent these persons
purchase the reserved shares. Any reserved shares not so purchased will be
offered to the general public on the same basis as the other shares offered by
this prospectus.
Persons participating in this offering may over-allot or effect
transactions that stabilize, maintain or otherwise affect the market price of
the common stock at levels above those that might otherwise prevail in the open
market, including by entering stabilizing bids, effecting syndicate covering
transactions or imposing penalty bids. A stabilizing bid means the placing of
any bid or the effecting of any purchase of the purpose of pegging, fixing or
maintaining the price of the common stock. A syndicate covering transaction
means the placing of any bid on behalf of the underwriting syndicate or the
effecting of any purchase to reduce a short position created in connection with
this offering. A penalty bid means an arrangement that permits the underwriters
to reclaim a selling concession from a syndicate member in connection with this
offering when shares of common stock sold by the syndicate member are purchased
in syndicate covering transactions. These transactions may be effected on the
Nasdaq National Market, in the over-the-counter market or otherwise.
Stabilizing, if commenced, may be discontinued at any time.
Before this offering, there was no public market for the common stock. The
initial public offering price for the common stock will be determined by
negotiations between ourselves and the representatives of the underwriters.
Among the factors to be considered in determining the initial
61
<PAGE> 66
public offering price will be prevailing market and economic conditions, our
revenues and earnings, market valuations of other companies engaged in
activities similar to ours, estimates of our business potential and prospects,
the present state of our business operations, our management and other factors
deemed relevant.
Thomas Weisel Partners LLC, one of the representatives of the underwriters,
was organized and registered as a broker-dealer in December 1998. Since December
1998, Thomas Weisel Partners has been named as a lead or co-manager on 166 filed
public offerings of equity securities, of which 113 have been completed, and has
acted as a syndicate member in an additional 92 public offerings of equity
securities. Thomas Weisel Partners does not have any material relationship with
us or any of our officers, directors or other controlling persons, except with
respect to its contractual relationship with us pursuant to the underwriting
agreement entered into in connection with this offering.
LEGAL MATTERS
The validity of the shares of common stock that we are offering will be
passed upon for us by Arnall Golden & Gregory, LLP. Certain legal matters in
connection with this offering will be passed upon for the underwriters by Testa,
Hurwitz & Thibeault, LLP.
EXPERTS
The audited financial statements and schedule included in this prospectus
and elsewhere in the registration statement have been audited by Arthur Andersen
LLP, independent public accountants, as indicated in their reports with respect
thereto, and are included herein in reliance upon the authority of said firm as
experts in giving said reports.
ADDITIONAL INFORMATION
We have filed with the Securities and Exchange Commission, Washington, D.C.
20549, a registration statement on Form S-1 under the Securities Act with
respect to the shares of common stock we are offering. This prospectus does not
contain all of the information set forth in the registration statement and the
exhibits and schedule filed with it. We have omitted certain items in accordance
with the rules and regulations of the Commission. For further information with
respect to our business and the common stock we are offering, please see the
registration statement and the exhibits and schedule filed therewith. Statements
contained in this prospectus as to the contents of any contract or any other
document referred to are not necessarily complete, and in each instance,
reference is made to the copy of such contract or other document filed as an
exhibit to the registration statement, each statement being qualified in all
respects by such reference. You may inspect a copy of the registration
statement, and the exhibits and schedule filed with it, without charge at the
public reference facilities maintained by the Commission in Room 1024, 450 Fifth
Street, N.W., Washington, D.C. 20549, and the Commission's regional offices
located at the Northwestern Atrium Center, 500 West Madison Street, Suite 1400,
Chicago Illinois 60661 and Seven World Trade Center, 13th Floor, New York, New
York 10048, and you can obtain copies of all or any part of the registration
statement from these offices upon the payment of the fees prescribed by the
Commission. You can obtain information on the operation of the public reference
room by calling the Commission at 1-800-SEC-0330. The Commission maintains a
World Wide Web site that contains reports, proxy and information statements and
other information regarding registrants that file electronically with the
Commission. The address of the site is http://www.sec.gov. We have
electronically filed the registration statement, including all exhibits and
schedule filed with it, with the Commission.
62
<PAGE> 67
FIRST HORIZON PHARMACEUTICAL CORPORATION
INDEX TO FINANCIAL STATEMENTS
<TABLE>
<CAPTION>
PAGE
----
<S> <C>
Report of Independent Public Accountants.................... F-2
Balance Sheets.............................................. F-3
Statements of Operations.................................... F-4
Statements of Stockholders' Equity.......................... F-5
Statements of Cash Flows.................................... F-6
Notes to Financial Statements............................... F-7
</TABLE>
F-1
<PAGE> 68
REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS
To First Horizon Pharmaceutical Corporation:
We have audited the accompanying balance sheets of FIRST HORIZON
PHARMACEUTICAL CORPORATION (formerly Horizon Pharmaceutical Corporation, a
Delaware corporation) as of December 31, 1998 and 1999, and the related
statements of operations, stockholders' equity and cash flows for each of the
three years in the period ended December 31, 1999. These financial statements
are the responsibility of the Company's management. Our responsibility is to
express an opinion on these financial statements based on our audits.
We conducted our audits in accordance with auditing standards generally
accepted in the United States. Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the financial statements
are free of material misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements. An
audit also includes assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a reasonable basis
for our opinion.
In our opinion, the financial statements referred to above present fairly,
in all material respects, the financial position of First Horizon Pharmaceutical
Corporation as of December 31, 1998 and 1999, and the results of its operations
and its cash flows for each of the three years in the period ended December 31,
1999 in conformity with accounting principles generally accepted in the United
States.
ARTHUR ANDERSEN LLP
Atlanta, Georgia
February 17, 2000 (except with respect to
the matters discussed in Note 12
as to which the date is May 3, 2000.)
F-2
<PAGE> 69
FIRST HORIZON PHARMACEUTICAL CORPORATION
BALANCE SHEETS
<TABLE>
<CAPTION>
DECEMBER 31, MARCH 31,
------------------------- -----------
1998 1999 2000
----------- ----------- -----------
(UNAUDITED)
<S> <C> <C> <C>
ASSETS
Current Assets:
Cash and cash equivalents............................ $ 425,023 $ 219,688 $ 735,337
Accounts receivable, net of allowance for doubtful
accounts, discounts and contractual adjustments of
$35,395, $55,783 and $125,188 at December 31,
1998, 1999 and March 31, 2000 respectively........ 1,147,248 2,900,623 2,861,497
Inventories.......................................... 402,397 798,615 1,795,464
Samples and other prepaid expenses................... 470,382 553,614 1,691,725
Deferred tax assets.................................. 146,931 550,780 550,781
----------- ----------- -----------
Total current assets......................... 2,591,981 5,023,320 7,634,804
----------- ----------- -----------
Property and equipment, net............................ 305,247 422,096 469,025
Other Assets:
Note receivable from related party................... 30,000 30,000 50,372
Intangibles, net..................................... 5,873 5,602,328 5,528,886
----------- ----------- -----------
Total other assets........................... 35,873 5,632,328 5,579,258
----------- ----------- -----------
Total assets................................. $ 2,933,101 $11,077,744 $13,683,087
=========== =========== ===========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable..................................... $ 553,318 $ 794,088 $ 1,773,379
Accrued expenses..................................... 795,645 2,892,727 3,593,219
Borrowings under revolving loan agreement............ 602,928 800,000 2,000,000
Current portion of long-term debt.................... -- 1,270,389 1,270,389
----------- ----------- -----------
Total current liabilities.................... 1,951,891 5,757,204 8,636,987
----------- ----------- -----------
Long-Term Liabilities:
Long-term debt, net of current maturities............ -- 1,628,497 1,305,319
Deferred tax liabilities............................. 25,080 76,479 76,479
----------- ----------- -----------
Total liabilities............................ 1,976,971 7,462,180 10,018,785
----------- ----------- -----------
Commitments and Contingencies (Notes 1,5,6,8,10 and 11)
Stockholders' Equity:
Preferred stock, 1,000,000 shares authorized and none
outstanding....................................... -- -- --
Common stock, $0.001 par value; 40,000,000 shares
authorized; 7,981,248 and 8,539,643 shares issued
and outstanding at December 31, 1998, 1999 and
March 31, 2000 respectively....................... 7,982 8,540 8,540
Additional paid-in capital........................... 2,615,434 5,788,220 5,788,220
Deferred compensation................................ 0 (1,284,374) (1,197,105)
Accumulated deficit.................................. (1,667,286) (896,822) (935,353)
----------- ----------- -----------
Total stockholders' equity................... 956,130 3,615,564 3,664,302
----------- ----------- -----------
Total liabilities and stockholders' equity... $ 2,933,101 $11,077,744 $13,683,087
=========== =========== ===========
</TABLE>
The accompanying notes are an integral part of these balance sheets.
F-3
<PAGE> 70
FIRST HORIZON PHARMACEUTICAL CORPORATION
STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>
THREE
MONTHS ENDED
YEAR ENDED DECEMBER 31, -------------------------
------------------------------------- MARCH 31, MARCH 31,
1997 1998 1999 1999 2000
---------- ---------- ----------- ----------- -----------
(UNAUDITED) (UNAUDITED)
<S> <C> <C> <C> <C> <C>
Net revenues....................... $5,557,700 $9,252,058 $18,624,514 $4,199,934 $7,119,638
Operating costs and expenses
Cost of revenues................. 1,136,691 1,903,054 3,140,416 719,432 1,061,737
Selling, general and
administrative expenses,
excluding the non-cash expense
presented below................ 4,545,254 6,789,358 12,400,439 2,550,153 5,491,653
Non-cash selling general and
administrative expense......... 133,500 -- 143,986 10,722 87,269
Depreciation and amortization.... 30,273 35,225 424,274 79,302 114,639
Research and development
expense........................ -- 255,000 860,350 142,945 375,292
---------- ---------- ----------- ---------- ----------
Total operating costs and
expenses................ 5,845,718 8,982,637 16,969,465 3,502,554 7,130,590
---------- ---------- ----------- ---------- ----------
Operating (loss) income............ (288,018) 269,421 1,655,049 697,380 (10,952)
---------- ---------- ----------- ---------- ----------
Other income (expense):
Interest expense................. (5,496) (14,017) (356,598) (55,758) (72,060)
Interest income.................. 2,909 4,383 11,950 2,197 5,591
Other............................ 3,629 (2,749) 8,059 2,450 9,822
---------- ---------- ----------- ---------- ----------
Total other income
(expense)............... 1,042 (12,383) (336,589) (51,111) (56,647)
---------- ---------- ----------- ---------- ----------
Income before benefit (provision)
for income taxes................. (286,976) 257,038 1,318,460 646,269 (67,599)
Benefit (provision) for income
taxes............................ 106,530 (121,484) (547,996) (270,368) 29,068
---------- ---------- ----------- ---------- ----------
Net (loss) income.................. $ (180,446) $ 135,554 $ 770,464 $ 375,901 $ (38,531)
========== ========== =========== ========== ==========
Net (loss) income per common share:
Basic............................ $ (0.02) $ 0.02 $ 0.10 $ 0.05 $ (0.00)
========== ========== =========== ========== ==========
Diluted.......................... $ (0.02) $ 0.02 $ 0.09 $ 0.04 $ (0.00)
========== ========== =========== ========== ==========
Weighted average common shares
outstanding:
Basic............................ 7,576,580 7,978,234 8,028,673 7,981,248 8,539,643
========== ========== =========== ========== ==========
Diluted.......................... 7,576,580 8,584,329 8,975,493 8,759,904 8,539,643
========== ========== =========== ========== ==========
</TABLE>
The accompanying notes are an integral part of these statements.
F-4
<PAGE> 71
FIRST HORIZON PHARMACEUTICAL CORPORATION
STATEMENTS OF STOCKHOLDERS' EQUITY
<TABLE>
<CAPTION>
COMMON STOCK ADDITIONAL
------------------ PAID-IN DEFERRED ACCUMULATED
SHARES AMOUNT CAPITAL COMPENSATION DEFICIT TOTAL
--------- ------ ---------- ------------ ----------- ----------
<S> <C> <C> <C> <C> <C> <C>
Balance, December 31, 1996........... 5,830,000 $5,830 $1,139,553 $ -- $(1,622,394) $ (477,011)
Conversion of debt to equity....... 1,261,248 1,262 787,021 -- -- 788,283
Proceeds from sale of stock........ 880,000 880 549,120 -- -- 550,000
Deferred compensation.............. -- -- 133,500 -- -- 133,500
Net loss........................... -- -- -- -- (180,446) (180,446)
--------- ------ ---------- ----------- ----------- ----------
Balance, December 31, 1997........... 7,971,248 7,972 2,609,194 -- (1,802,840) 814,326
Stock options exercised............ 10,000 10 6,240 -- -- 6,250
Net income......................... -- -- -- -- 135,554 135,554
--------- ------ ---------- ----------- ----------- ----------
Balance, December 31, 1998........... 7,981,248 7,982 2,615,434 -- (1,667,286) 956,130
Conversion of debt to equity....... 558,395 558 1,744,426 -- -- 1,744,984
Deferred compensation.............. -- -- 1,428,360 (1,284,374) -- 143,986
Net income......................... -- -- -- -- 770,464 770,464
--------- ------ ---------- ----------- ----------- ----------
Balance, December 31, 1999........... 8,539,643 $8,540 $5,788,220 $(1,284,374) $ (896,822) $3,615,564
========= ====== ========== =========== =========== ==========
Deferred Compensation (unaudited).. -- -- -- 87,269 -- 87,269
--------- ------ ---------- ----------- ----------- ----------
Net Loss (unaudited)............... -- -- -- -- (38,531) (38,531)
--------- ------ ---------- ----------- ----------- ----------
Balance, March 31, 2000
(unaudited)........................ 8,539,643 $8,540 $5,788,220 $(1,197,105) $ (935,353) $3,664,302
========= ====== ========== =========== =========== ==========
</TABLE>
The accompanying notes are an integral part of these statements.
F-5
<PAGE> 72
FIRST HORIZON PHARMACEUTICAL CORPORATION
STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>
THREE MONTHS ENDED
YEAR ENDED DECEMBER 31, --------------------------
----------------------------------- MARCH 31, MARCH 31,
1997 1998 1999 1999 2000
--------- --------- ----------- ----------- -----------
(UNAUDITED) (UNAUDITED)
<S> <C> <C> <C> <C> <C>
Cash flows from operating activities:
Net (loss) income................................... $(180,446) $ 135,554 $ 770,464 $ 375,901 $ (38,531)
Adjustments to reconcile net (loss) income to net
cash (used in) provided by operating activities:
Depreciation and amortization................... 30,273 35,225 424,274 79,302 114,639
Non-cash interest expenses...................... -- -- 144,984 --
Deferred tax provision.......................... (108,867) 102,000 (352,450) --
Non-cash compensation expense................... 133,500 -- 143,986 10,722 87,269
Loss on disposal of equipment................... -- 4,404 --
Changes in assets and liabilities net of
acquired assets and liabilities:
Accounts receivable........................... (226,597) (486,629) (1,753,375) (822,353) 39,126
Inventories................................... 35,309 (261,368) (396,218) (1,874) (996,849)
Samples and other prepaid expenses............ (304,815) (139,445) (83,232) 1,435 (1,138,112)
Note receivable from related party............ -- (30,000) -- -- (20,372)
Accrued expenses.............................. 153,621 446,429 1,763,019 317,500 700,492
Accounts payable.............................. 272,031 13,288 356,850 (106,307) 979,291
--------- --------- ----------- ----------- -----------
Net cash (used in) provided by operating
activities................................ (195,991) (180,542) 1,018,302 (145,674) (273,047)
--------- --------- ----------- ----------- -----------
Cash flows from investing activities:
Purchase of intangibles........................... 500 -- (4,000,000) (4,000,000) --
Purchase of property and equipment................ (121,272) (208,464) (185,709) (75,020) (68,959)
--------- --------- ----------- ----------- -----------
Net cash used in investing activities....... (120,772) (208,464) (4,185,709) (4,075,020) (68,959)
Cash flows from financing activities:
Proceeds from revolving loan agreement............ -- 563,013 197,072 1,200,000
Proceeds from long-term debt...................... -- -- 4,000,000 4,000,000 (342,345)
Principal payments on long-term debt.............. (19,457) -- (1,235,000) (47,764) --
Proceeds from issuance of common stock............ 550,000 6,250 -- --
--------- --------- ----------- ----------- -----------
Net cash provided by financing activities... 530,543 569,263 2,962,072 3,952,236 857,655
--------- --------- ----------- ----------- -----------
Net change in cash and cash equivalents............. 213,780 180,257 (205,335) (268,458) 515,649
Cash and cash equivalents, beginning of period...... 30,986 244,766 425,023 425,023 219,688
--------- --------- ----------- ----------- -----------
Cash and cash equivalents, end of period............ $ 244,766 $ 425,023 $ 219,688 $ 156,565 $ 735,337
========= ========= =========== =========== ===========
</TABLE>
The accompanying notes are an integral part of these statements.
F-6
<PAGE> 73
FIRST HORIZON PHARMACEUTICAL CORPORATION
NOTES TO FINANCIAL STATEMENTS
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
DESCRIPTION OF BUSINESS
First Horizon Pharmaceutical Corporation (formerly Horizon Pharmaceutical
Corporation, the "Company") is an emerging pharmaceutical company that markets
and sells brand name prescription drugs to high-prescribing primary care and
select specialty physicians in the United States through their nationwide sales
and marketing field force. The Company focuses on the treatment of chronic
conditions, including cardiovascular diseases, respiratory and
gastroenterological disorders, and pain and inflammation. The Company's strategy
is to acquire and obtain licenses for pharmaceutical products that other
companies do not actively market, and to increase sales through aggressive
promotion and marketing. In addition, the Company seeks to maximize the value of
their drugs by developing new patentable formulations, using new delivery
methods and seeking regulatory approval for new indications.
USE OF ESTIMATES
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect certain reported amounts and disclosures. Accordingly,
actual results could differ from those estimates.
INTERIM UNAUDITED FINANCIAL INFORMATION
The financial statements as of March 31, 2000 and for the three months
ended March 31, 1999 and 2000 are unaudited; however, in the opinion of
management, all adjustments (consisting solely of normal recurring adjustments)
necessary for a fair presentation of the unaudited financial statements for
these interim periods have been included. The results of interim periods are not
necessarily indicative of results to be obtained for a full year.
REVENUE RECOGNITION
Revenues from product sales are recognized upon shipment to customers and
are shown net of sales adjustments. Provisions for discounts, rebates to
customers, returns, and other adjustments are provided in the same period that
the related sales are recorded. Cost of revenues is comprised of purchased
product costs.
ROYALTIES AND COMMISSION COSTS
The Company pays royalties and commissions on the sale of certain products.
These costs are included in selling general and administrative costs in the
accompanying statement of operations. Total royalties and commission costs were
$81,000, $194,000, $620,000, $91,000 and $358,000 for the years ending December
31, 1997, 1998 and 1999, and for the three months ended March 31, 1999 and 2000,
respectively.
RESEARCH AND DEVELOPMENT
Research and development expenses consist primarily of costs incurred to
develop formulations, engage contract research organizations to conduct clinical
studies, test products under development and engage medical and regulatory
consultants. The Company expenses all research and development costs as
incurred. Research and development costs were $0, $255,000, $860,350, $142,945,
and $375,292 for the years ended December 31, 1997, 1998 and 1999, and for the
three months ended March 1, 1999 and 2000, respectively.
F-7
<PAGE> 74
FIRST HORIZON PHARMACEUTICAL CORPORATION
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -- (CONTINUED)
RETURNS AND REBATE ALLOWANCES
The Company provides all customers with a right of return within six months
of the expiration date of the product, and as a result records a provision for
returns at the time of sale. The Company is contractually obligated to pay
rebates on the sale of certain prescription drugs. The reserve for returns and
rebates is estimated based upon historical experience and other relevant
information, in accordance with generally accepted accounting principles. There
is no certainty that future returns and rebates will not exceed established
reserves.
CASH AND CASH EQUIVALENTS
The Company considers only those investments that are highly liquid, and
readily convertible to cash with an original maturity of three months or less to
be cash equivalents. The Company had no cash equivalents at December 31, 1998,
1999 or March 31, 2000.
CONCENTRATION OF CREDIT RISK
The Company extends credit on an uncollateralized basis primarily to
wholesale drug distributors and retail pharmacy chains throughout the United
States. Historically, the Company has not experienced significant credit losses
on its accounts.
The Company's five largest customers accounted for approximately 79%, 66%,
and 68% of accounts receivable at December 31, 1998, 1999 and March 31, 2000,
respectively.
The following table represents a summary of sales to significant customers
as a percentage of the Company's total revenues:
<TABLE>
<CAPTION>
CUSTOMER 1997 1998 1999
- -------- ---- ---- ----
<S> <C> <C> <C>
McKesson HBOC, Inc.......................................... 29% 29% 28%
Cardinal Health, Inc........................................ 28 28 19
Bergen Brunswig Corporation................................. 12 12 10
</TABLE>
The Company relies on third-party suppliers to produce its products. The
supply of a product whose sales comprised 24% of the Company's sales in 1999 is
exclusively available through a single supplier.
Two products accounted for 46%, 49%, 51%, 41% and 51% of the Company's
sales in 1997, 1998 and 1999, and for the three months ended March 31, 1999 and
2000, respectively.
SEGMENT REPORTING
The Company operates in a single segment, the sale and marketing of
prescription drugs.
INVENTORIES
Inventories consist of purchased pharmaceutical products and are stated at
the lower of cost or market. Cost is determined using the first-in, first-out
method.
SAMPLES AND OTHER PREPAID EXPENSES
Samples and other prepaid expenses primarily consist of product samples
used in the sales and marketing efforts of the Company's products. Samples are
expensed upon distribution.
F-8
<PAGE> 75
FIRST HORIZON PHARMACEUTICAL CORPORATION
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -- (CONTINUED)
PROPERTY AND EQUIPMENT
Property and equipment are stated at cost. Major improvements, which extend
the lives of existing property and equipment, are capitalized. Depreciation is
provided for on the straight-line basis over the estimated useful lives of the
assets. Accelerated depreciation is used for income tax purposes. Expenditures
for maintenance and repairs that do not extend the lives of the applicable
assets are charged to expense as incurred.
The estimated useful lives of the classes of assets generally are as
follows:
<TABLE>
<S> <C>
Office equipment........................................... Five to ten years
Furniture and fixtures..................................... Five to ten years
Computer hardware and software............................. Three to seven years
Leasehold improvements..................................... Five years
</TABLE>
The components of property and equipment as of December 31, 1998 and 1999,
and March 31, 2000 are as follows:
<TABLE>
<CAPTION>
1998 1999 MARCH 31, 2000
-------- --------- --------------
(UNAUDITED)
<S> <C> <C> <C>
Office equipment................................ $ 36,583 $ 42,315 $ 52,437
Furniture and fixtures.......................... 81,641 131,065 162,764
Computer hardware and software.................. 172,892 294,414 321,552
Leasehold improvements.......................... 89,617 98,648 98,648
-------- --------- ---------
380,733 566,442 635,401
Less accumulated depreciation and
amortization.................................. (75,486) (144,346) (166,376)
-------- --------- ---------
Property and equipment, net........... $305,247 $ 422,096 $ 469,025
======== ========= =========
</TABLE>
Depreciation and amortization expense related to property and equipment,
for the years ended December 31, 1997, 1998, 1999, and for the three months
ended March 31, 1999 and 2000, was $29,924, $34,745, $68,860, $14,560 and
$22,030, respectively.
In the event that facts and circumstances indicate that the carrying
amounts of property and equipment may be impaired, an evaluation of
recoverability is performed using the estimated future undiscounted cash flows
associated with the asset compared to the asset's carrying amount to determine
if a write-down is required.
In March 1998, the American Institute of Certified Public Accountants
issued Statement of Position, or "SOP," No. 98-1, "Accounting for the Costs of
Computer Software Developed or Obtained for Internal Use." SOP 98-1 requires
that entities capitalize certain costs related to internal-use software once
certain criteria have been met. The Company was required to implement SOP No.
98-1 for the year ending December 31, 1999. The adoption of SOP No. 98-1 had no
impact to the financial condition or results of operations of the Company.
INTANGIBLE ASSETS
The costs of obtaining patents and product licenses are capitalized and
amortized on a straight-line basis over the estimated periods benefited by the
asset (15 to 20 years). Amortization of such assets is included in depreciation
and amortization expense in the accompanying financial statements. Amortization
expense for the years ended December 31, 1997, 1998, and 1999, and for
F-9
<PAGE> 76
FIRST HORIZON PHARMACEUTICAL CORPORATION
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -- (CONTINUED)
the three months ended March 31, 1999 and 2000 was $979, $480, $269,326, $32,342
and $73,442, respectively.
The Company continually reevaluates the propriety of the carrying amount of
intangibles as well as the related amortization period to determine whether the
current events and circumstances warrant adjustments to the carrying values
and/or estimates of useful lives. This evaluation is performed using the
estimated projected future undiscounted cash flows associated with the asset
compared to the asset's carrying amount to determine if a write-down is
required. To the extent such projections indicate that the undiscounted cash
flows are not expected to be adequate to recover the carrying amounts, the
assets are written down to fair value as determined by discounting future cash
flows.
INCOME TAXES
The Company provides for income taxes in accordance with Statement of
Financial Accounting Standards ("SFAS") No. 109 "Accounting for Income Taxes."
SFAS No. 109 requires recognition of deferred tax assets and liabilities using
currently enacted tax rates.
ADVERTISING COSTS
The Company follows the policy of charging the costs of advertising to
expense as incurred. Advertising expenses were $46,188, $39,233, $178,929,
$45,725 and 453,726 for the years ending December 31, 1997, 1998 and 1999, and
for the three months ended March 31, 1999 and 2000, respectively.
FAIR VALUE OF FINANCIAL INSTRUMENTS
The Company's borrowings under its variable rate long-term debt agreements
are recorded at cost, which approximates fair value.
EARNINGS PER SHARE
As required by SFAS No. 128, "Earnings Per Share," the Company has
presented basic and diluted earnings per common share amounts in the
accompanying financial statements. Basic earnings per common share is calculated
based on the weighted average common shares outstanding during the year, while
diluted earnings per common share also gives effect to all potential dilutive
stock equivalents during each year such as options, warrants, and contingently
issuable shares. The Company incurred a net loss in 1997 and for the three
months ended March 31, 2000 and, as such, the weighted average number of common
shares used for diluted earnings per common share does not consider the
potential dilutive effect of 502,126 and 1,557,571 common stock equivalents,
respectively, as such consideration would have an antidilutive effect on
earnings per common share.
F-10
<PAGE> 77
FIRST HORIZON PHARMACEUTICAL CORPORATION
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -- (CONTINUED)
Below is the calculation of basic and diluted net (loss) income per common
share:
<TABLE>
<CAPTION>
YEAR ENDED DECEMBER 31, THREE MONTHS ENDED
------------------------------------- -------------------------------
1997 1998 1999 MARCH 31, 1999 MARCH 31, 2000
---------- ---------- ----------- -------------- --------------
(UNAUDITED) (UNAUDITED)
<S> <C> <C> <C> <C> <C>
Net (loss) income.......... $ (180,446) $ 135,554 $ 770,464 $ 375,901 $ (38,531)
========== ========== =========== ========== ==========
Weighted average common
shares
outstanding -- basic..... 7,576,580 7,978,234 8,028,673 7,981,248 8,539,643
Dilutive effect of stock
options.................. N/A 606,095 946,820 778,656 N/A
---------- ---------- ----------- ---------- ----------
Weighted average common
shares
outstanding -- diluted... 7,576,580 8,584,329 8,975,493 8,759,904 8,539,643
========== ========== =========== ========== ==========
Basic net (loss) income per
share.................... $ (0.02) $ 0.02 $ 0.10 $ 0.05 $ (0.00)
========== ========== =========== ========== ==========
Diluted net (loss) income
per share................ $ (0.02) $ 0.02 $ 0.09 $ 0.04 $ (0.00)
========== ========== =========== ========== ==========
</TABLE>
RECLASSIFICATIONS
Certain prior year amounts have been reclassified to conform with the
current year financial statement presentation.
RESTATED FINANCIAL STATEMENTS
The financial statements for the period ending December 31, 1997 have been
restated to reflect certain adjustments for accrued expenses net of taxes.
SUPPLEMENTAL CASH FLOW DISCLOSURES
The Company purchased intangible assets for $4,000,000 in cash with an
additional $1,800,000 financed by the seller. Pursuant to the acquisition, the
Company also assumed estimated liabilities of $218,460 for returns of products
shipped by the seller prior to the acquisition date in 1999.
The Company issued 1,261,248 and 558,395 shares of common stock in the
conversion of outstanding convertible debt (including accrued interest) totaling
$788,283 and $1,744,984 and in 1997 and 1999, respectively.
<TABLE>
<CAPTION>
YEAR ENDED THREE MONTHS ENDED
DECEMBER 31, ---------------------
------------------------- MARCH 31, MARCH 31,
1997 1998 1999 1999 2000
---- ------- -------- --------- ---------
(UNAUDITED)
<S> <C> <C> <C> <C> <C>
Cash paid for taxes................... $ -- $ -- $777,927 $ 9,380 $324,741
==== ======= ======== ======== ========
Cash paid for interest................ $970 $10,855 $235,889 $ 27,010 $135,939
==== ======= ======== ======== ========
</TABLE>
NEW ACCOUNTING PRONOUNCEMENTS
In June 1998, the Financial Accounting Standards Board issued SFAS No. 133,
"Accounting for Derivative Instruments and Hedging Activities." The Company must
adopt SFAS No. 133 for the year ending December 31, 2000. SFAS No. 133
established methods of accounting for derivative financial
F-11
<PAGE> 78
FIRST HORIZON PHARMACEUTICAL CORPORATION
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -- (CONTINUED)
instruments and hedging activities related to those instruments as well as other
hedging activities. Management believes adoption of SFAS No. 133 will not have a
material impact on the Company's financial condition or results of operations.
Effective January 1, 1998, the Company adopted SFAS No. 130, "Reporting
Comprehensive Income," which requires additional disclosure and presentation of
amounts comprising comprehensive income beyond net income. The Company had no
items of other comprehensive income amounts for the periods presented. As a
result, the adoption had no impact on the Company's reporting under generally
accepted accounting principles.
2. REVOLVING LOAN AGREEMENT
In May 1998, the Company entered into a revolving loan agreement with a
bank under which the Company can borrow up to $1,000,000, subject to borrowing
base limitations based on eligible accounts receivable and inventory balances,
as defined in the agreement. The revolving loan agreement was amended and
restated on December 22, 1998 to provide for partial financing of a product
acquisition through a term loan. Under the amended agreement, terms of the
revolving loan facility provide for up to $2,500,000, subject to borrowing base
limitations based on eligible accounts receivable and inventory, as defined in
the agreement. Borrowings under the revolving loan facility bear interest at the
bank's prime rate, and are due on January 31, 2001. At December 31, 1999, the
outstanding balance under the revolving loan was $800,000 with an interest rate
of 8.5%, and the Company had additional availability under the terms of the
agreement of approximately $1,700,000. During January 2000, the loan agreement
was amended and restated to provide for borrowings up to $3,500,000 through June
30, 2000, reverting back to $2,500,000 from June 30, 2000 to January 31, 2001.
The revolving loan agreement contains certain restrictive covenants including,
among other things, minimum EBITDA levels and debt to equity ratio. Any failure
to comply with these requirements could have a material adverse effect on the
Company's operations, unless waivers are obtained.
F-12
<PAGE> 79
FIRST HORIZON PHARMACEUTICAL CORPORATION
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
3. LONG-TERM DEBT
Long-term debt consists of the following at December 31, 1998 and 1999, and
March 31, 2000:
<TABLE>
<CAPTION>
1998 1999 MARCH 31, 2000
-------- ----------- --------------
(UNAUDITED)
<S> <C> <C> <C>
Term note payable (initial amount of
$2,400,000) to a bank bearing interest at
the lesser of Prime or LIBOR plus 2%
(7.96% at December 31, 1999), with
monthly payments of $40,000 plus accrued
interest maturing in December 2001....... $ -- $ 1,840,000 $ 1,720,000
Obligation to a seller of intangible assets
payable in quarterly installments of
$225,000 through February 2001, net of an
unamortized discount of $52,850, using an
interest rate of 8.75%................... -- 1,058,886 855,708
-------- ----------- -----------
-- 2,898,886 2,575,708
Less current maturities.................... -- (1,270,389) (1,270,389)
-------- ----------- -----------
Total............................ $ -- $ 1,628,497 $ 1,305,319
======== =========== ===========
</TABLE>
The term note payable contains certain restrictive covenants including,
among other things, minimum EBITDA levels and debt to equity ratio. Any failure
to comply with these requirements could have a material adverse effect on the
Company's operations, unless waivers are obtained.
Future maturities of long-term debt are $1,270,389 and $1,628,497 for the
years ended December 31, 2000 and 2001, respectively.
4. ACCRUED EXPENSES
Accrued expenses consists of the following:
<TABLE>
<CAPTION>
DECEMBER 31,
--------------------- THREE MONTHS ENDED
1998 1999 MARCH 31, 2000
-------- ---------- ----------------------
(UNAUDITED)
<S> <C> <C> <C>
Employee compensation and benefits.... $510,578 $ 949,325 $ 585,957
Customer return allowance............. 140,000 272,423 325,524
Product rebates....................... -- 851,248 1,479,404
Interest.............................. 15,028 64,011 25,480
Other................................. 130,039 755,720 1,176,854
-------- ---------- ----------
$795,645 $2,892,727 $3,593,219
======== ========== ==========
</TABLE>
5. STOCKHOLDER'S EQUITY
In 1998, the Company approved a four-for-one common stock split, thus
increasing authorized common shares from 10 million to 40 million. All common
stock information for all periods presented herein has been restated to give
effect to this stock split.
F-13
<PAGE> 80
FIRST HORIZON PHARMACEUTICAL CORPORATION
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
5. STOCKHOLDER'S EQUITY -- (CONTINUED)
Through 1996, the Company borrowed $635,000 from related parties accruing
interest at Prime plus 2%. During 1997, the Company issued 1,261,248 shares of
common stock by converting the $635,000 of debt to shareholders, plus accrued
interest of $153,283 to common stock at a rate of $0.625 per share, the then
estimated fair market value. Additionally, the Company issued 880,000 shares of
common stock at $0.625 per share in exchange for $550,000 in cash.
In 1998, 10,000 shares of common stock were issued upon exercise of stock
options at an exercise price of $0.625 per share.
In December 1999, the Company issued 558,395 shares of common stock to the
Company's majority stockholder upon the conversion of $1.6 million of
convertible debt incurred in January 1999 for the purchase of a product license
and accrued interest of $144,984 thereon to common stock. The shares were
converted at a rate of $3.125 as stipulated in the applicable agreement. The
original debt agreement stipulated an interest rate of Prime plus 2% (10.25% at
the conversion date) with the full principal amount due by December 1, 2001.
Under the Company's Restated Certificate of Incorporation the Board of
Directors has the authority, without further action by the stockholders, to
issue up to 1,000,000 shares of preferred stock in one or more series and to fix
the rights, preferences, privileges and restrictions thereof, including dividend
rights, conversion rights, voting rights, terms of redemption, liquidation
preferences, sinking fund terms and the number of shares constituting any series
or the designation of such series, without any further vote or action by the
stockholders. The issuance of preferred stock could adversely affect the voting
power of holders of common stock and the likelihood that such holders will
receive dividend payments and payments upon liquidation. The issuance of
preferred stock may have the effect of delaying, deferring or preventing a
change in control of the Company, which could have a depressive effect on the
market price of our common stock. The Company has no present plan to issue any
shares of preferred stock. As of December 31, 1998 and 1999 and March 31, 2000
there were no shares of preferred stock outstanding.
6. STOCK OPTIONS
Pursuant to the Company's 1997 Non-Qualified Stock Option Plan (the
"Plan"), the Board of Directors approved the issuance of options to purchase
shares of common stock of the Company to various employees. Under the Plan,
4,000,000 shares (adjusted for the 1998 four-for-one stock split) of common
stock were reserved for issuance. Vesting periods range from immediate to four
years, and options granted generally expire seven years from the date of grant.
All options also include accelerated vesting provisions in the event of a change
in control, as defined in the Plan.
F-14
<PAGE> 81
FIRST HORIZON PHARMACEUTICAL CORPORATION
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
6. STOCK OPTIONS -- (CONTINUED)
The Company has granted stock options to officers, directors, and employees
as follows:
<TABLE>
<CAPTION>
NUMBER WEIGHTED
OF SHARES AVERAGE
SUBJECT TO EXERCISE
OPTIONS PRICE
---------- --------
<S> <C> <C>
Outstanding at December 31, 1996........................... -- N/A
Granted.................................................. 870,000 $0.556
Canceled................................................. -- N/A
---------
Outstanding at December 31, 1997........................... 870,000 0.556
Granted.................................................. 122,000 1.875
Canceled................................................. (10,000) 1.375
Exercised................................................ (10,000) 0.625
---------
Outstanding at December 31, 1998........................... 972,000 0.712
Granted.................................................. 785,500 2.494
Canceled................................................. (5,000) 2.250
Exercised................................................ -- N/A
---------
Outstanding at December 31, 1999........................... 1,752,500 $1.506
=========
Granted (unaudited)...................................... 47,500 8.350
Cancelled (unaudited).................................... (5,000) 2.125
Exercised (unaudited).................................... -- N/A
---------
Outstanding at March 31, 2000 (unaudited).................. 1,795,000 1.685
=========
Shares vested at December 31, 1999......................... 753,750
=========
Shares vested at March 31, 2000 (unaudited)................ 830,625
=========
</TABLE>
At December 31, 1999, approximately 2,237,500 shares remained reserved for
issuance under the 1997 Plan. Subsequent to year-end the Company retired the
1997 Plan. Prior to the retirement of the 1997 Plan the Company's board approved
the issuance of an additional 47,500 options, exercisable at $8.35 per share. At
February 14, 2000, 1,800,000 options were issued and outstanding under the 1997
Plan. The intent of Company management is to no longer issue options under the
1997 Plan. The following table sets forth the range of exercise prices, number
of shares, weighted average exercise price, and remaining contractual lives by
similar price and grant date at December 31, 1999.
<TABLE>
<CAPTION>
OUTSTANDING EXERCISABLE
--------------------------- -----------------------
OUTSTANDING WEIGHTED WEIGHTED EXERCISABLE WEIGHTED
AT AVERAGE AVERAGE AT AVERAGE
DECEMBER 31, REMAINING EXERCISE DECEMBER 31, EXERCISE
RANGE OF EXERCISE PRICE 1999 CONTRACTUAL LIFE PRICE 1999 PRICE
- ----------------------------- ------------ ---------------- -------- ------------ --------
<S> <C> <C> <C> <C> <C>
$0.500 - $0.625 856,000 4.9 years $0.556 706,000 $0.540
1.875 - 1.880 234,000 7.7 years 1.876 41,500 1.877
2.500 - 2.650 662,500 9.6 years 2.605 6,250 2.500
--------- -------
Total 1,752,500 753,750
========= =======
</TABLE>
F-15
<PAGE> 82
FIRST HORIZON PHARMACEUTICAL CORPORATION
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
6. STOCK OPTIONS -- (CONTINUED)
The Company applies APB Opinion 25 and related interpretations in
accounting for its stock options. Accordingly, the Company obtained appraisals
of the fair market value of the stock on the date of the option grant and will
recognize compensation expense over the vesting period of the options. The
Company has recognized compensation expense related to stock option grants of
$133,500, $0, $143,986, $10,722 and $87,269 in 1997, 1998 and 1999, and for the
three months ended March 31, 1999 and 2000 respectively. Had compensation costs
for these options been determined using the minimum value option pricing model
prescribed by SFAS 123, "Accounting for Stock Based Compensation," the Company's
Pro forma net (loss) income per common share would have been reported as
follows:
<TABLE>
<CAPTION>
DECEMBER 31,
-------------------------------
1997 1998 1999
--------- -------- --------
<S> <C> <C> <C>
Net (loss) income:
As reported..................................... $(180,446) $135,554 $770,464
Pro-forma....................................... (251,889) 111,734 476,823
Net (Loss) Income per Common Share -- basic:
As Reported..................................... (0.02) 0.02 0.10
Pro-forma....................................... (0.03) 0.01 0.06
Net (Loss) Income per Common Share -- diluted:
As Reported..................................... (0.02) 0.02 0.09
Pro-forma....................................... (0.03) 0.01 0.05
</TABLE>
The weighted average minimum value of options granted during 1997, 1998 and
1999 is estimated at $0.44, $1.51, and $2.01 per share. The minimum value of
options is estimated on the date of the grant using the following weighted
average assumptions:
<TABLE>
<CAPTION>
DECEMBER 31,
------------------------
1997 1998 1999
---- ---- ----
<S> <C> <C> <C>
Risk-free interest rate........................... 6.19% 5.53% 5.57%
Expected dividend yield........................... -- -- --
4 4 4
Expected lives.................................... years years years
Expected volatility............................... --% --% --%
</TABLE>
On February 14, 2000, the Board of Directors and stockholders approved the
2000 Stock Plan. This plan provides for the granting of incentive stock options
under the Internal Revenue Code of 1986; options that do not qualify as
incentive stock options, stock awards or stock bonuses, and sales of stock. The
2000 Stock Plan provides for the grants of these options and other awards to
officers, directors, full- and part-time employees, advisors and consultants.
Only full-time employees may receive incentive stock options. The Company has
reserved 2,000,000 shares of common stock for issuance under the 2000 Stock
Plan. The Company's compensation committee administers the 2000 Stock Plan and
has the sole authority to determine the meaning and application of the terms of
the plan and all grant agreements, the persons to whom option or stock grants
are made, the nature and amount of option or stock grants, the price to be paid
upon exercise of each option, the period within which options may be exercised,
the restrictions on stock awards, and the other terms and conditions of awards.
The 2000 Stock Plan will terminate in February 2010. Subsequent to the approval
of this plan, the Company's Board of Directors approved the grant of options to
purchase 177,950 shares of common stock which will become effective upon the
issuance of stock by the Company in a public offering. Such options will be
exercisable at the offering price.
F-16
<PAGE> 83
FIRST HORIZON PHARMACEUTICAL CORPORATION
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
6. STOCK OPTIONS -- (CONTINUED)
The Company adopted an employee stock purchase plan on February 14, 2000
that is intended to qualify as an employee stock purchase plan within the
meaning of Section 423 of the Internal Revenue Code. The Company has reserved
500,000 shares of common stock for the stock purchase plan. In order to
participate in the stock purchase plan, employees must meet eligibility
requirements, including length of employment. Participating employees will be
able to direct the Company to make payroll deductions of up to 7% of their
compensation during an offering period for the purchase of shares of the
Company's common stock. Each offering period will be six months, beginning on
July 1, 2000. The stock purchase plan will provide participating employees with
the right, subject to specific limitations, to purchase the Company's common
stock at a price equal to 85% of the lesser of the fair market value of the
Company's common stock on the first or last day of the offering period. The
Board of Directors has the authority to amend, suspend or discontinue the stock
purchase plan as long as the change will not adversely affect participants
without their consent and as long as the Company receives the shareholder
approval required by law. The stock purchase plan will terminate on December 31,
2010.
7. INCOME TAXES
The benefit (provision) for income taxes for 1997, 1998 and 1999 consisted
of the following components:
<TABLE>
<CAPTION>
DECEMBER 31,
--------------------------------
1997 1998 1999
-------- --------- ---------
<S> <C> <C> <C>
Current....................................... $ (2,337) $ (19,484) $(900,446)
Deferred...................................... 108,867 (102,000) 352,450
-------- --------- ---------
Total............................... $106,530 $(121,484) $(547,996)
======== ========= =========
</TABLE>
A reconciliation of the statutory rate to the effective rate as recognized
in the statement of operations is as follows:
<TABLE>
<CAPTION>
DECEMBER 31,
--------------------
1997 1998 1999
---- ---- ----
<S> <C> <C> <C>
Federal statutory rate.................................... 35% (35)% (35)%
State taxes, net.......................................... 4 (4) (4)
Nondeductible meals and entertainment expenses............ (2) (8) (3)
-- --- ---
37% (47)% (42)%
== === ===
</TABLE>
F-17
<PAGE> 84
FIRST HORIZON PHARMACEUTICAL CORPORATION
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
7. INCOME TAXES -- (CONTINUED)
Deferred tax assets and liabilities reflect the impact of temporary
differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts recognized for income tax purposes.
Significant components of the Company's net deferred tax assets as of December
31, 1998 and 1999 are as follows:
<TABLE>
<CAPTION>
1998 1999
-------- --------
<S> <C> <C>
Current deferred tax assets:
Net operating loss carryforward........................... $ 33,196 $ --
Accrued liabilities....................................... 60,335 439,785
Deferred compensation..................................... 53,400 110,995
-------- --------
146,931 550,780
-------- --------
Long-term deferred tax liabilities:
Depreciation and amortization............................. 25,080 76,479
-------- --------
Net deferred tax assets........................... $121,851 $474,301
======== ========
</TABLE>
8. LICENSE AGREEMENTS AND PRODUCT RIGHTS
On January 1, 1996, the Company obtained exclusive distribution rights from
Unisource, Inc. for Tanafed in North America through December 31, 2003 with an
option for an additional seven years. The agreement requires the Company to
purchase all of their requirements for Tanafed from Unisource, including at
least certain minimum quantities of Tanafed in each year of the agreement. The
Company entered into a patent and license agreement with the raw materials'
supplier for Tanafed dated January 2000, which provides a license to a patent
covering an active ingredient in Tanafed.
On October 31, 1998, the Company entered into an agreement with Inpharmakon
Corporation in which the Company acquired rights to the proprietary information
for a migraine product for which the Company plans to conduct clinical studies
and submit a new drug application. The agreement expires on October 31, 2008,
but the Company may renew it indefinitely after expiration. If the Company does
not obtain regulatory approval of the drug within a specified time after filing
for such approval and thereafter commence and continue to aggressively market
and sale the product, Inpharmakon may terminate the agreement. In the event that
Inpharmakon terminates the agreement for failure to achieve these milestones,
Inpharmakon may purchase rights to develop the drug. The Company must also pay
up to an aggregate of $950,000 in non-refundable fees to Inpharmakon at various
developmental milestones through and including regulatory approval of the
product, and, in the event of commercial sales of the product, the Company must
pay royalties at rates which management believes are within industry customary
ranges. If the Company elects to sell the business opportunity to a third party,
the Company must share the proceeds of the sale with Inpharmakon.
On January 29, 1999, the Company acquired exclusive rights in the United
States to Robinul and Robinul Forte tablets from American Home Products
Corporation. The Company agreed to pay royalties on net sales as long as the
Company sells the product. The Company negotiated for AHP, or its designee, to
continue to manufacture and supply the product to the Company until January 29,
2001. The Company has an agreement with a supplier, dated April 23, 1999, for
the supplier to become qualified under applicable regulations to manufacture and
supply the requirements for Robinul. Under this agreement, the supplier will
manufacture the products for five
F-18
<PAGE> 85
FIRST HORIZON PHARMACEUTICAL CORPORATION
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
8. LICENSE AGREEMENTS AND PRODUCT RIGHTS -- (CONTINUED)
years from the time the supplier becomes a qualified manufacturer plus renewal
terms of one year until either party elects to not renew. The agreement with the
supplier requires that the Company purchase certain designated minimum
quantities. The Company has capitalized the cost of obtaining the license and is
amortizing it over an estimated economic life of 20 years.
On March 25, 1999, the Company acquired the rights from Penwest
Pharmaceuticals Co. to the application of Penwest's controlled release TIMERx
technology to the active ingredient in the migraine product. Under the Penwest
agreement, the Company has the right to manufacture, use and sell the developed
product in North America and Mexico for a period extending fifteen years from
the date a new drug application is issued for the product, as well as a license
to the TIMERx(R) patents for such purpose. The Company must pay Penwest an
aggregate of up to approximately $2,600,000 of non-refundable fees upon
achieving specified development milestones through the first anniversary of the
first commercial sale of the product following regulatory approval and royalties
upon any sales of the migraine product. Penwest may terminate the agreement in
the event the Company fails to timely achieve designated performance milestones
within prescribed time periods.
In July 1999, the Company entered in to an agreement with Pohl-Boskamp for
the exclusive rights to distribute, market and sell Nitrolingual Pumpspray
beginning on February 1, 2000 in the United States for five years plus an
additional five year renewal period subject to establishing mutually acceptable
minimum purchase requirements. Under the agreement, Pohl-Boskamp supplies the
Company with their requirements of product at prices that decrease as volume
purchased in each year increases. The Company must purchase designated minimum
quantities in each year of the agreement and pay a royalty on net sales of the
product. Aventis had exclusive rights through January 2000 to a version of the
product containing CFC named Nitrolingual Spray. To promote earlier adoption of
Nitrolingual Pumpspray, the Company obtained exclusive rights from Aventis to
market this CFC product in the United States as of November 22, 1999.
Each of the Company's third-party manufacturing agreements requires that
the Company purchase all of their product requirements from the manufacturers
that are a party to those agreements.
The Company uses third-party manufacturers for the production of its
products for development and commercial purposes. Given the general
under-utilization of resources, the availability of excess capacity for
manufacturing in the marketplace, and the lower cost of outsourcing, the Company
intends to continue to outsource manufacturing for the near-term.
The Company currently uses the services of six third-party manufacturers
for manufacturing of the Company's products pursuant to the Company's product
specifications. The Company has manufacturing and supply agreements with five of
these manufacturers. The remaining terms of these agreements generally range
from one to five years. Under some of these agreements, the manufacturers or
other third parties own the rights to the product that the Company has under
their marketing licenses. Except for our Defen-LA, Protuss-D, and Zoto-HC
products, these agreements generally state that the product supplier will
provide products only to us. The Company has not entered into agreements for
alternative manufacturing sources for any of its products. The suppliers of
Nitrolingual Pumpspray and the raw materials for Tanafed hold patents for their
respective products.
F-19
<PAGE> 86
FIRST HORIZON PHARMACEUTICAL CORPORATION
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
9. RETIREMENT PLAN
In 1996, the Company began a qualified defined contribution 401(k) plan,
which provides benefits to substantially all employees. The annual contribution,
if any, to the trust is at the discretion of the Board of Directors of the
Company. There were no employer contributions to the plan for the year ended
December 31, 1997. Employer contributions to the plan for the years ended
December 31, 1998 and 1999, and for the three months ended March 31, 1999 and
2000 were $20,695, $36,055, $8,781 and $29,593, respectively.
10. COMMITMENTS AND CONTINGENCIES
The Company leases its facilities under a cancelable operating lease that
expires in August 2003. The total rent expense was $38,962, $90,315, $211,533,
$51,498, and $63,759 for the years ended December 31, 1997, 1998, and 1999, and
for the three months ended March 31, 1999 and 2000, respectively. The Company
leases vehicles for certain employees under cancelable lease agreements expiring
in 2001. The total vehicle lease expense under the lease agreement for the years
ended December 31, 1997, 1998 and 1999, and for the three months ended March 31,
1999 and 2000 was $0, $0, $434,393, $0 and $244,540, respectively.
The total minimum future commitment under leases for years succeeding
December 31, 1999 is as follows:
<TABLE>
<CAPTION>
<S> <C>
Year ending December 31,
2000...................................................... $ 999,969
2001...................................................... 621,903
2002...................................................... 198,073
2003...................................................... 137,640
2004...................................................... 8,525
----------
Total............................................. $1,966,110
==========
</TABLE>
Subsequent to year end, the Company entered in employment contracts with
certain executives. These contracts provide base salaries ranging from $80,000
to $110,000.
11. RELATED-PARTY TRANSACTIONS
The Company purchases repackaging services from Diversified Healthcare
Services, a related party. For the years ended December 31, 1997, 1998, and 1999
and the three months ended March 31, 1999 and 2000, the amounts paid for
repackaging were approximately $83,000, $132,000, $282,000, $43,800 and $84,134,
respectively.
The Company pays royalties to a related party for particular products sold.
For the years ended December 31, 1997, 1998, and 1999 and the three months ended
March 31, 1999 and 2000, the amounts paid for royalties were approximately
$91,000, $160,000, $163,000, $29,344, and $42,797 respectively.
During 1997, the Company converted $385,000 in loans from Kamal Kapoor, a
related party, plus $124,363 accrued interest, into 814,978 shares of common
stock at a rate of $0.625 per share.
During 1997, the Company converted $150,000 in loans from the John N.
Kapoor Trust dated September 30, 1989, an affiliate of the Company, plus $3,345
accrued interest, into 245,352 shares of common stock at a rate of $0.625 per
share.
F-20
<PAGE> 87
FIRST HORIZON PHARMACEUTICAL CORPORATION
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
11. RELATED-PARTY TRANSACTIONS -- (CONTINUED)
The Chairman and Chief Executive Officer of the Company did not receive a
salary for the year ended December 31, 1999.
During 1997, the Company converted $100,000 in loans from EJ Financial
Enterprises, plus $25,575 accrued interest, into 200,918 shares of common stock
at a rate of $0.625 per share.
On January 27, 1997, the Company issued 320,000 shares of its common stock
to the John Kapoor Trust in exchange for $200,000.
On June 30, 1997, the Company issued 560,000 shares of its common stock to
Kapoor-Pharma Investments in exchange for $350,000.
The Company extended a non-interest bearing note receivable to an officer
of the Company during 1998. As of December 31, 1998 and 1999 the amount due to
the Company under this note was $30,000.
During 1998, the Company entered into a collaboration agreement with
Inpharmakon Corporation, an affiliate of an officer of the Company, under which
Inpharmakon will assist the Company in developing their FHPC 01 product. The
Company paid $200,000, and $1,352 to Inpharmakon in 1998 and 1999, respectively,
under this agreement.
On January 11, 1999, Kapoor-Pharma Investments, an affiliate of the
Director of the Company, loaned the Company $1,600,000 at an interest rate of 2%
over the Prime Rate of Interest. In November 1999, the Company converted
principal and $144,984 of accrued interest totaling $1,744,984 into 558,395
shares of common stock at $3.125 per share, pursuant to the terms of the loan
agreement.
12. SUBSEQUENT EVENTS (UNAUDITED)
PRODUCT AGREEMENTS
On April 14, 2000, the Company acquired exclusive rights from
Warner-Lambert to distribute, market, and sell the drug Ponstel in the United
States for $9.5 million in cash and a $3.5 million promissory note to the
seller. The Company financed $9.5 million of the transaction under a bridge loan
agreement with LaSalle Bank. The agreement includes the purchase of the
licensing rights described above as well as certain trademarks. In addition the
Company agreed to purchase all of the outstanding inventory of Ponstel for
approximately $100,000. The promissory note is payable in full upon the receipt
of proceeds from an initial public offering of the Company's common stock and in
all cases no later than November 30, 2000.
The Company negotiated with Warner-Lambert to continue to manufacture and
supply the Ponstel product to the Company through December 31, 2000. The Company
is currently in negotiations to secure a replacement manufacturer for Ponstel.
On April 14, 2000, the Company entered into an agreement with
Warner-Lambert to purchase exclusive rights in the United States and other
countries to market, distribute and sell a drug called Cognex, as well as rights
to a new unapproved version of Cognex, called Cognex CR. The purchase of Cognex
is contingent on Warner-Lambert receiving Federal Trade Commission ("FTC")
approval for the transaction and the satisfaction of other customary conditions.
If the Company acquires Cognex, the Company will be required to pay $3.5 million
in cash for the product. Warner-Lambert may terminate this agreement if the
transaction has not closed by June 30, 2000, unless it has not closed because of
a delay in receiving FTC approval.
F-21
<PAGE> 88
FIRST HORIZON PHARMACEUTICAL CORPORATION
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
12. SUBSEQUENT EVENTS (UNAUDITED) -- (CONTINUED)
The Company must also pay Warner-Lambert up to $1.5 million in additional
purchase price if the Company obtains FDA approval to market Cognex CR. The
Company may have to undertake additional studies for this approval. In the event
that the Company voluntarily stops selling Cognex for 60 days or more other than
for reasons outside their control, the FTC may order that Cognex revert back to
Warner-Lambert and be divested by the FTC to another purchaser.
The agreement for the Cognex transaction provides for a sublicense to the
Company of Warner-Lambert's rights to an active ingredient in Cognex. The
Company will be required to pay royalties on net sales of Cognex. However, the
Company will be entitled to apply the amount of royalties that Warner-Lambert
has prepaid for these patents and the Company does not expect to pay royalties
in the near future.
The agreement for Cognex provides for a supply agreement under which an
affiliate of Warner-Lambert will manufacture and supply Cognex to the Company
and supply to the Company the active ingredient in Cognex for two years after
the Cognex transactions close, subject to a one year renewal. The Company will
pay Warner-Lambert's affiliate a production fee for its manufacture of Cognex
and the active ingredient. The supply agreement contains designated quantities
of Cognex and its active ingredient that Warner-Lambert's affiliate will supply
and that the Company must purchase. The Company plans to secure a replacement
manufacturer for Cognex and is currently in negotiations with a potential
manufacturer.
As a condition to closing the Cognex purchase the Company intends to enter
into a transition services agreement with Warner-Lambert under which
Warner-Lambert will provide transitional administrative services to the Company
until November 30, 2000 in connection with the sale of Cognex in European
countries. These services will include maintenance of Cognex registrations,
contact with regulatory authorities including reporting requirements, responding
to customer complaints, sales administration, shipping management, billing,
processing of returns, storage, responding to any regulatory inquiries or
investigations, responding to any customer complaints and communicating with
physicians in relation to the product. Warner-Lambert may terminate this
agreement if any person or entity acquires ownership or control of 50% or more
of the Company's common stock or acquires substantially all of the Company's
assets.
BRIDGE LOAN AGREEMENT
In conjunction with the product acquisitions discussed above, the Company
entered into an amended credit facility with LaSalle Bank that provided for
bridge financing of up to $13,000,000 to finance the Company's product
acquisitions. On April 14, 2000 the Company borrowed $9,500,000 under this
bridge loan for the Company's purchase of Ponstel. The Company intends to borrow
an additional $3,500,000 to purchase Cognex if the Cognex transaction is closed
prior to conclusion of the Company's public offer of common stock. Borrowings
under the bridge loan bear interest at the Company's choice of the prime rate of
LIBOR plus 1.5% and in the event that the bridge loan is not paid in full within
six months thereafter the loan shall bear interest at the Company's choice of
prime rate or LIBOR plus 2.0%. Interest on the bridge loan is payable monthly
beginning on May 1, 2000. Borrowings under the bridge loan mature upon the
Company's receipt of proceeds from a public offering of the Company's common
stock and no later than April 14, 2001. In the event that the Company does not
complete a public offering within six months, the Company shall make monthly
principal installments of $150,000 commencing October 30, 2000 through May 2,
2001, with the remaining outstanding balance at that point in time due as a
balloon payment.
F-22
<PAGE> 89
FIRST HORIZON PHARMACEUTICAL CORPORATION
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
12. SUBSEQUENT EVENTS (UNAUDITED) -- (CONTINUED)
Under the terms of the bridge loan agreement, the Company must maintain a
minimum net worth plus subordinated debt of $3,300,000 plus 75% of net income, a
ratio of liabilities to net worth plus subordinated debt after the conclusion of
the Company's public offering of common stock of 2.25 to 1.00, a minimum
specified EBITDA, ranging from $100,000 to $200,000 and a fixed charge coverage
ratio ranging from .75 to 1.00 to 1.25 to 1.00. The agreement limits the
Company's ability to incur additional indebtedness, and prohibits substantial
asset sales and cash dividends. Additionally the agreement amends the maturity
dates of the revolving loan agreement (Note 2) and the term note payable (Note
3) between LaSalle Bank and the Company to May 2, 2001. In addition to the
collateral assigned under the original agreements with LaSalle Bank, the Company
pledged, as collateral for the bridge loan, a security interest in the Ponstel
trademarks to LaSalle Bank.
As additional collateral, for the bridge loan financing, John Kapoor (a
director of the Company) and his wife pledged a security interest in the
securities and investments of the Kapoor Children's 1992 Trust totaling $10
million. As consideration for the Pledge, the Company will pay the Kapoor
Children's Trust $100,000 per year, for as long as the pledge is in effect, and
all of the Trusts expenses incurred in connection with perfecting the security
interest.
INPHARMAKON COLLABORATION AGREEMENT
On May 3, 2000 the Company entered into an agreement with Inpharmakon
Corporation, a related party, to amend certain payment terms under the existing
product development agreement between Inpharmakon and the Company whereby the
Company must pay to Inpharmakon an additional $200,000 within thirty days of
completion of a public offering of the Company's common stock. In the event that
the Company does not complete a public offering of their common stock by October
20, 2000 the Company is obligated to pay Inpharmakon an additional $100,000 and
provided further that in the event the Company has not completed a public
offering of their common stock by April 20, 2001 the Company must pay an
additional $100,000 to Inpharmakon.
F-23
<PAGE> 90
3,800,000 SHARES
(1ST HORIZON LOGO)
COMMON STOCK
-----------------------
PROSPECTUS
-----------------------
CHASE H&Q
BANC OF AMERICA SECURITIES LLC
THOMAS WEISEL PARTNERS LLC
-----------------------
, 2000
-----------------------
YOU SHOULD RELY ONLY ON THE INFORMATION CONTAINED IN THIS PROSPECTUS. WE
HAVE NOT AUTHORIZED ANYONE TO PROVIDE YOU WITH INFORMATION DIFFERENT FROM THAT
CONTAINED IN THIS PROSPECTUS. WE ARE OFFERING TO SELL, AND SEEKING OFFERS TO
BUY, SHARES OF COMMON STOCK ONLY IN JURISDICTIONS WHERE OFFERS AND SALES ARE
PERMITTED. THE INFORMATION CONTAINED IN THIS PROSPECTUS IS ACCURATE ONLY AS OF
THE DATE OF THIS PROSPECTUS, REGARDLESS OF THE TIME OF DELIVERY OF THIS
PROSPECTUS OR OF ANY SALE OF OUR COMMON STOCK.
UNTIL , 2000 (25 DAYS AFTER COMMENCEMENT OF THE OFFERING),
ALL DEALERS THAT BUY, SELL, OR TRADE OUR COMMON STOCK, WHETHER OR NOT
PARTICIPATING IN THIS OFFERING, MAY BE REQUIRED TO DELIVER A PROSPECTUS. THIS
REQUIREMENT IS IN ADDITION TO THE DEALERS' OBLIGATION TO DELIVER A PROSPECTUS
WHEN ACTING AS UNDERWRITERS AND WITH RESPECT TO THEIR UNSOLD ALLOTMENTS OR
SUBSCRIPTIONS.
<PAGE> 91
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
ITEM 13. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION
The following table sets forth all expenses, other than the underwriting
discounts and commissions, payable by the Registrant in connection with the sale
of the common stock being registered. All the amounts are estimates except for
the registration fee, the Nasdaq listing fee and the NASD filing fee.
<TABLE>
<CAPTION>
ITEM AMOUNT
- ---- ------
<S> <C>
Registration fee............................................ $ 16,152
Nasdaq National Market listing fee.......................... 83,875
NASD filing fee............................................. 6,618
Blue sky qualification fees and expenses.................... 5,000
Printing and engraving expenses............................. 125,000
Legal fees and expenses..................................... 400,000
Accounting fees and expenses................................ 328,355
Transfer agent and registrar fees........................... 10,000
Miscellaneous............................................... 25,000
----------
Total............................................. $1,000,000
==========
</TABLE>
- ------------------------
* To be provided by amendment.
ITEM 14. INDEMNIFICATION OF DIRECTORS AND OFFICERS
As permitted by Delaware law, the Registrant's Restated Certificate of
Incorporation provides that no director of the Registrant will be personally
liable to the Registrant or its stockholders for monetary damages for breach of
fiduciary duty as a director, except for liability (a) for any breach of duty of
loyalty to First Horizon or to its stockholders, (b) for acts or omissions not
in good faith or that involve intentional misconduct or a knowing violation of
law, (c) under Section 174 of the Delaware General Corporation Law, or (d) for
any transaction from which the director derived an improper personal benefit.
The Registrant's Restated Certificate of Incorporation further provides that the
Registrant must indemnify its directors and executive officers and may indemnify
its other officers and employees and agents to the fullest extent permitted by
Delaware law. The Registrant maintains a policy of directors and officers
insurance that provides insurance against certain expenses and liabilities which
may be incurred by directors and officers.
The Underwriting Agreement (Exhibit 1) will provide for indemnification by
the underwriters of the Registrant, its directors, its officers who sign the
registration statement, and the Registrant's controlling persons for certain
liabilities, including liabilities arising under the Securities Act.
ITEM 15. RECENT SALES OF UNREGISTERED SECURITIES
During the last three years, the Registrant has sold or issued the
following unregistered securities:
(1) As of December 8, 1999, the Registrant issued an aggregate of
558,395 shares of its common stock for an aggregate consideration of
$1,744,984 to an accredited investor pursuant to the conversion of a
convertible promissory note issued to such accredited investor as of
January 11, 1999.
(2) As of December 7, 1998, the Registrant made effective a four for
one stock split with respect to its issued and outstanding common stock.
II-1
<PAGE> 92
(3) As of April 20, 1998, the Registrant issued 10,000 shares of its
common stock for an aggregate consideration of $6,250 to an employee
pursuant to the exercise of its stock option.
(4) As of June 30, 1997, the Registrant issued 560,000 shares of its
common stock for an aggregate consideration of $350,000 to one accredited
investor.
(5) At various times during the relevant three-year time period, the
Registrant issued to certain employees and consultants options to purchase
in the aggregate up to 1,725,500 shares of its common stock at exercise
prices ranging from $0.50 to $2.65 per share.
Exemption from the registration provisions of the Securities Act for the
transaction described in paragraph 2 above was claimed on the basis that such
transaction did not constitute an "offer," "offer to sell," "sale," or "offer to
buy" under Section 5 of the Securities Act. Exemption from the registration
provisions of the Securities Act for the other transactions described above was
claimed under Section 4(2) of the Securities Act and the rules and regulations
promulgated thereunder on the basis that such transaction did not involve any
public offering, the purchasers were sophisticated with access to the kind of
information registration would provide and that such purchasers acquired such
securities without a view towards distribution thereof. In addition, exemption
from the registration provisions of the Securities Act for the transactions
described in paragraphs 3 and 5 was claimed under Section 3(b) of the Securities
Act on the basis that such securities were sold pursuant to a written
compensatory benefit plans or pursuant to a written contract relating to
compensation and not for capital raising purposes under Rule 701 of the
Securities Act.
ITEM 16. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
(a) The following is a list of exhibits filed as a part of this
registration statement.
<TABLE>
<CAPTION>
EXHIBIT
NO. DESCRIPTION
- ---------- -----------
<C> <C> <S>
1* -- Form of Underwriting Agreement
3.1* -- Restated Certificate of Incorporation of the Registrant
3.2* -- Amended and Restated Bylaws of the Registrant
4.1+ -- Form of Stock Certificate
4.2* -- Amended and Restated Loan and Security Agreement dated as of
December 22, 1998 between the Registrant and LaSalle Bank
National Association
4.3* -- First Amendment to Amended and Restated Loan and Security
Agreement dated as of May 10, 1999 between the Registrant
and LaSalle Bank National Association
4.4* -- Second Amendment to Amended and Restated Loan and Security
Agreement dated as of January 2, 2000 between the Registrant
and LaSalle Bank National Association
4.5* -- Third Amendment to Amended and Restated Loan and Security
Agreement dated as of April 14, 2000 between the Registrant
and LaSalle Bank National Association
4.6* -- Reimbursement Agreement dated April 14, 2000 between the
Registrant and Kapoor Children's 1992 Trust
5+ -- Opinion of Arnall Golden & Gregory, LLP
10.1* -- 1997 Non-Qualified Stock Option Plan
10.2* -- 2000 Stock Plan
10.3* -- Form of Nonqualified Stock Option Agreement
</TABLE>
II-2
<PAGE> 93
<TABLE>
<CAPTION>
EXHIBIT
NO. DESCRIPTION
- ---------- -----------
<C> <C> <S>
10.4* -- Form of Employment Agreement dated as of January 1, 2000
between the Registrant and certain of its executive officers
10.5* -- Convertible Term Loan Note dated January 11, 1999 made by
the Registrant for the benefit of Kapoor Pharma Investments,
L.P., as amended by Amendment No. 1 to the Convertible Term
Note dated January 11, 1999 made by the Registrant for the
benefit of Kapoor Pharma Investments, L.P.
10.6* -- Convertible Term Note Agreement dated January 11, 1999
between the Registrant and Kapoor Pharma Investments, L.P.,
as amended by Amendment No. 1 to the Convertible Term Note
dated January 11, 1999 made by the Registrant for the
benefit of Kapoor Pharma Investments, L.P.
10.7* -- Lease Agreement dated June 28, 1998 between the Registrant
and ASC North Fulton Associates Joint Venture
10.8*** -- Product Development and Supply Agreement dated March 25,
1999 between the Registrant and Penwest Pharmaceuticals Co.
10.9*** -- Collaboration Agreement dated October 31, 1998 between the
Registrant and Inpharmakon Corporation
10.10*** -- Exclusive Patent License Agreement dated January 1, 2000
between the Registrant and Jame Fine Chemicals, Inc.
10.11*** -- Exclusive Distribution Agreement dated January 1, 1996
between the Registrant and Unisource, Inc.
10.12*** -- Manufacturing and Supply Agreement dated April 23, 1999
between the Registrant and Mikart, Inc.
10.13*** -- Product Supply Agreement dated January 29, 1999 between the
Registrant and American Home Products Corporation
10.14*** -- License Agreement dated January 29, 1999 between the
Registrant and American Home Products Corporation
10.15*** -- Distribution Agreement dated July 22, 1999 between the
Registrant and G. Pohl-Boskamp GmbH & Co.
10.16* -- Form of Indemnity Agreement between the Registrant and its
directors and executive officers
10.17*** -- Asset Purchase Agreement dated April 10, 2000 between the
Registrant and Warner-Lambert Company
10.18*** -- Supply Agreement dated April 14, 2000 between the Registrant
and Warner-Lambert Company
10.19*** -- Asset Purchase Agreement dated April 14, 2000 between the
Registrant and Warner-Lambert Company
10.20* -- Amendment No. 1 to the Product Development and Supply
Agreement, dated May 3, 2000 between the Registrant and
Penwest Pharmaceuticals Co.
10.21*** -- Amendment to the Collaboration Agreement, dated May 3, 2000
between the Registrant and Inpharmakon Corporation
23.1* -- Consent of Arthur Andersen LLP
23.2+ -- Consent of Arnall Golden & Gregory, LLP (included in Exhibit
5)
</TABLE>
II-3
<PAGE> 94
<TABLE>
<CAPTION>
EXHIBIT
NO. DESCRIPTION
- ---------- -----------
<C> <C> <S>
24.1* -- Powers of Attorney
27 * -- Financial Data Schedule (for SEC use only)
</TABLE>
- ---------------
* Previously filed
** To be filed by amendment
*** First Horizon has requested confidential treatment for certain portions of
this exhibit pursuant to Rule 406 of the Securities Act of 1933, as
amended.
+ Filed herewith
(b) The following is the schedule filed as a part of the registration
statement: Schedule II -- Valuation and Qualifying Accounts.
ITEM 17. UNDERTAKINGS
The Registrant hereby undertakes to provide the underwriters at the closing
specified in the Underwriting Agreement certificates in such denominations and
registered in such names as required by the underwriters to permit prompt
delivery to each purchaser.
Insofar as indemnification for liabilities arising under the Securities Act
may be permitted to directors, officers, and controlling persons of the
Registrant pursuant to the provisions described in Item 14 or otherwise, the
Registrant has been advised that in the opinion of the Securities and Exchange
Commission, such indemnification is against public policy as expressed in the
Securities Act and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the
Registrant of expenses incurred or paid by a director, officer, or controlling
person of the Registrant in the successful defense of any action, suit, or
proceeding) is asserted by such director, officer, or controlling person in
connection with the securities being registered, the Registrant will, unless in
the opinion of its counsel the matter has been settled by controlling precedent,
submit to a court of appropriate jurisdiction the question whether such
indemnification by it is against public policy as expressed in the Securities
Act and will governed by the final adjudication of such issue.
The undersigned Registrant undertakes that: (1) for purposes of determining
any liability under the Securities Act, the information omitted from the form of
prospectus filed as part of the registration statement in reliance upon Rule
430A and contained in the form of prospectus filed by the Registrant pursuant to
Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be
part of the registration statement as of the time it was declared effective, and
(2) for the purpose of determining any liability under the Securities Act, each
post-effective amendment that contains a form of prospectus shall be deemed to
be a new registration statement relating to the securities offered therein, and
the offering of such securities at that time shall be deemed to be the initial
bona fide offering thereof.
II-4
<PAGE> 95
SIGNATURES
In accordance with the requirements of the Securities Act of 1933, the
Registrant has duly caused this registration statement on Form S-1 to be signed
on its behalf by the undersigned, in the City of Roswell, State of Georgia on
the 19th day of May, 2000.
FIRST HORIZON PHARMACEUTICAL CORPORATION
By: /s/ R. BRENT DIXON
---------------------------------------
R. Brent Dixon
President
In accordance with the requirements of the Securities Act of 1933, this
registration statement was signed below by the following persons in the
capacities and on the dates indicated.
<TABLE>
<CAPTION>
SIGNATURE TITLE DATE
--------- ----- ----
<C> <S> <C>
/s/ MAHENDRA G. SHAH, PH.D.* Chairman of the Board and Chief May 19, 2000
- --------------------------------------------- Executive Officer (principal
Mahendra G. Shah, Ph.D. executive officer)
/s/ R. BRENT DIXON President and Director May 19, 2000
- ---------------------------------------------
R. Brent Dixon
/s/ JOHN. N. KAPOOR, PH.D.* Director May 19, 2000
- ---------------------------------------------
John. N. Kapoor, Ph.D.
/s/ BALAJI VENKATARAMAN* Vice President and Chief Financial May 19, 2000
- --------------------------------------------- Officer (principal financial and
Balaji Venkataraman accounting officer)
/s/ JON S. SAXE* Director May 19, 2000
- ---------------------------------------------
Jon S. Saxe
/s/ PIERRE LAPALME* Director May 19, 2000
- ---------------------------------------------
Pierre Lapalme
/s/ R. BRENT DIXON
*By: --------------------------------------
R. Brent Dixon
Attorney-in-Fact
</TABLE>
II-5
<PAGE> 96
REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS
To First Horizon Pharmaceutical Corporation:
We have audited in accordance with auditing standards generally accepted in
the United States, the financial statements of FIRST HORIZON PHARMACEUTICAL
CORPORATION (formerly Horizon Pharmaceutical Corporation, a Delaware
corporation) included in this registration statement and have issued our report
thereon dated February 17, 2000. Our audit was made for the purpose of forming
an opinion on the basic financial statements taken as a whole. The schedule
located in this registration statement at item 16(b) is the responsibility of
the company's management and is presented for purposes of complying with the
Securities and Exchange Commission's rules and are not part of the basic
financial statements. This schedule has been subjected to the auditing
procedures applied in the audit of the basic financial statements and, in our
opinion, fairly state in all material respects the financial data required to be
set forth therein in relation to the basic financial statements taken as a
whole.
ARTHUR ANDERSEN LLP
Atlanta, Georgia
February 17, 2000
II-6
<PAGE> 97
SCHEDULE II
FIRST HORIZON PHARMACEUTICAL CORPORATION
VALUATION AND QUALIFYING ACCOUNTS
YEARS ENDED DECEMBER 31, 1997, 1998 AND 1999
<TABLE>
<CAPTION>
BALANCE AT CHARGED TO CHARGED
BEGINNING COSTS AND TO OTHER
CLASSIFICATION OF YEAR EXPENSES ACCOUNTS DEDUCTIONS BALANCE
-------------- ---------- ---------- ---------- ---------- --------
<S> <C> <C> <C> <C> <C> <C>
1997 Allowance for doubtful accounts $ -- $ 25,924 $ -- $ (12,674) $ 13,250
Allowance for customer returns 100,000 38,289 -- (38,289) 100,000
1998 Allowance for doubtful accounts 13,250 40,714 (18,569) 35,395
Allowance for customer returns 100,000 80,994 (40,994) 140,000
1999 Allowance for doubtful accounts 35,395 51,493 (31,105) 55,783
Allowance for customer returns 140,000 366,904 (234,481) 272,423
Allowance for product rebates -- 1,294,072 (442,824) 851,248
</TABLE>
II-7
<PAGE> 98
EXHIBIT INDEX
The following is a list of exhibits filed as a part of this registration
statement.
<TABLE>
<CAPTION>
EXHIBIT
NO. DESCRIPTION
- --------- -----------
<C> <C> <S>
1* -- Form of Underwriting Agreement
3.1* -- Restated Certificate of Incorporation of the Registrant.
3.2* -- Amended and Restated By-Laws of the Registrant.
4.1+ -- Form of Stock Certificate
4.2* -- Amended and Restated Loan and Security Agreement dated as of
December 22, 1998 between the Registrant and LaSalle Bank
National Association
4.3* -- First Amendment to Amended and Restated Loan and Security
Agreement dated as of May 10, 1999 between the Registrant
and LaSalle Bank National Association
4.4* -- Second Amendment to Amended and Restated Loan and Security
Agreement dated as of January 2, 2000 between the Registrant
and LaSalle Bank National Association
4.5* -- Third Amendment to Amended and Restated Loan and Security
Agreement dated as of April 14, 2000 between the Registrant
and LaSalle Bank National Association
4.6* -- Reimbursement Agreement dated April 14, 2000 between the
Registrant and the Kapoor Children's 1992 Trust
5+ -- Opinion of Arnall Golden & Gregory, LLP
10.1* -- 1997 Non-Qualified Stock Option Plan
10.2* -- 2000 Stock Plan
10.3* -- Form of Nonqualified Stock Option Agreement
10.4* -- Form of Employment Agreement dated as of January 1, 2000
between the Registrant and certain of its executive officers
10.5* -- Convertible Term Loan Note dated January 11, 1999 made by
the Registrant for the benefit of Kapoor Pharma Investments,
L.P., as amended by Amendment No. 1 to the Convertible Term
Note dated January 11, 1999 made by the Registrant for the
benefit of Kapoor Pharma Investments, L.P.
10.6* -- Convertible Term Note Agreement dated January 11, 1999
between the Registrant and Kapoor Pharma Investments, L.P.,
as amended by Amendment No. 1 to the Convertible Term Note
dated January 11, 1999 made by the Registrant for the
benefit of Kapoor Pharma Investments, L.P.
10.7* -- Lease Agreement dated June 28, 1998 between the Registrant
and ASC North Fulton Associates Joint Venture
10.8*** -- Product Development and Supply Agreement, dated March 25,
1999 between the Registrant and Penwest Pharmaceuticals Co.
10.9*** -- Collaboration Agreement dated October 31, 1998 between the
Registrant and Inpharmakon Corporation
10.10*** -- Exclusive Patent License Agreement dated January 1, 2000
between the Registrant and Jame Fine Chemicals, Inc.
10.11*** -- Exclusive Distribution Agreement, dated January 1, 1996,
between the Registrant and Unisource, Inc.
</TABLE>
II-8
<PAGE> 99
<TABLE>
<CAPTION>
EXHIBIT
NO. DESCRIPTION
- --------- -----------
<C> <C> <S>
10.12*** -- Manufacturing and Supply Agreement, dated April 23, 1999,
between the Registrant and Mikart, Inc.
10.13*** -- Product Supply Agreement, dated January 29, 1999, between
the Registrant and American Home Products Corporation
10.14*** -- License Agreement, dated January 29, 1999, between the
Registrant and American Home Products Corporation
10.15*** -- Distribution Agreement dated July 22, 1999 between the
Registrant and G. Pohl-Boskamp GmbH & Co.
10.16* -- Form of Indemnity Agreement between the Registrant and its
directors and executive officers
10.17*** -- Asset Purchase Agreement dated April 10, 2000 between the
Registrant and Warner-Lambert Company
10.18*** -- Supply Agreement dated April 14, 2000 between the Registrant
and Warner-Lambert Company
10.19*** -- Asset Purchase Agreement dated April 14, 2000 between the
Registrant and Warner-Lambert Company
10.20* -- Amendment No. 1 to the Product Development and Supply
Agreement, dated May 3, 2000 between the Registrant and
Penwest Pharmaceuticals Co.
10.21*** -- Amendment to the Collaboration Agreement, dated May 3, 2000
between the Registrant and Inpharmakon Corporation
23.1* -- Consent of Arthur Andersen LLP
23.2+ -- Consent of Arnall Golden & Gregory, LLP (included in Exhibit
5)
24.1* -- Powers of Attorney
27* -- Financial Data Schedule (for SEC use only)
</TABLE>
- ---------------
* Previously filed.
** To be filed by amendment.
*** First Horizon has requested confidential treatment for certain portions of
this exhibit pursuant to Rule 406 of the Securities Act of 1933, as amended.
+ Filed herewith
II-9
<PAGE> 1
EXHIBIT 4.1
CERTIFICATE OF STOCK
COMMON STOCK $.01 PAR VALUE
[PICTURE OF CORPORATE LOGO]
FIRST HORIZON PHARMACEUTICAL CORPORATION
NUMBER SHARES
FH
INCORPORATED UNDER THE
LAWS OF THE CUSIP 29051K 10 6
STATE OF DELAWARE SEE REVERSE FOR CERTAIN DEFINITIONS
This Certifies that
is the owner of
FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF
FIRST HORIZON PHARMACEUTICAL CORPORATION
[HORIZON
CORPORATE
SEAL] This certificate and the shares represented thereby are
transferable only on the books of the corporation in person or by
duly authorized attorney upon surrender of this certificate
properly endorsed. This certificate is not valid unless
countersigned and registered by the Transfer Agent and Registrar.
WITNESS the facsimile seal of the corporation and facsimile
signatures of its duly authorized officers.
COUNTERSIGNED AND REGISTERED:
BY LASALLE BANK NATIONAL ASSOCIATION
TRANSFER AGENT AND REGISTRAR
DATED: AUTHORIZED SIGNATURE
/s/ Gregory P. Hauck /s/ Brent Dixon
- ------------------------------------ ----------------------------------
SECRETARY PRESIDENT
<PAGE> 2
FIRST HORIZON PHARMACEUTICAL CORPORATION
THE CORPORATION WILL FURNISH WITHOUT CHARGE TO EACH SHAREHOLDER WHO SO
REQUESTS, THE POWERS, DESIGNATIONS, PREFERENCES AND RELATIVE, PARTICIPATING,
OPTIONAL OR OTHER SPECIAL RIGHTS OF EACH CLASS OF STOCK OR SERIES THEREOF OF
THE CORPORATION, AND THE QUALIFICATIONS, LIMITATIONS OR RESTRICTIONS OF SUCH
PREFERENCES AND/OR RIGHTS.
The following abbreviations, when used in the inscription on the face
of this certificate, shall be construed as though they were written out in full
according to applicable laws or regulations.
<TABLE>
<CAPTION>
<S> <C> <C>
TEN COM - as tenants in common UNIF GIFT MIN ACT- ............Custodian............
TEN ENT - as tenants by the entireties (Cust) (Minor)
JT TEN - as joint tenants with right under Uniform Gifts to Minors
of survivorship and not as Act..............................
tenants in common (State)
</TABLE>
Additional abbreviations may also be used though not in the above list.
For value received, _____________________________ hereby sell, assign and
transfer unto
PLEASE INSERT SOCIAL SECURITY OR OTHER
IDENTIFYING NUMBER OF ASSIGNEE
______________________________________
________________________________________________________________________________
(PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING ZIP CODE, OF ASSIGNEE)
________________________________________________________________________________
________________________________________________________________________________
_________________________________________________________________________ shares
of the Common Stock represented by the within Certificate, and do hereby
irrevocably constitute and appoint _____________________________________________
Attorney to transfer the said stock on the books of the within named
Corporation with full power of substitution in the premises.
Dated: ____________________
_________________________________________
NOTICE: THE SIGNATURE TO THIS ASSIGNMENT
MUST CORRESPOND WITH THE NAME AS WRITTEN
UPON THE FACE OF THE CERTIFICATE IN
EVERY PARTICULAR WITHOUT ALTERNATION OR
ENLARGEMENT OR ANY CHANGE WHATSOEVER.
Signature Guaranteed:
_____________________________________________________
THE SIGNATURE SHOULD BE GUARANTEED BY AN ELIGIBLE
GUARANTOR INSTITUTION PURSUANT TO S.E.C. RULE 17Ad-15.
<PAGE> 1
EXHIBIT 5
LETTERHEAD OF ARNALL GOLDEN & GREGORY, LLP
WRITER'S DIRECT DIAL NUMBER
(404) 873-8500
WRITER'S DIRECT DIAL FACSIMILE
(404) 873-8501
May 19, 2000
First Horizon Pharmaceutical Corporation
660 Hembree Parkway, Suite 106
Roswell, Georgia 30076
Re: Form S-1 Registration Statement
Commission File Number 333-30764
Ladies and Gentlemen:
We have acted as counsel to First Horizon Pharmaceutical Corporation, a
Delaware Corporation (the "Company") in connection with the registration of
4,370,000 shares of Common Stock of the Company (the "Shares"). The Company has
filed a Registration Statement on Form S-1 under the Securities Act of 1933, as
amended.
In acting as counsel, we have reviewed (a) the Registration Statement,
(b) the Company's Restated Certificate of Incorporation, (c) the Company's
Amended and Restated By-Laws, (d) the Company's minute book, (e) the stock
records of the Company and (f) such other records, documents, statutes and
decisions as we have deemed relevant. In our examination, we have assumed the
genuineness of all signatures, the authenticity of all documents submitted to us
as originals and the conformity with the original of all documents submitted to
us as copies thereof.
Based upon and subject to the foregoing, we are of the opinion that,
when issued in accordance with the Registration Statement, the Shares will be
legally issued, fully paid and non-assessable.
We consent to the filing of this opinion as an exhibit to the
Registration Statement and the reference to this firm under the caption "Legal
Matters" contained therein and elsewhere in the Registration Statement. This
consent is not to be construed as an admission that we are a party whose consent
is required to be filed with the Registration Statement under the provisions of
the Securities Act of 1933, as amended.
Sincerely,
ARNALL GOLDEN & GREGORY, LLP
